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Introduction 
Conventional cancer therapies, such as chemotherapy and radiation, target cell replication in 
general, damaging healthy proliferating tissues like the haematopoietic and gastrointestinal 
systems in the process. This activity in normal cells not only causes barely acceptable side-
effects, it also limits the dose that can be administered, thereby hampering effectiveness. 
Two main issues have fostered the belief that therapies targeted specifically to tumour cell 
characteristics would be virtually impossible: (1) cancer cells do not develop entirely new 
traits, but deregulate cellular processes found in normal cells and (2) they do so by the 
acquisition of an indefinite variety of genetic mutations. Extensive research into the molecular 
changes of cancer cells, however, has recently led to the recognition that in order for a cell to 
become a tumour cell, e.g. to grow autonomously without responding to inhibitory 
mechanisms, a limited number of (incompletely) defined pathways is altered in every case. 
Therefore, the seemingly endless variety of mutations that occur can be grouped into this 
limited number of tumour essential pathways, with the biological endpoint of each altered 
pathway representing an indispensable trait of the tumourigenic phenotype. These new 
insights have opened the door for the development of novel therapies, termed molecular 
therapy of cancer, designed to target specific tumour characteristics, rather than targeting 
normal cellular processes or each and every individual mutation. To explain the molecular 
basis of tumour-specific therapies, this introductory chapter will first provide a summary of the 
hallmarks of cancer as they are currently defined and understood. Next, I will provide 
examples of how this knowledge can be translated into the development of novel therapeutic 
agents that cause tumour-selective cell death, based on already identified tumour essential 
pathways. Subsequently, some proteins are discussed that have shown tumour-selective cell 
killing but have not yet been linked to a distinct tumour trait. In addition to representing 
potential therapeutic agents by themselves, these proteins could confirm the described 
cancer hallmarks, identify new players in these pathways or even expose additional 
unrecognised tumour essential pathways, which in turn could lead to new cancer targets. 
One of the proteins in this category is Apoptin, and a summary of the current knowledge of 
its activity in tumour and normal cells will complete this chapter, preceding the first data on 
the activity of Apoptin in vivo presented in subsequent chapters. 
From soldier to mutineer 
Tumorigenesis is a multi-step process that reflects the acquisition of a variety of genetic changes 
in a somatic cell, each conferring one or another type of growth advantage. These traits are not 
consciously designed; rather, they arise under selection pressure. Hence, tumour development 
can be seen as analogous to Darwinian evolution; i.e. from a stochastic occurrence of genetic 
mutations, only those cells that have acquired an advantageous trait can continue to grow, 
9 
Chapter 1: Introduction 
whereas all other cells with a less suitable mutation will perish or at best remain 1. In fact, it has 
been an evolutionary imperative tor multicellular organisms to efficiently suppress the genesis of 
mutated cells leading to deregulated growth, while at the same time allowing cell proliferation 
when needed 2. Therefore, proliferation of individual cells in metazoans is highly regulated and 
subjected to a multitude of restrictions. These control mechanisms explain why cancer is a 
relatively rare event in an average human life time; many starting neoplasms tail to disable all 
restrictions and thus never reach the stage of true malignancy. Restrictions imposed on normal 
tissues include reliance on extracellular growth signals, requirement for survival signals 
generated by attachment to the extracellular matrix and soluble survival factors, the presence of 
growth inhibitory signals, a control mechanism in the form of programmed cell suicide and 
limited life span. 
It has been known tor some time that certain proteins are targeted frequently in all kinds of 
tumours arising under different circumstances. For instance, over half of all lung carcinomas 
were shown to have mutations in the tumour suppressor protein p53 3, which also occurs in 30% 
of hepatocellular carcinomas 4, 65% of colon cancers 5 and - 40% of breast cancers 6. Further, 
constitutive active forms of Ras 7, loss of heterozygosity of the RB locus 4 and activation of 
telomerase 8'9 occur frequently in human cancers. Tumours that do not have mutations in these 
'hotspot' proteins are often found to have mutations in regulatory or effector proteins associated 
with them. In fact, studies in both mice and man have shown that mutations in hotspot proteins 
or their regulators are mutually exclusive indicating that a single pathway needs to be 
inactivated 10•11 . These data led to the notion that a limited number of key pathways exist that 
need to be affected in order for a cell to become cancerous. From the vast amount of research 
on molecular changes in cancer, a number of cancer 'hallmarks' have emerged and were 
enumerated by Hanahan and Weinberg 1. Some represent the breaching of anticancer defence 
mechanisms, resulting in the ability to grow independently of growth signals, in the lack of 
growth control, resistance to apoptosis, and immortality. In addition, tumour cells will have to 
attract blood vessels and invade and metastasize into surrounding tissues. Finally, genomic 
instability enables tumour cells to 'stack the deck'; i.e. it provides the necessary platform tor the 
frequent occurrence of de novo mutations. This set of acquired capabilities represents the 
fundamental difference between tumour and normal cells and provides crucial targets for cancer 
therapy. During the past decade, several of the underlying genetic changes that confer the 
essential traits to tumour cells have been characterized and will be summarized in the next 
chapter. 
Multiple paths lead to cancer 
The evolutionary aspect of carcinogenesis causes the particular sequence in which the tumour-
essential capabilities arise to differ for each cell. Furthermore, the end result of the necessary 
feature can be achieved in numerous ways. Most, if not all, processes in a cell are regulated to 
allow the integration of different signals into the appropriate response. Alteration of a specific trait 
can therefore occur at different levels in such a signalling cascade. For instance, to acquire 
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continuous growth, a growth stimulating molecule can be amplified or its effector molecule might 
be mutated into a constitutively active form. On the other hand, an inhibitory molecule could be 
downregulated, mutated into an inactive form or completely abolished by deletion of some or all 
of its gene to obtain the same effect. Both quantitative and qualitative changes of positive or 
negative regulators, or effector molecules, can therefore result in the altered outcome of a 
particular signalling pathway. In addition, a specific genetic event could confer only part of a 
required trait to the cell, whereas another event could contribute to several tumour capabilities 
simultaneously. For instance, constitutive activation of a protein such as Ras that stimulates cell 
division but also facilitates cell movement contributes to both enhanced proliferation and 
invasion. The frequency with which a particular genetic event alters a pathway depends on the 
cell type and its associated selection pressure, giving rise to tissue-specific 'road-maps' to 
malignancy. Hence, certain tumour types will display mutations predominantly in a negative 
regulator of a pathway, whereas tumours arising from a distinct tissue acquire the same trait 
mainly by mutating the downstream effector. 
Together, these features explain the seemingly endless diversity of genetic alterations 
obseNed in cancer. Nonetheless, all tumour cells are thought to reach the biological end-points 
described by the following hallmarks, which represent disruptions of common pathways (see 
figure 1). 
liMitless 
Ealico..-ti~ 
fott--iio..l 
~rti:''~ 
10 <M-.+1-
15~ sj"cr.IS 
Figure 1 The hallmarks of cancer. 
A new model of cancer has emerged postulating that most if not all cancers have acquired the same set of functional 
capabilities during their development. These characteristics are called 'cancer hallmarks' and are lined up at the 
bottom. Some key players in the processes conveying these capabilities are depicted; square boxes enclose proto-
oncogenes and ovals, tumour-suppressor proteins. It is thought that perturbation of every one of these pathways is 
necessary to allow malignant growth, but different tumours have deregulated different proteins within a given cascade 
to achieve the same end result. For the purposes of clarity, this representation is simplified and illustrative rather than 
comprehensive. Loosely based on ref's 1 and 72. 
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Cancer Hallmarks 
Growth stimulation 
The decision to divide 
Somatic cells are usually quiescent unless they are specifically instructed to proliferate. Growth 
factor receptors on the cell surface detect systemic (endocrine) signals or signals from 
neighbouring cells (paracrine). Most cell types are dependent on growth factors secreted by a 
different cell type in order to proliferate, thus preventing self-sustained proliferation. In addition, 
cells only respond to mitogenic signals that are tenacious; in other words, they need prolonged 
exposure for at least several hours before they enter the cell cycle 12. In most tissues, mitogenic 
signals alone are not enough; a secondary signal is required to allow proliferation. This signal is 
conveyed by integrins that are connected to the extracellular matrix (ECM), thereby confirming 
that the cell is in its appropriate place. Successful binding to specific moieties of the ECM 
enables the integrin receptors to transmit survival signals into the cytoplasm that result in 
resistance to apoptosis and allow entrance into the active cell cycle 13. The combination of 
dependency on growth factors secreted by surrounding cell types and the necessity to adhere to 
the ECM effectively 'traps' epithelial cells within a certain tissue that supplies their specified 
microenvironment 2 . Cells that are not physically connected to the ECM, like haematopoietic 
cells, face yet another restriction: antagonistic pleiotropy, in which a proliferative signal is usually 
accompanied by a death signal, and unless the latter is specifically overruled by additional 
survival factors, the cell will undergo programmed cell death instead of division 14. 
Self-sufficiency in growth signals 
To proliferate continuously, tumour cells need to become independent from endo- and paracrine 
growth stimuli, which can be achieved in several ways. In general, growth factors for a certain 
cell type are produced by a distinct cell type, one that is non-responsive to this particular factor. 
Some cancer cells are able to synthesize their own growth factors, such as platelet-derived 
growth factor (PDGF) or transforming growth factor-O (TGFO), which in contrast to physiological 
heterotypic signalling, results in autocrine stimulation. Other cancers acquire a constitutively 
active component of the mitogenic cascade that results in ligand-independent signalling. Growth 
factor receptors usually have tyrosine kinase activities in their cytoplasmic domain which enable 
them to activate the Ras-Raf-Mitogen-activated protein (MAP) kinase cascade leading to mitosis. 
Mutant Ras proteins that provide continuous mitogenic stimulation are found in approximately 
25% of all cancers 15. These mutant forms have a constitutive GTPase activity leading to 
activation of the serine/threonine kinase Raf-1 which in turn phosphorylates MAPkinase kinase 
(MEK), which then phosphorylates extracellular-signal regulated kinase (ERK). At the end of this 
signalling cascade a number of genes driving proliferation are activated 16. 
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Growth control 
Internal checkpoints 
A web of growth inhibitory factors is superimposed upon the requirement for positive growth 
signals, and those must be overcome for cell-cycle entry. During the initial phase of the cell 
cycle, G1, cells acquire all the necessary information to proceed safely into the next phase, S, in 
which their genetic material has to be faithfully duplicated. Cells must not only evaluate their 
extracellular environment to ensure the presence of all necessary requirements (e.g. nutrient 
availability, mitogenic input, etc), but also must check whether there is any DNA damage that 
needs to be repaired before .committing to cell division 17. In early G1, removal of mitogens 
allows cells to return to GO. Later on in G1, however, the cells become committed to a new round 
of replication and are no longer dependent on mitogens. This point of no return is termed 
restriction point (R) and is regulated by the retinoblastoma (RB) family of proteins (figure 2). 
Phosphorylation of these proteins inactivates them and leads to progression of the cell cycle 18 . 
However, this decision to commit to a cell cycle is influenced by anti-proliferative signals such as 
those induced by transforming growth factor-13 (TGF-13). TGF-13 prevents phosphorylation of RB, 
thereby blocking a cell's advance through G1 19 . Some cells, such as hepatocytes, are kept 
continuously in the quiescent (GO) state. However, after liver damage, these cells can be 
reactivated to enter the cell cycle in order to replace the lost hepatocytes. Alternatively, other cell 
types, thought to be at higher risk for mutations, are induced to relinquish their proliferative 
potential permanently by undergoing terminal differentiation. 
Insensitivity to anti-growth signals 
For progression through the cell cycle, two holoenzyme complexes must be formed to inactivate 
the key inhibitor of the restriction point, RB. These complexes consist of a cyclin associated with 
a cyclin-dependent kinase (Cdk), specifically, cyclin D1-Cdk4 and cyclin E-Cdk2. In quiescent 
cells, cyclin D1 levels are low, so cyclin D1-Cdk4 complexes do not form, and high levels of the 
Cdk-inhibitors p21 and/or p27 suppress cyclin E-Cdk2 activity (figure 2). Persistent mitogen 
stimulation induces cyclin D1 and regulates its assembly with Cdk4, a process facilitated by 
p21/p27 binding 20. These Cdk-inhibitors are not very effective in blocking the cyclin D1-Cdk4 
enzymatic activity and sequestration of p21/p27 by this complex results in the activation of cyclin 
E-Cdk2 as well 21 . Both G1 cyclin-dependent kinases can then collaborate to phosphorylate and 
inactivate RB and fellow family members p107 and p130. The repression of the E2F family of 
transcription factors by RB proteins is consequently released, allowing E2Fs to induce genes 
that are necessary for DNA replication 22·23 . 
Cyclin-D dependent kinases can be specifically inhibited by proteins from the INK4 locus. 
Whereas some of these latter proteins appear to be primarily involved in development, p16 plays 
a specialized role in countering signals that abnormally drive cell proliferation. Mice lacking p16 
are tumour prone and develop a wide spectrum of cancers, particularly after exposure to 
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Figure 2. Regulation of G1/S transition by the RB pathway. 
Progression through the G1 phase of the cell cycle is controlled by the functional state of the RB family of proteins, 
pRB, p107 and p130. In G,, RB proteins are non-phosphorylated, a state that allows them to bind, among others, the 
E2F family of transcription factors, preventing E2F-dependent transcription. The cyclin-dependent kinases 4 and/or 6 
become active upon binding to the mitogen-stimulated D-type cyclins. Phosphorylation of RB proteins by CDK4/6-
cyclin D complexes leads to their partial inactivation, which allows transcription of E2F-controlled genes such as cyclin 
E1, which in turn activates the downstream CDK2 kinase. The activity of CDK4/6 is negatively regulated by the INK4 
family of cell cycle inhibitors through prevention of binding to cyclin D. CDK4/6-cyclin D complexes may also activate 
CDK2 by binding p21/p27 proteins and thus preventing them from blocking CDK2-cyclin E activity. 
Hyperphosphorylation of RB proteins by CDK2-cyclin E complexes is required for proper G1/S transition and the 
initiation of S-phase. The position of the restriction (R) point is approximate. Adapted from ref. 18. 
chemical carcinogens or X-rays 24-26• During cellular senescence, p16 is selectively upregulated, 
as will be discussed with the cancer hallmark of achieving immortality (see section "Mortal 
cells"). 
Mutations in the pathway controlling G1 progression are found in virtually all tumours. RB 
disruption was first described in retinoblastoma, but is now catalogued in many other tumour 
types. Inactivation of p16 and overexpression of cyclin 01 or mutations in Cdk4 also occur 
frequently in cancer, and have been shown to be mutually exclusive with RB loss, providing 
evidence for both the necessity to inactivate this pathway and for the activity of these proteins 
within the same pathway. For example, in small cell lung cancer, 15% of the cases had 
inactivated p16, 5% overexpressed cyclin D or Cdk4 and 80% had lost RB 11 . The fact that the 
Cdk-inihibitors p21 and p27 are essential for cyclin D1-Cdk4 assembly renders their mutation 
unfavourable for tumour development and this indeed is less frequently observed 27•28. 
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Cell suicide 
When in doubt: die 
If any of the required signals to divide are not correct, the cell will undergo apoptosis, a multi-
step cell-death programme that is present in latent form in every cell of the body. Because the 
subject of this thesis, Apoptin, exerts its anti-tumour activity by inducing apoptosis, I will describe 
this process and its regulation in more detail. 
Apoptosis can be initiated either by extracellular death factors or by intracellular signals 
acting through the mitochondrial pathway (figure 3), both leading to the activation of cysteine 
aspartyl proteases (caspases). Many of the signals that elicit apoptosis following intracellular 
stress, such as genotoxic damage, lack of integrin signalling or oncogene activation, converge 
on the mitochondria, which respond by releasing cytochrome c. In the cytosol, cytochrome c 
forms a complex with Apaf-1 (apoptotic protease activating factor-1) and the inactive 
procaspase-9 29 • Within this complex, known as the apoptosome, the initiator caspase 9 is 
activated and subsequently activates 'executioner' caspases, mainly caspases-3, -6 and -7. 
These active execution caspases cleave themselves to amplify the apoptotic signal, and also 
cleave an array of substrates resulting in the execution of the actual cell death, which is 
characterised by specific biochemical and morphological features 30• For instance, the chromatin 
condenses due to disruption of Jamins and the DNA is fragmented because the inhibitor of the 
endonuclease CAD (caspase-activated deoxyribonuclease) is cleaved and thus removed. In 
addition, caspase cleavage of cytoskeletal proteins such as actin leads to cell fragmentation and 
protuberances of the plasma membrane (blebs), ultimately giving rise to membrane-bound 
apoptotic bodies that contain the cell remnants. Exposure of phosphatidy/ serines on these 
bodies facilitates engulfment and phagocytosis by neighbouring cells to prevent inflammatory 
reactions to contents that would otherwise be released from the dying cell 30•31 • Besides the 
prototypic caspase-dependent apoptosis, less-well-defined cell-death pathways that do not 
require caspase activation also exist. These pathways share some, but not all, characteristics of 
the process classically described as apoptosis 32•33. 
Death receptor signalling is able to bypass the mitochondria and directly activate caspase-3 
via caspase-8. When a death factor engages its cognate receptor, the cytoplasmic death 
domains recruit an intracellular adaptor protein, e.g. FADD (Fas-associated death domain 
protein), which in turn recruits and activates the initiator caspases-8 and -10 to form a death-
inducing signalling complex (DISC) 34. In some cell types, caspase-8 concomitantly induces 
cytochrome c release by cleavage of Bid, possibly to amplify the apoptotic signal in the case of 
naturally low levels of caspase-8 35. 
To allow sufficient control over tissue homeostasis, the apoptotic cascade is regulated at 
different levels. For instance, FADD-Iike adaptor proteins (FLIPs) can interfere with the binding of 
FADD to death receptors, thereby inhibiting caspase-8 activation 36. In addition, Bc/-2 and 
several anti-apoptotic relatives act as guardians of mitochondrial integrity, among putative other 
15 
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Figure 3. Apoptotic pathways. 
A schematic diagram showing some of the known components of the intrinsic and death receptor apoptotic 
programmes. Proteins in squares inhibit apoptosis while those in circles promote apoptosis. See text for explanation. 
An asterisk denotes components that are frequently mutated or aberrantly expressed in human cancers. Abbreviations 
used: casp, caspase; cyt, cytochrome. Adapted from ref 244. 
functions, and it seems that all mammalian cell types require the protection of at least one Bcl-2 
homologue to ensure their existence 37• Besides these pro-survival proteins, the Bcl-2 family 
contains two groups of pro-apoptotic proteins that share at least one conserved Bcl-2 homology 
(BH) domain: the Bax death family which contains three homology domains, and a more 
distantly related group, which shares only the short BH3 motif. The pro-apoptotic members 
stimulate cytochrome c release, whereas the anti-apoptotic members inhibit it, and the decision 
to undergo apoptosis is in part dependent on the balance between these proteins. For example, 
one means by which p53 elicits apoptosis in response to DNA damage is via upregulation of the 
expression of pro-apoptotic Bax 38 . 
In healthy cells, the BH3-only proteins are restrained in diverse ways, including 
phosphorylation and sequestration in the cytoskeleton. When released by death signals, BID-like 
16 
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BH3 domains seem to activate apoptosis directly through targeting of Bax and Bak, whereas 
BAD-like BH3 domains 'sensitise' or enable apoptosis by neutralizing Bcl-2 and related pro-
survival proteins 39 . BH3-only proteins cannot kill in the absence of Bax and Bak, which 
apparently act further downstream. Bax and Bak oligomerise in the mitochondrial outer 
membrane and probably breach its integrity, releasing pro-apoptotic proteins such as 
cytochrome c. However, the precise mechanism by which Bax and Bak are activated, and how 
they are inhibited by Bcl-2 remain uncertain. In addition, it has become clear that Bcl-2 can also 
protect against certain types of stress-induced apoptosis, such as that initiated by calcium-
deregulation in the endoplasmatic reticulum 40. Under those circumstances, mitochondrial 
disruption is neither necessary nor sufficient, indicating that Bcl-2 might prevent the activation of 
caspases independently from its function at the mitochondria 37• 
Downstream of the mitochondria, apoptosis is modulated further by inhibitor of apoptosis 
proteins (lAPs) that bind to and inhibit activated caspases, in some cases by targeting them for 
degradation 41 • However, when mitochondria are breached, they release a series of proteins that 
promote cell death. Besides cytochrome c, these include SMAC/DIABLO (second mitochondria-
derived activator of caspase/direct lAP binding protein with low pi) and the serine protease 
HtrA2/0mi, both of which antagonize lAPs. Also the apoptosis-inducing factor AIF and 
endonuclease G are released and facilitate DNA fragmentation, thereby adding weight to the 
pro-apoptotic side of the balance 37• 
The high degree of regulation surrounding the apoptotic process ensures that cells are able 
to integrate different survival and death signals to come to the appropriate decision. In some 
cells, such as those of haematopoietic origin, apoptosis is the default status that needs to be 
specifically overruled by survival signals. Ligation of interleukin (IL)-3 with its cognate receptor on 
haematopoietic cells results in the activation of the phosphatidylinositol-3 kinase (PI3K), which 
ultimately causes phosphorylation and thereby inhibition of pro-apoptotic BAD and FOX03a 42•43 . 
Survival factors, however, are often limited in supply and spatially restricted, preventing 
continuous growth 44•45• In the case of epithelial cells, the disruption of contact with the 
extracellular matrix results in loss of survival signalling via PI3K and thereby cell death, in this 
case termed anoikis. 
An important regulator in the decision to die upon intracellular stresses such as DNA 
damage, hypoxia or shortened telomeres (see section "Mortal cells") is the tumour suppressor 
protein p53. Dependent on the cell type, cell environment, strength of the insult and intracellular 
p53 levels, the cellular response to p53 activation can be DNA repair, differentiation, cell-cycle 
arrest, apoptosis or senescence. P53 can induce expression of several death effectors in both 
the death-receptor and mitochondrial apoptotic pathways, such as Fas, Bax and the BH3-only 
proteins Noxa and Puma. In addition to inducing these pro-apoptotic genes, p53 can also 
activate the expression of genes that inhibit survival signalling 46. For instance, PI3K is an 
activator of protein kinase B (PKB, a.k.a. Akt) that phosphorylates and activates MDM2, which in 
turn targets p53 for degradation. The inhibition of p53 by PKB, however, is counteracted by the 
ability of p53 to induce expression of PTEN, a phosphatase that can inhibit the activation of 
17 
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PKB 47 48 . Moreover, the p53 pathway is connected to the RB pathway in that deregulated E2F 
activity induces the transcription of ARF, which is an alternative reading frame of the INK4a locus 
encoding p16. ARF negatively regulates MDM2, thereby increasing p53 stability 49. Thus, p53 is a 
crucial sentinel integrating the response of a cell to survival, proliferation and damage signals, 
and the various pathways are intimately interconnected. 
Evading the death sentence 
In general, any of the cellular responses to p53 activation, be it cell cycle arrest, senescence or 
apoptosis, inhibits tumour development 48. Moreover, because disruption of the RB pathway 
triggers compensatory p53-dependent cell cycle arrest or even apoptosis, dysregulation of the 
cell cycle (the above-mentioned hallmark) results in an additional imperative for tumour cells to 
disrupt the p53 pathway. Malignant progression is therefore dependent on loss of p53 function, 
either through mutation in the p53 gene itself or by defects in the signalling pathways that are 
upstream or downstream. The importance of inactivation of the p53 pathway either directly or 
indirectly is underscored by the finding that any impairment of p53 function is associated with 
increased tumour susceptibility in mice 50, together with the fact that mutations in p53 are found 
in about half of all human cancers 51 . Alternatively, many cancers show enhanced activity of the 
PI3K/PKB signalling cascade to avoid apoptosis, either by loss of PTEN or through amplification 
of the catalytic subunit of PI3K, depending on the tissue of origin 52. 
Besides altering the p53 and PI3K pathway, tumour cells can acquire resistance to apoptosis 
by overexpression of anti-apoptotic molecules or by inactivation of pro-apoptotic genes. In fact, 
the first clue that apoptosis was important for cancer was the discovery that translocation of the 
gene BCL-2 (8-ce\1 lyrnphorna-2) in follicular lymphoma resulted in reduced cell death rather 
than in enhanced proliferation 53. Later on, mouse studies confirmed the oncogenic potential of 
elevated Bcl-2, although the stochastic onset of tumours in mice mimicking the BCL2-
translocation indicated that additional mutations were required for transformation 54. Particularly, 
dramatic synergy was observed when Bcl-2 was co-expressed with oncogenes that enforce 
proliferation, such as Myc 55•56. As the Bcl-2 pro-survival proteins are all likely to be oncogenes, 
the pro-apoptotic members probably constitute tumour suppressors and thus need to be 
inactivated during carcinogenesis. Specifically, downregulation of Bax is commonly found in 
haematopoietic malignancies 57 and absence of both Bax and Bak enhance transformation far 
greater than the loss of either alone 58. Further, metastatic melanomas often lose expression of 
Apaf-1 59 , whereas apoptosis through death receptors is averted by overexpression of FLIP, 
simultaneously allowing the tumour cell to escape T-ee\\ mediated cytotoxicity 60 . 
Notwithstanding the well-documented necessity for tumour cells to inactivate apoptotic 
signals, many tumours in vivo exhibit a high percentage of apoptotic cells. This state is a 
consequence of the evolutionary nature of tumorigenesis, in which mutations are selected by 
environmental pressure (figure 4). Premalignant cells that completely lack inhibition of apoptosis 
are obviously unable to establish an autonomously growing colony. However, premalignant cells 
do not get to 'choose' the alteration with the most profound effect; rather, they stochastically 
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acquire mutations. If this mutation allows the cell and its progeny to undergo more cell divisions 
before it is eliminated by apoptosis, a tumour mass will arise. Consequently, distinct tumours 
can display substantial differences in their ability to evade apoptosis; some may be endowed 
with a robust block downstream in the apoptotic cascade, whereas in others, only some of the 
key initiating factors of apoptosis have been disabled, resulting in delayed apoptosis via other 
signals, nevertheless cumulating in a selective growth advantage. 
Mortal cells 
Live short and prosper 
The finite life span of mammalian cells forms another barrier to tumorigenesis. When cells are 
explanted from living tissues into culture, they undergo only a limited number of cell divisions 
before arresting in a state known as replicative senescence. Such cells are irreversibly arrested 
in the G1 phase of the cell cycle and are no longer sensitive to growth factor stimulation. When 
an oncogene such as Ras becomes overactive, cells will undergo the same fate, in this case 
termed premature senescence. There has been some debate whether senescence is related to 
in vitro cell culture rather than to a relevant mechanism occurring in vivo. Recently, however, it 
was demonstrated that p53 and p16 cooperatively induce a senescence programme in vivo 61 . In 
these studies, murine lymphoma harboring mutated p53 responded poorly to chemotherapy due 
to their apoptosis defect. But when the apoptotic block was downstream of p53, these 
lymphomas underwent a drug-induced senescence programme that was dependent on intact 
p53 and p16, significantly increasing the prognosis of these mice compared to those sustaining 
lymphoma due to direct p53 mutations. Concordantly, to overcome the senescent state in vitro, 
cells need to inactivate both RB and p53 62. The cells are then able to continue growing, but only 
to a certain point termed crisis. Crisis is characterized by massive cell death and karyotypic 
disarray associated with end-to-end fusion of chromosomes 63•64. The limited number of cell 
doublings endowed to each cell is thought to be calculated by progressive telomere shortening. 
Telomeres cap the ends of eukaryotic chromosomes with tandem repeats of the sequence 
TIAGGG bound to a complex array of proteins, preventing the ends of the chromosomes from 
being recognized as DNA breaks, and, therefore, from being processed by DNA-repair activities. 
With each round of cell division, the 3' ends of chromosomal DNA are incompletely replicated, 
leading to the progressive shortening of the telomere. Critically short telomeres are detected as 
damaged DNA and result in activation of the DNA-damage checkpoint, leading to cell-cycle 
arrest and/or apoptosis 65•6B 
Whereas telomere shortening occurs in most somatic cells, certain cell types, such as germ 
cells and a subpopulation of stem cells, have an active enzyme-complex that prevents net 
telomere shortening as they divide. This enzyme, called telomerase, is a cellular reverse 
transcriptase that comprises a catalytic subunit, TERT, and an RNA component, TERC, and 
exerts its function by adding TIAGGG repeats onto pre-existing telomeres 65. In this way, 
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Figure 4. Clonal evolution of a cancer 
All cancers evolve by Darwinian principles: clonal 
proliferation, genetic diversification within the clone, 
and selective pressure enabling mutant subclones to 
bridge the bottlenecks (such as cell-cycle 
checkpoints and apoptosis imposition). This 
simplified diagram illustrates the large number of cell 
divisions required to obtain all functional mutations 
for the cancer-selective capabilities, as well as the 
simultaneous existence of an apoptotic population 
within the growing colony. Each circle represents a 
cell, acquiring the first (dot) or additional, sequential 
mutations (! and x). Black circles represent dying 
cells. Adapted from ref 245. 
telomerase maintains telomeres above a minimum-length threshold, thus preventing telomere 
exhaustion and chromosomal instability and allowing immortal growth. 
Limitless replicative potential 
As discussed above, tumour masses arise when their proliferative potential exceeds their 
apoptotic onslaught, a requirement that partly explains why the growth of tumours in vivo is 
relatively slow. Suppose, for instance, that of every nine new tumour cells, six die rapidly. In this 
case, the mass will increase at only one third of the rate of its proliferation. Therefore, an 
enormous amount of cell doublings are required to form a tumour 67 (figure 4). As the tumour 
cells continue to proliferate, they will eventually reach the natural end of their life span, indicated 
by critically short telomeres. These dysfunctional telomeres signal DNA damage repair and 
subsequently cell-cycle arrest and/or apoptosis. The latter need to be overcome in order for 
malignant growth to continue; this usually occurs by reactivation of telomerase. But by this point, 
the dysfunctional telomeres will have been subjected to DNA repair, resulting in end-to-end 
chromosomal fusions and the occurrence of anaphase bridges during mitosis, which could 
contribute to the genetic instability that is characteristic of cancer cells. 
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The importance of disabling this life span 'clock' is demonstrated by the finding that over 90% of 
all human tumours have reactivated telomerase at some point during their development to 
achieve immortality 68-70. In addition to its telomere-preserving activity, telomerase has recently 
been suggested to have additional roles in tumour growth and survival by accelerating the 
growth of epithelial cells through regulation of genes that mediate the RB-E2F pathway 71 • 
Of note, human cells need to circumvent two barriers, cellular crisis and replicative 
senescence, to achieve immortalisation 72 • Mouse cells, on the other hand, have telomeres 3-10 
times longer than do human cells and express constitutive telomerase in most tissues. 
Telomeres, therefore, do not seem to limit the replicative lifespan of mouse cells. In addition, 
even though the study from Schmitt et al. implicated p16 in the replicative senescence of murine 
cells 61 , other studies have demonstrated a dominant role for the p53 pathway in mouse cells. 
Specifically, ablation of either Arf or p53 seemed sufficient to overcome Ras-induced 
senescence in mouse cells in vitro, in contrast to human cells that needed to inactivate both the 
RB and p53 tumour-suppressor pathways 72 . These differences may partly explain why it is so 
difficult to transform human cells, whereas rodent cells can undergo spontaneous 
immortalisation following extended in vitro culture 73 . Hence, although mouse models can and 
have provided valuable insights into the biology of human cancer, it is important to keep in mind 
that fewer cancer hallmark pathways are likely to be involved in murine carcinogenesis than in 
human. 
Blood supply 
Formation of blood vessels 
During embryogenesis and in wound healing and inflammation, new blood vessels are induced 
to extrude from existing vessels, a process called angiogenesis. Angiogenesis can be initiated 
by local hypoxia, a process that activates hypoxia-inducible factor-1 a (HIF-1 a), which in turn 
promotes the expression of several growth factors responsible for endothelial recruitment and 
proliferation 74'75 . The initiation of angiogenesis is regulated by a balance of angiogenesis 
inducers and inhibitors. Well known stimulators of angiogenesis include vascular endothelial 
growth factors (VEGFs), which act through a family of tyrosine kinase receptors, VEGFRs 76• A 
prototypical angiogenesis inhibitor is thrombospondin-1, which binds a transmembrane receptor 
on endothelial cells coupled to intracellular Src-like tyrosine kinases 77. 
Sustained angiogenesis 
Tumours cannot grow beyond a certain size without sufficient blood to supply oxygen and 
nutrients and therefore must induce angiogenesis when the tumour mass exceeds - 1 mm3 78 . 
In some tumours, thrombospondin itself is downregulated 79·80, but thrombospondin is also a 
downstream effector of p53 81 . Consequently, loss of p53 results in a drop of thrombospondin-1 
levels as well, shifting the balance towards angiogenesis. Alternatively, cancer cells start 
producing angiogenic factors including basic-fibroblast-like growth factor (bFGF), vascular 
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endothelial growth factor (VEGF), interleukin 8 (IL-8) and transforming growth factor-13 (fGF-13). 
Several cancer types exhibit overexpression of VEGF, but new insights suggest that surrounding 
'normal' cells can also play a role in tumorigenesis, for instance by upregulation of VEGFR in 
tumour-surrounding endothelial cells 82. 
Tissue remodelling 
Cellular socialization 
Cell-cell and cell-matrix contacts are important in inhibiting inappropriate growth and are thus 
obligatory for a cell to ensure its survival and proliferation. Complementary to the activation of 
PI3K signalling by integrin-ECM attachment, cell-cell connections endorse proliferation via the 
Wnt signalling pathway. Cell-cell adherens junctions assemble by means of interactions among 
the extracellular domains of cadherin receptors on the surface of adjacent cells. The cytoplasmic 
domains of cadherins bind to 13-catenin or plakoglobin (y-catenin), which are linked to the 
cortical actin cytoskeleton by a-catenin 83. Most of the 13-catenin present in the cell is 
sequestered by E-cadherin. Free 13-catenin is rapidly phosphorylated by glycogen kinase 313 
(GSK3-13) in the adenomatous polyposis coli (APC)/GSK3-13/axin complex and subsequently 
degraded by the ubiquitin-proteasome pathway. When GSK3-13 activity is blocked by activation 
of Wnt signalling after ligation to its cognate receptor, 13-catenin accumulates at high levels in the 
cytoplasm. Subsequently, it translocates to the nucleus, where it binds to members of the T cell 
factor/lymphocyte enhancer factor (fCF/LEF) family of transcription factors, whose targets 
include c-Myc, cyclin Di and metalloproteinase matrilysin (MMP-7) 84•85. 
The body also requires non-resident cells, not only for the delivery of oxygen and nutrients, 
but also for immune surveillance. In order to patrol through different tissues in search for 
pathogens, immune cells need a complicated set of capabilities including the ability to 
'extravasate' from blood vessels into a tissue, pass through the basal membrane and move from 
one tissue to the next. Extravasation requires adhesion and disassociation with endothelial 
ligands while migrating through the endothelial layer, a process termed diapedesis 86 . Next, the 
basal membrane, consisting of collagen, laminin and proteoglycans, needs to be degraded by 
the activation of matrix metalloproteases (MMPs) 87·88. To achieve mobility, several intracellular 
pathways must be activated, including Ras/MAPK and the tyrosine kinase receptor c-met, 
responsible for cytoskeletal reorganizations and the induction of lamellipodia, extrusions from the 
cytoplasm that provide anchorage and direction 89·90 . 
Invasion & metastasis 
In order for tumours to metastasise and grow, neoplastic cells must invade and migrate into 
surrounding tissues. These phenotypic changes are initially mediated by alterations in the 
expression of cell-surface molecules such as integrins, release of proteases that remodel the 
ECM, and the deposition of new ECM molecules. These activate signalling cascades that 
regulate gene expression, cytoskeletal reorganization, cell adhesion and cell survival. These 
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alterations then contribute to enhanced migration and proliferation, leading to invasion, 
metastasis and an improved ability to suNive in different microenvironments 91 • 
The importance of cell-cell contact is underscored by the obseNation that hereditary 
predisposition to gastric cancer results from germline mutations in the E-cadherin gene 
CDH1 92•93. Furthermore, Joss of E-cadherin is associated with the transition from adenoma to 
carcinoma and the acquisition of metastatic capacity 94• Mutations in the tumour-suppressor 
gene APC are frequently detected in colon cancer. Importantly, disruption of cell-cell contact not 
only decreases cellular adhesion, but it also results in altered intracellular signalling. The 
combination of loss of cell adhesion with activation of 13-catenin-mediated transcription might 
explain why mutations in this pathway are found in cancer, although they seem mostly restricted 
to gastrointestinal varieties 85 . 
Besides facilitating escape to and from the circulation by degrading the basal membrane, 
matrix metalloproteases (MMPs) have a significant effect on the ability of tumour cells to grow in 
a secondary site 95 . Both upregulation of MMP expression or downregulation of endogenous 
MMP inhibitors such as TIMP1 can be obseNed in human cancer 96. 
The finding that genetic analyses of biopsies from breast carcinoma in situ (i.e. restricted to 
one site) can already predict whether this tumour will eventually metastasise, has prompted 
some to state that 'invasion and metastasis' does not represent a cancer hallmark but merely 
emerges (or not) from the other hallmarks 97•98. However, it could also be that, since the 
metastasis phenotype actually encompasses a whole set of acquired capabilities, this hallmark 
is dependent on two distinct determining factors. It is probable that part of the capabilities for 
invasion are provided by other pathways, such as Ras activation, which also influences 
cytoskeleton mobility, but other capabilities so far appear to be unrelated to the remaining 
pathways, such as MMP expression. If the stochastic selected mutations in the hallmark 
pathways described previously represent the most favourable setting for a tumour cell to invade, 
then additional capabilities are likely still needed to degrade the basal membrane, intra- and 
extravasate and home in a new tissue. In this setting, such capabilities could be attained by just 
a single mutation in e.g. an MMP-1 regulator. But when the necessary alterations in the pathways 
of the other hallmarks have taken place at an unfavourable level, for instance by activation of a 
downstream activator of Ras instead of Ras itself, this would amount to a whole set of additional 
mutations that must be acquired by this tumour to make invasion possible. The chance of 
acquiring all these new mutations versus the acquisition of only a few could be the determining 
factor that predicts whether this particular tumour will be able to metastasize. It could even be 
that certain mutations in other hallmark pathways are incompatible with invasion. In any case 
further research is needed to establish exclusive alterations for invasion/metastasis that cannot 
be achieved by alterations in the other hallmark pathways, which would then validate the 
existence of the cancer hallmark, 'invasion and metastasis'. 
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Genetic instability 
Preventing the fixation of mutations 
Endogenous DNA damage occurs at a high frequency, whether base loss by spontaneous 
hydrolysis of DNA glycosyl bonds 99, pyrimidine dimerization elicited by UV light 100 , or breakage 
of a double-stranded DNA molecule due to ionizing radiation 101 . As many mutations result in 
loss of function or even lethality, repair of these lesions is crucial to a cell's survival. It is also 
important to finish the repair before a cell enters S phase and the mutations become 'fixed', i.e. 
passed on to a daughter cell unable to recognise nor repair the mutation. Different types of DNA 
lesions are recognised and repaired by different sets of proteins; for instance, bulky DNA 
adducts such as UV photoproducts are resolved by nucleotide excision repair (NER), and 
double stranded breaks by homologous recombination or non-homologous endjoining. Usually, 
DNA damage sensors continuously 'scan' the DNA for aberrancies and subsequently recruit the 
repair machinery in a local fashion, ensuring that the damage is repaired quickly. However, if the 
repair is slow due to multiple lesions at one site or genomic localisation, a global DNA damage 
response is triggered (also termed DNA damage checkpoint), by activating a signalling cascade 
involving Rad53p and Chk1 p that arrests cell-cycle progression until repair has occurred 102•103. 
Stacking the deck 
The concept that the genesis and progression of cancers are based on natural selection of 
stochastically acquired mutations implies that de novo mutations need to occur frequently. This 
process might be accelerated by loss of DNA repair functions and checkpoints, for instance by 
p53 mutation, but also other genomic caretaker proteins are found to be lost in cancer 104. 
Indeed, most cancers exhibit not only subtle genetic alterations but also dramatic karyotypic 
changes, including gain and loss of chromosomes, gross chromosomal rearrangements, and 
amplification or deletion of DNA segments. However, the extent to which genomic instability is a 
prerequisite for tumour development remains unclear, as it could be a mere consequence of a 
tumourigenic event such as telomere erosion. And although many tumours show genomic 
instability, others are found to have relatively stable genomes 2. Therefore, an intense debate is 
currently ongoing about the role of genetic instability in cancer 105 . 
Some state that a mutator phenotype is required to obtain all necessary mutations conveying 
the former cancer hallmarks within a human life time 106 . The difficulty in determining the mutation 
rate in normal cells coupled with new insights into the number of cell divisions necessary to 
reach a certain tumour mass (see section on limitless replicative potential) have prompted others 
to favour the idea that normal mutation rates would be sufficient to transform a normal cell into a 
malignant one 67. This idea is supported by studies that fail to detect gross chromosomal 
abnormalities in premalignant human cancer 107 , suggesting that genomic instability is not 
involved in the initiation of cancer. 
Convincing evidence for the opposite view, however, comes from studies by Lengauer and 
Vogelstein 108-111 . They compared the accumulation of gross chromosomal changes in two types 
24 
Cancer hallmarks 
of colon cancer cells: those with a mismatch repair defect and those without. Cancer cells with a 
mismatch repair defect contained a normal chromosome number even after the course of many 
cell divisions. In contrast, cells that had become cancerous due to other mutations acquired 
chromosomal changes 10 to 100 times faster than the mismatch repair defective cells. If 
genomic instability would have been a consequence of malignancy, the mismatch repair 
deficient cells should also have displayed chromosomal disarray over time. Moreover, this group 
did detect major chromosome abnormalities in biopsies of very small precancerous colon 
adenomas. These data support that an increased rate of mutation, achieved by either the 
absence of DNA repair or by cruder measures, is required for the ability of a cell to become a 
tumour cell, rendering genomic instability a cancer hallmark. 
Reconstituting cancer 
To provide further evidence that the genetic alterations associated with the hallmarks of cancer 
are indeed necessary and sufficient to transform normal cells into tumour cells, Hahn and 
coworkers performed a series of elegant reconstitution experiments 112. The minimal required 
elements to enforce tumourigenic conversion of normal human cells proved to be the ectopic 
expression of the telomerase catalytic subunit in combination with an oncogenic allele of H-ras 
and the simian virus 40 (SV40) early region. Not only were these cells no longer dependent on 
adhesion for their growth and had gained an infinite life-span, this combination of genetic 
changes also resulted in in vivo tumour formation in nude mice including an invasive 
phenotype 113• The SV40 early region encodes at least two proteins: the large T (LT) and small t 
(st) antigens. The L T oncogene is known to inactivate both p53 and RB, but it also has additional 
functions whose significance are largely unknown 114• Replacement of LT by two other viral 
oncogenes known to inhibit p53 and RB, human papilloma virus proteins E6 and E7, 
respectively, was not sufficient to convey tumourigenic growth to primary cells in the presence of 
active Ras and telomerase activity. Addition of st antigen on the other hand was again able to 
complement Ras, telomerase and the disruption of p53 and RB, in inducing the oncogenic 
phenotype, indicating that at least one other pathway is perturbed by both LT and st that is 
required for tumorigenesis 112. Although the myriad functions of these viral proteins makes it 
difficult to determine the exact pathways involved, these studies nevertheless indicate that 
perturbation of a limited number of pathways is sufficient to transform normal cells into fully 
malignant cells. They also convincingly showed that it is unlikely that the reconstituted tumour 
cells had acquired additional mutations in their culture time prior to the injection into nude mice, 
since there were no signs of genetic instability 115 . This does not argue against the view that 
genomic instability is a cancer hallmark, because in this case, all mutations have been directly 
introduced, in contrast to the selection process in regular carcinogenesis where only 
occasionally a necessary mutation arises amidst thousands of irrelevant mutations. Of note, 
these studies have been conducted with human cells in immune-compromised mice, and 
therefore pre.clude any comments on the effect of the immune system on tumorigenesis. 
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Evidence exists that under some conditions, immunosurveillance plays a role in eliminating 
tumour cells, consequently adding an additional selection force to the arising tumour mass. In 
other words, only those tumour cells that have acquired mutations preventing immune attack will 
continue to proliferate. The current debate over whether immune escape is indeed a cancer 
hallmark is summarized in references 116 and 117. In addition, the reconstitution studies have 
focused on adherent cells and it can be envisaged that the acquisition and requirement of 
cancer hallmarks that apply to non-adherent cells, e.g. from the haematopoietic system, differ. 
Not only does a limited number of cancer-hallmark pathways seem to suffice for 
tumorigenesis, but their disruption appears to be required throughout tumour progression to 
maintain the malignant phenotype, despite numerous additional genetic alterations. For 
instance, stable inactivation of oncogenic alleles of K-ras in human pancreatic carcinoma cells 
through use of a viral RNA interference vector led to loss of tumourigenicity (as measured by soft 
agar assays and growth in nude mice) 118. In addition, re-expression of wild-type p53 in tumour 
cells with mutant p53 results in apoptosis, regardless of multiple genetic changes 119·120. Further, 
full-blown pancreatic tumours in transgenic mice caused by an inducible myc ongene 
completely disappeared after removal of ectopic myc expression 121 . These studies reveal that 
tumour cells remain dependent on their malignant alterations; a fact that may provide an 
opportunity for therapeutic approaches targeting tumour cells specifically while leaving normal 
cells unharmed. 
Molecular therapy of cancer 
Although the differences between tumour and normal cells appear subtle, based as they are on 
the deregulation of normal cellular processes, significant qualitative and quantitative differences 
have now been identified. Not only do tumour cells remain critically dependent on the acquired 
mutations, but they also lose flexibility in responding to altered circumstances and cytotoxic 
insults. Due to continuous activation, overexpression or complete ablation of certain factors, 
responses can no longer be accurately modified. This inflexibility most likely contributes to the 
therapeutic window achieved with chemotherapy and radiation. Notwithstanding the dramatic 
improvement in survival of cancer patients since the implementation of these drugs, new 
therapies are still required to be able to successfully treat all cancer patients. Besides their dose-
limiting toxicity, which prevents total eradication of certain tumours, chemo- and radiation 
therapy mainly depend on intact apoptotic pathways to exert their anticancer activity. Because 
these same pathways need to be inactivated in one way or another to allow malignant 
progression in the first place, many tumours are rendered resistant to this type of therapy. 
Studying the molecular basis of cancer, resulting in the recognition of mandatory alterations in a 
restricted number of key pathways for the establishment of all tumours, has allowed the rational 
design of cancer therapies that should be more refined and more effective. Succesful examples 
of such molecular therapeutic approaches will be described in the following paragraphs. In 
addition, the identification of proteins that selectively kill tumour cells can contribute to 
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understand carcinogenesis further, and in turn provide an opportunity for the development of 
novel therapeutic strategies, as will be exemplified in the second half of this chapter. 
Tumour-specific therapies 
Tyrosine kinase inhibitors 
The drug trastuzumab (Herceptin) serves as the first success story for therapeutic strategies 
based on molecular studies of oncogenes. An accidentally cloned gene encoding a growth 
factor receptor for endothelial growth factor (EGF), termed HER2 (human EGFR-related gene), 
resulted in the discovery that the gene encoding the HER2/neu receptor tyrosine kinase is 
amplified up to i 00-fold in the tumour cells of about 30% of patients with invasive breast 
cancer 122. Genentech Inc. developed an antibody directed to the extracellular domain of HER-2, 
called trastuzumab, which showed good antiturnour activity in preclinical models, particularly 
when used in combination with a second agent such as doxorubicin or paclitaxel (Taxol) 123. The 
therapeutic antibody appears to work by several mechanisms including internalization and 
down-regulation of HER-2 receptor, induction of cell-cycle inhibitors such as p27 and immune-
mediated responses 124 Trastuzumab is well tolerated by patients and the drug was approved by 
the U.S. Food and Drug Administration (FDA) in i 999 for the treatment of HER-2-positive breast 
cancer 125. Responses of up to 60 to 70% have been noted for trastuzumab in combination with 
paclitaxel. Improved efficacy was also achieved in patients treated with both trastuzumab and 
doxorubicin, but this combination also results in greater cardia-toxicity 126, likely because HER-2 
is expressed in heart tissue and doxorubicin is known to be a cardio-toxic agent 127. 
Another tumour-specific elevation of tyrosine-kinase activity was discovered in chronic 
myelogenous leukaemia (CML) resulting from a chromosomal translocation, known as the 
Philadelphia chromosome, that creates a fusion of the Bcr and Abl genes. A pharmacological 
screen aimed at finding a selective inhibitor of this tyrosine kinase yielded a phenylamino 
derivative that was further refined into the compound called Glivec (or Gleevec or imitanib) 128. An 
in vitro screen identified two other kinases effectively inhibited by Glivec, namely c-KIT and 
PDGFR. Glivec was shown to prevent downregulation of the cell-cycle inhibitor p27 by BCR-ABL 
and to induce apoptosis in cells from CML patients by suppressing the activation of the 
antiapoptotic Bcl-xL protein 129•130• After corroboration of preclinical data with impressive 
responses in clinical trials for CML, Glivec was approved by the FDA in 2001 131 . The activity of 
Glivec against c-KIT, eliminating its constitutive MAPK and PKB activation, and against PDGFR, 
inhibiting autocrine growth factor stimulation by tumourigenic PDGF expression, is being 
evaluated for the treatment of other tumour types such as gliomas and ovarian cancer 128 . Two 
other inhibitors of a distinct tyrosine kinase -the epidermal-growth-factor-receptor (EGFR)- called 
Tarceva and lressa, are currently in phase Ill clinical trials 127•132. 
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Farnesyltransferase inihibitors 
Activating oncogenic mutations of the ras gene are common in cancer, occurring in 30% of solid 
tumours in adults. Inhibitors of the enzyme farnesyl protein transferase prevent an essential 
lipidation of the Ras oncogene proteins; without this lipidation, Ras signalling is inhibited. 
However, at least 20 other proteins have been identified so far which are also substrates for 
farnesyl transferase, including RhoB and downstream effectors of PI3K, thus farnesyltransferase 
inhibitors (FTis) cannot be considered Ras-specific drugs 127·133•134. Whether inhibiting the 
farnesylation of other proteins is involved in mediating the transformation-selective properties of 
FTis has yet to be established. Paradoxically, FTis had little effect on the proliferation of 
untransformed cells, although the function of wildtype, farnesylated Ras protein is important for 
their proliferation 134. In patients, general farnesyltransferase inhibitors showed some activity 
against gliomas but also caused substantial toxicity 7. Specific inhibitors of FT have yielded more 
encouraging results in phase I and II clinical trials with up to 30% response rates in haematologic 
malignancies trials. Although the clinical effects are more modest than was expected based on 
the preclinical data, the toxicity is manageable, and several FTis are currently undergoing further 
clinical testing in combination with chemotherapeutics and radiation 135•136. 
Targeting apoptosis pathways 
Unfortunately, one of the requirements for cancerous growth, namely inactivation of apoptotic 
pathways, concomitantly limits the effectiveness of therapies that exert their anticancer activity 
via the induction of apoptosis. Particularly, specific mutations in p53 have been linked to primary 
resistance to doxorubicin treatment and early relapse in patients with breast cancer 137. Reduced 
Bax expression was also associated with a poor response to chemotherapy 138. Furthermore, it 
has been shown that Bcl-2 expression confers resistance to many kinds of chemotherapeutic 
drugs and irradiation 139-141 . 
On the other hand, the blockage of apoptosis in tumour cells is not necessarily robust. Many 
tumour cells barely survive and they are highly sensitized to apoptosis due to a barrage of death 
signals that must be continuously overruled 2. The consequence of an apoptotic signal might 
therefore be quite different for normal cells, which enjoy a stress-free environment and the 
presence of survival signals to counteract any activation of the death programme, compared to 
the labile state of cancer cells. The concept that apoptosis is the cumulative response to many 
signals, indicates that loss of any of these signals might enhance survival by reducing the 
apoptotic burden below the threshold that is necessary for the execution of death, thus enabling 
tumour cells to continue growing 48 . Conversely, this situation also means that adding an extra 
insult might tilt the response towards apoptosis in tumour cells, while remaining harmless in 
normal cells. Despite their toxicity, chemotherapy and irradiation obviously show some 
selectivity, which can be attributed to the apoptosis-primed state of tumour cells. Interestingly, 
molecular studies have demonstrated that apoptotic pathways are in part redundant 142-144, 
eliciting research to design therapies tailored to particular tumour types acting on still-active 
components. 
28 
Molecular therapy of cancer 
The death-receptor (DR) mediated apoptosis programme provides a target for more tumour-
specific therapy. Death factors such as FasL and TNF-related apoptosis-inducing ligand (TRAIL) 
are primarily involved in the apoptosis-inducing activities of immune effectors such as natural 
killer cells and cytotoxic lymphocytes against virus-infected or oncogenically transformed cells. 
Some of the death receptors, however, are not able to transduce signals. Instead, they seem to 
act as decoys that compete for the interaction of death factors with their signalling receptors 145. 
In humans, two signalling death receptors, DR4 and DR5, and two decoy receptors, DcR1 and 
DcR2, have been identified. For unknown reasons, although the death receptors are expressed 
ubiquitously, normal cells are enriched for decoy receptor expression. As a result, soluble TRAIL 
induces apoptosis in a broad spectrum of human cancer cell lines both in vitro and in vivo, as 
well as in primary tumour cells derived from patients 146. Like TRAIL, monoclonal antibodies that 
functionally engage DR4 or DR5 also show antitumour activity in certain xenograft studies. Most 
normal human cell types tested so far, including epithelial, endothelial, fibroblastic and smooth 
muscle cells, were not affected by TRAIL. Some other normal cell types, such as astrocytes, 
hepatocytes and keratinocytes, however, were sensitive to apoptosis induction by TRAIL under 
certain circumstances. Several recombinant versions of TRAIL have been generated in the hope 
for a less toxic variant and are currently under preclinical assessment 147 . 
Targeting telomerase 
The fact that cancer cells are dependent on telomerase-mediated rescue of short telomeres has 
initiated the development of telomerase inhibitors to selectively target tumour growth. Anti-
telomerase oligonucleotides have been shown to effectively inhibit proliferation of cancer cells in 
vitro, and similar oligomers have demonstrated low toxicity and reasonable bioavailability in 
humans 148. However, since telomerase expression is not exclusively restricted to tumour cells, 
some side effects can be anticipated, although stem cells deep in the renewal tissues proliferate 
only intermittently 149 and typically have longer telomeres than tumour cells. Nevertheless, 
preclinical data should preclude detrimental effects to stem cells prior to clinical phase entry. 
Furthermore, telomerase inhibitors are unlikely to produce acute anti-proliferative effects due to 
the lag-time needed for telomere erosion. Rather telomerase inhibitors are expected to be most 
effective in combination with or as adjuvant to other conventional or experimental cancer 
treatments 150 . Alternatively, approaches have been designed to exploit the relative cancer-
specificity of telomerase expression without targeting telornerase itself. These include the use of 
the hTERT promoter to selectively allow viral replication of a lytic virus or to drive the expression 
of toxic genes (see section "Cancer gene therapy") 150 In addition, hTERT represents a nearly 
universal tumour-associated antigen that has been shown to elicit cytotoxic T lymphocyte 
responses in patients 151 -153 , and a vaccination protocol using autologous dendritic cells loaded 
with a hTERT-peptide is now tested in phase I clinical trials 154. 
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Anti-angiogenesis 
Cancer cells begin the recruitment of new blood vessels early in tumoriogenesis 155. The ensuing 
continuous presence of angiogenic factors prevents the tumour endothelium from maturing into 
a developed vessel network, and tumour vessels show an abnormal morphology, with an 
irregular diameter, thin walls and leakiness. The relative deficiency of supporting cells such as 
pericytes could also contribute to these morphological features in tumour vasculature. 
Importantly, tumour and normal vasculature differ also at the molecular level 156. The tumour-
specific angiostatic effects of compounds such as Endostatin and Angiostatin, first described by 
Folkman, are thought to act on these molecular differences 157• A recent dose-finding trial with 
human Endostatin (rh-Endo) in patients with refractory solid tumours had variable effects on 
tumour blood flow and caused a significant increase in endothelial and tumour cell apoptosis, 
but clear anti-cancer effects were not observed 158 . 
Another potential target for anti-angiogenic therapy is VEGF, an important mediator of 
angiogenesis and maintenance of tumour vasculature. Recently, a specific antibody called 
bevacizumab (Avastin) has been developed to neutralize this mediator. Phase II clinical trials for 
metastatic breast and colorectal cancer showed moderate toxicity, including hypertension and 
thrombosis. Objective responses were uncommon (- 9%), but significant prolongation of life 
after treatment was observed 159. 
Yet other potential angiogenesis targets are the matrix metalloproteases (MMPs), proteins 
involved in multiple aspects of tumour physiology including tumour cell metastasis and 
endothelial cell invasion m Unfortunately, there are more than 20 different MMPs and only 
limited data on their individual targets, distribution and contribution to carcinogenesis. Together 
with the absence of efficacy markers, these complications likely contributed to the disappointing 
results seen in human trials of MMP inhibitors (MPI) so far. Although a significant survival benefit 
was reported for patients treated with marimastat, another trial was prematurely terminated 
because the MPI seemed to stimulate disease progression in patients with pancreatic and small-
cell lung cancer. Hopefully, newly gained insights in the mechanisms of MMPs will allow a better 
design of the current trials with MPis 160, or lead to more specifically-tailored drugs. 
Survivin 
Survivin is a bifunctional protein that suppresses apoptosis and regulates cell division 161 . Its 
expression is among the most tumour-specific of all human gene products, rendering survivin a 
potential drug target 162. Although survivin is expressed during normal foetal development, the 
expression is barely detected in terminally differentiated adult tissues except for testis, thymus 
and placenta. In contrast, it is abundantly expressed in a wide variety of malignant tissues. 
Although its precise function and mechanism of action remain to be elucidated, survivin was 
shown to be a member of the inhibitor of apoptosis protein (lAP) family, and its binding to and 
inactivation of active caspase-9 is dependent on phosphorylation of survivin on threonine 34 
(T34) 163·164_ Interestingly, a mutant of survivin in which T34 is mutated to nonphosphorylatable 
alanine (T34A) disrupts cell division and induces apoptosis when overexpressed in tumour 
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cells 165 , presumably by competing with endogenous survivin for access to the kinase, thereby 
preventing the phosphorylation of the wild-type survivin protein or other crucial substrates of the 
same kinase. Treatment of subcutaneous breast cancer xenografts with replication-deficient 
adenoviruses (see section "Cancer Gene Therapy") expressing survivin(T34A) resulted in an anti-
tumour effect that surpassed that of the drug paclitaxel 165 . In vitro, normal fibroblasts, smooth 
muscle cells and endothelial cells proved refractory to survivin(T34A)-expressing adenovirus 165, 
presumably because endogenous survivin expression in normal cells is minimal. After VEGF 
stimulation, survivin is significantly upregulated in endothelial cells, suggesting that it has a 
function in normal cells as well. Possibly, tumour cells are more dependent on the anti-apoptotic 
stimulus of survivin than are healthy cells. 
Recently, a survivin-derived peptide was found to be a tumour-specific antigen, capable of 
eliciting a specific CTL response in vitro 166. In addition, it was shown that the promoter regulating 
survivin expression is selectively upregulated in tumour cells compared to normal cells, 
advocating its use in cancer gene therapy to drive tumour-specific expression of toxic genes or 
in the creation of a tumour-selective replicative oncolytic virus (see section "Cancer gene 
therapy") 167,16s. 
Melanoma differentiation-associated gene-7 
Melanoma differentiation-associated gene-7 (mda-7) was identified with subtraction hybridization 
as a gene that is upregulated during terminal differentiation of human melanoma cells. 
Subsequently, it was shown that mda-7 expression is lost during progression of melanoma, 
suggesting that downregulation of mda-7 facilitates progression to invasive and metastatic 
changes 169 . Ectopic expression of mda-7 by means of a replication-defective adenovirus 
induced apoptosis selectively in diverse human cancer cells in vitro and in vivo by p53-
independent activation of caspases -9 and -3. In contrast, normal human fibroblasts or epithelial 
cells were unaffected by mda-7 expression 170-172. 
It has been suggested that MDA-7 exploits a hyperactive Ras/MAPK pathway to induce 
transcription of the growth-arrest and DNA-damage (GADD) family of genes. This requirement 
would explain why the apoptosis induction is specific for tumour cells and why, for instance, 
immortalized melanocytes are resistant to overexpression of mda-7 173. However, another group 
showed that adenoviruses expressing mda-7 specifically induce and activate the double-
stranded RNA-dependent protein kinase (PKR), a mediator in antiviral defence, which 
phosphorylates the a-subunit of eiF-2, resulting in termination of translation of viral transcripts 174 
PKR also appears to mediate anti-tumour activity through the activation of multiple transduction 
pathways involved in growth inhibition and apoptosis induction including NF-kB, p53, MAPK and 
FADD 175-m Chemical inhibition of PKR or deletion of the PKR gene by targeted disruption leads 
to inhibition of MDA-7-induced apoptosis, suggesting that the activation of PKR and its 
downstream targets may constitute a critical pathway for MDA-7-mediated apoptosis 174. While 
the mechanism awaits further elucidation, the adenoviral vector expressing the mda-7 gene is 
currently undergoing Phase I clinical trials because of its tumour-selective killing capacities. So 
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far, it has been found to be safe with only mild toxicities and phase II clinical trials have been 
initiated to determine its efficacy 178• 
Heat Shock Proteins 
Heat shock proteins (HSPs) and their co-chaperones have a critical role both in the recovery of 
cells from stress as well as in cytoprotection, guarding cells from subsequent insults. 
Chaperones recognize unstructured regions of proteins and exposed hydrophobic stretches of 
amino acids, and subsequently sequester or refold stress-denatured proteins, preventing their 
irreversible aggregation with other proteins in the cell. In addition to their role in protecting cells 
from stress, nearly all HSPs are constitutively expressed under normal growth conditions, where 
they function to maintain protein homeostasis by regulating the quality control of protein folding. 
Interestingly, cells that have lost their ability to regulate cell growth, such as tumour cells, often 
express high levels of multiple HSPs compared with their normal parental cells 179 . Depletion of 
Hsp90 by geldanamycin or of Hsp70 by antisense methods caused growth arrest or cell death in 
transformed cells, but not in their non-transformed counterparts 18o-182. Thus, high expression of 
these chaperone proteins appears to be a prerequisite for the survival of human cancer cells of 
various origins, although why this is beneficial has yet to be clearly established. One possibility is 
the ability of chaperones to suppress and buffer mutations that occur during the transformation 
process, a characteristic which could promote cell viability and even enhance the growth of 
otherwise mutant cells. In that sense, HSP upregulation may be a hallmark of cancer 
complementary to genome instability, because it allows cells to survive a high load of nonsense 
mutations, thereby increasing the chances for the occurrence of an advantageous mutation. 
Because of their potential role in tumorigenesis, HSPs have been selected as targets for 
molecular therapy. For example, the Hsp90 inhibitor geldanamycin exerts its anti-tumour effect 
by inhibiting the intrinsic ATPase activity of Hsp90, resulting in degradation of Hsp90-client 
proteins via the ubiquitin proteasome pathway. 17 -allylamino-17 -demethoxygeldanamycin 
(17AAG), a geldanamycin derivative, showed good activity and cancer selectivity in preclinical 
models 183•184 and has now progressed to Phase I clinical trials 185 . Second generation Hsp90 
inhibitors are being designed to overcome some of the drawbacks of 17AAG, including limited 
oral bioavailability and solubility. Compounds that target specific functions of Hsp90 may provide 
even greater clinical benefit, and may also contribute to understanding the tumour-selective 
nature of this therapy 186 . 
Cancer gene therapy 
Viruses have been of interest to tumour biologists for decades for a variety of reasons. Initially, 
the existence of oncogenes was revealed by analysis of molecular interactions of proteins from 
tumourigenic viruses like the Rous sarcoma virus and simian virus 40. Since then, several viral 
genes have proven useful in the elucidation of normal and tumour cell signalling. In addition, 
viruses have been employed as transfer vehicles for the delivery of genes in vivo. Currently, the 
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field of cancer gene therapy encompasses a range of strategies and technologies, from direct 
killing of tumour cells based on the intracellular signalling pathways that have gone awry in these 
cells, to eliciting an immune response to tumour antigens. Immunotherapy of cancer depends on 
complex interactions between tumour cells and the immune system, and comprises a distinct 
intellectual challenge that is beyond the scope of this thesis. The former approach, eliminating 
tumours by direct transduction of genes or viruses, comprises three main strategies: the 
compensation of mutations in tumour suppressors and oncogenes, the exploitation of bystander 
effects in so-called molecular chemotherapy and tumour-selective replication. Notwithstanding 
recent advances in the delivery of genes by non-viral methods or other viral vectors such as the 
herpes simplex virus, I will restrict this paragraph to replication-deficient and -competent 
adenoviral vectors. 
Replication-deficient vectors 
The most frequent target for mutation compensation has been p53. Viral vectors can be used to 
introduce the healthy p53 gene into cancer cells in order to induce cell cycle arrest and 
apoptosis. This approach has been widely tested in human trials, and although the safety data 
were excellent, in most cases tumour transduction has been insufficient to achieve clinical 
responses 187. 
The classic example of molecular chemotherapy or gene-directed enzyme prodrug therapy 
is the transfer of Herpes Simplex virus type I thymidine kinase (TK), which catalyzes the 
phosphorylation of systemically administrable non-toxic ganciclovir (GCV) into a toxic metabolite 
that frustrates DNA replication 188. Importantly, GCV-triphosphate can escape producer cells via 
gap junctions and by this means create a bystander effect, allowing cells not directly transduced 
by the vector to be killed 189. In a clinical trial for glioma, patients were randomized to receive Ad-
TK, packaging cells for retrovirus with TK or Ad-LacZ 190. The patients injected with Ad-TK 
survived significantly longer than the other groups, suggesting that clinical responses can be 
achieved even with this relatively basic approach. Considering the highly variable expression of 
the receptor used for adenoviral intemalisation (CAR) on human primary tumours, it seems likely 
that efficacy could be further increased with the enhancement of infectivity 191-1 93, perhaps 
rendering this approach feasible for the local treatment of small tumour nodules. An important 
consideration remains that TK-GCV is not tumour-specific, instead it targets dividing cells, as 
well as mitochondrial DNA, thereby eliciting toxicity in non-dividing but mitochondria-rich 
hepatocytes 194. Thus for this approach targeting of the vector and/or expression of the gene 
would be advisable. 
Conditionally-replicating viruses 
An especially promising approach in cancer gene therapy is the use of replication-competent 
viruses. Their development has been based on the need for more effective tumour penetration. 
In theory, subsequent rounds of replication enable these viruses to penetrate deeper into the 
tumour until all of the cells have been infected. Each infected cell can produce thousands of 
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virions and therefore cause a substantial amplification of the infection, combined with a more 
effective antitumour effect if a lytic virus is used. Obviously, it is crucial to limit the replication of 
the agent to tumour cells. Hence, the identification of the 'cancer hallmark pathways' provided 
new possibilities for the development of conditionally-replicating adenoviruses (CRADs). Both 
adenovirus replication and tumour cell proliferation require the disabling of similar restraints, 
namely to relieve inhibitions on cell division and to evade apoptosis (figure 5). The fact that 
tumour cells have already inactivated some of the inhibitory factors for adenoviral replication 
allows for the design of tumour-selective adenovirus replication. For instance, both adenoviruses 
and tumour cells require a block in p53 function to replicate or proliferate efficiently. 
Adenoviruses eliminate p53 by producing E1 B55K, a protein that binds to p53 and, together with 
another viral protein E4orf6, targets it for destruction 195 . An attenuated adenovirus called mutant 
dl1520 or ONYX-015 lacks E1 B55K and therefore cannot destroy p53. In normal cells, p53 
blocks adenoviral replication, but in cancer cells that lack p53, ONYX-015 can replicate. As 
adenoviruses are lytic, cells allowing replication die in the process. 
The specificity of ONYX-015 for p53-deficient cells has been questioned. It was 
demonstrated that ONYX-015 replicates in some tumour cells that retain wild-type p53 196. 
However, as stated earlier, most tumour cells that retain wild-type p53 are likely to have other 
defects in the p53 pathway. For instance in tumour cells that lack ARF, p53 is not activated 
during ONYX-015 infection, and therefore cannot block replication. Re-introduction of ARF in 
such cells induced high levels of p53 and consequently inhibited ONYX-015 replication but not 
wild-type adenovirus replication 197. Furthermore, ONYX-015 does not always replicate efficiently 
in tumour cells that lack p53. This inefficiency may be due to additional functions of E1 B55K for 
the virus other than blocking p53. These functions affect selective export and translation of viral 
mRNAs during infection. Some tumour cells (such as C33a cervical carcinoma cells) 
complement these other functions of E1 B55K better than others (such as U20S osteosarcoma) 
198
• Recently, adenovirus mutants have been generated that specifically target the p53 binding 
function of E1 B55K while preserving its role(s) late in the viral life cycle 199. In cell culture studies, 
these viruses demonstrated a replication capacity that surpassed that of ONYX-015. 
While in vitro studies were carried out to obtain more information on the potency and 
selectivity of ONYX-15, clinical studies were already initiated. Treatment of patients with head 
and neck cancer revealed that the agent is safe, but objective tumour responses were seen in 
fewer than 15% of the patients. Most likely, the clinical response has been limited by poor 
distribution of the injected virus, which could be due to the high proportion of stromal and fibrotic 
tissue in these tumour types, and/or to insufficient complementation of the additional E1 B55K 
functions. In contrast to its limited effects as a single agent ONYX-015 has shown promising 
results in combination with chemotherapeutics. After treatment with ONYX-015 combined with 5-
fluorouracil and cisplatin, objective responses (>50% reduction in tumour size) were seen in 
63% of patients with recurrent head and neck cancer, and 26% had complete responses. A 
Phase Ill trial is now in progress 200• 
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Figure 5. Common alterations in the RB and p53 pathway in adenovirus-infected cells and 
tumours. 
Adenovirus E1A binds the tumour suppressor RB, thereby preventing it from repressing E2F. Subsequently, E2F 
activates host target genes that are involved in the S-phase of the cell cycle and the adenovirus E2 region. In tumours, 
the RB pathway can be inactivated in various ways, for instance by mutation of RB or inactivation of INK4A (see section 
"Growth control"). In addition, protein E7 of the human papillomavirus (HPV), implicated in cervical cancer, can bind 
and inhibit RB. One of the genes that E2F activates is Arf, an inhibitor of the oncoprotein MDM2 (see section "Cell 
suicide"). Inhibition of MDM2 results in upregulation of p53, which prevents both viral replication and tumour 
progression. Adenovirus E1 B 55K binds and inhibits p53 so that replication can proceed. P53 itself is mutated or 
deleted in around 60% of tumours and can be targeted for destruction by HPV E6 protein. Additionally, inactivation of 
Arf or upregulation of MDM2, resulting in loss of p53 function, are also found in human cancer. Adapted from ref 198. 
Another adenovirus protein, E1A, allows for the targeting of the RB pathway, as E1A binds and 
neutralizes RB and its relatives. As described, tumour cells need to inhibit RB to activate the 
transcription factor E2F, which in turn drives expression of genes involved in S-phase. 
Adenovirus, on the other hand, has hijacked E2F to activate expression of the E2 region of the 
viral genome. Thus, normal cells with functional RB should be resistant to E1A-defective viruses, 
whereas malignant cells should permit replication. Several E1A-defective viruses have been 
described and tested in preclinical models 201 . Early generation viruses, although not replicating 
in normal cells, still expressed some viral genes and thereby caused toxicity. Newer vectors not 
only contain a deletion within the E1A-CR2 region (essential for RB binding), but are more 
stringently dependent on RB inactivation due to replacement of the viral E1A and E4 promoter 
regions with the human E2F1 gene promoter. 
The combination of these features in this virus called ONYX-411 was essential for the 
selective killing of tumour cells in vitro, reduced in vivo systemic toxicity, and conveyed a survival 
benefit to mice carrying human breast cancer xenografts following systemic administration 202. 
Although E1 A has additional functions, such as binding p300 and activating the E4 region of the 
genome, in vitro studies demonstrated that ONYX-411 had a higher cell killing capacity than did 
ONYX-015, suggesting that the additional E1 B55K functions are more important for viral 
replication than are the additional E1A functions. 
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The potency of CRADs can be further increased by engineering them to overexpress the 
adenovirus death protein (ADP): this increases cell lysis and viral release, rendering the virus 
more active in vivo than an E1A mutant alone. Viruses that exploit these features are under 
development 198. Moreover, studies in preclinical models demonstrated that the oncolytic effect 
of CRADs directly correlates with infectivity. Therefore, the replicative potential and tumour-
specificity of CRADs are important determinants not only of their clinical efficacy, but also of their 
efficiency of progeny release and re-infection 200. 
An alternative approach to CRADs is the control of adenoviral-essential genes by tissue- or 
tumour-specific promoters. For example, the promoter/enhancer elements for prostate-specific 
antigen, L-plastin and a-fetoprotein, have been used to achieve selective expression in prostate, 
breast and hepatocellular carcinomas respectively 203-205. In contrast, control of E1A expression 
by the E2F promoter targets a wide range of tumour types. So far the efficacy of this 
tumour/tissue-specific promoter approach has been limited, as it is dependent on the promoter 
activity in target tumours and in normal tissues, which leads to reduced efficiency of viral 
replication in the tumour and reduced specificity 206 . 
Viruses + Cancer 
Tumour-tropism of viruses 
For one reason or another, many viruses have a natural tropism for tumour cells. It has been 
suggested that some RNA viruses take advantage of tumour-associated defects in the interferon 
response pathway. As an antiviral defence, cells activate the kinase PKR, resulting in termination . 
of translation of viral transcripts. However, in cells with an activated Ras signalling pathway, as is 
the case for most tumour cells, PKR kinase activity is impaired, allowing viruses such as reovirus, 
vesicular stomatitis and probably also the Newcastle disease virus to replicate 20a.208. 
Parvoviruses were first thought to be carcinogenic because they were isolated from tumours. 
However, they turned out to have tumour-tropism due to the fact that in normal cells, the single-
stranded viral genomes trigger a p53-dependent DNA-damage response that blocks cells in G2, 
preventing replication. Hence, replication in p53-deficient tumour cells will be more efficient 209 . In 
addition, free E2F, occurring in replicating cells and in cells with a deregulated RB pathway, 
stimulates parvovirus promoter activity 210. Although the precise mutations targeted by 
parvoviruses are unknown, it was shown that malignant transformation increases the sensitivity 
of these cells to killing by the non-structural proteins of parvovirus H-1 211 .212. By definition, the 
presence of these viruses in tumour masses demonstrates that they are not potent enough to kill 
all tumour cells 218 But their tumour-selective replication renders them suitable as replication-
competent vectors for more toxic genes. 
36 
Viruses + cancer 
Viruses as a source of anti-tumour activities 
Adenovirus type 2 (Ad2) early region 4 ORF 4 (E4orf4) is a small 14-KD Ad protein that has 
multiple functions during Ad infection. In mammalian cells, expression of Ad2 E4orf4 triggers a 
p53-independent cell death programme that is restricted to transformed cells. Over 40 human 
cancer cell lines representing most major classes of human tumours were sensitive to E4orf4-
induced cell death. In addition, E4orf4 had little effect on primary human cell types derived from 
various tissues. The effect of E4orf4 on tumour growth in vivo was studied by injection of a 
tetracycline-inducible E4orf4 adenovirus vector in human tumour cell lines xenografted on nude 
mice. In two different cancer cell types, expression of E4orf4 caused a reduction in tumour size 
more significant than that obtained using an adenovirus vector expressing p53 214. 
Cell death induced by Ad2 E4orf4 is associated with classical apoptotic hallmarks, including 
nuclear condensation, cell shrinkage and externalization of phosphatidylserines 215. However, 
caspase activation in E4orf4-induced apoptosis seems to be required in some cell types but not 
in others 216, suggesting that E4orf4 may induce multiple death programmes. 
Initial studies demonstrated that binding of E4orf4 to a B subunit of protein phosphatase 
PP2A, causing partial dephosphorylation of certain transcription factors, was important for the 
induction of cell death in tumour cells. Recently, in Saccharomyces cerevisiae, E4orf4 was 
shown to target PP2A to the anaphase-promoting complex/cyclosome (APC/C), leading to 
APC/C inactivation. As a result, yeast cells were arrested at the G2/M phase of the cell cycle 217. 
Similarly, E4orf4 can induce G2/M arrest in mammalian cells prior to apoptosis. However, 
mutational analysis demonstrated that binding to PP2A is necessary but not sufficient for the 
induction of apoptosis in mammalian cells, indicating that E4orf4 possesses one or more 
additional functions required for cell killing. Gingras et al. found that Ad2 E4orf4 induced a Src-
mediated cytoplasmic apoptotic signal requiring tyrosine phosphorylation of E4orf4, which 
rapidly led to caspase-independent membrane blebbing and cell death 218. A separate paper 
demonstrated an additional, Src-independent nuclear cell death induced by E4orf4 independent 
of E4orf4 phosphorylation 219 . No clinical data on E4orf4 have been described yet, but further 
elucidation of the activity of this tumour-specific viral protein could contribute to our knowledge 
of tumour genesis. 
Apoptin 
The identification of tumour-specific pathways as described in the first part of this chapter 
provided an explanation for the existence of proteins with tumour-specific activities, which in turn 
led to the development tumour-specific therapies. That targeting of these oncogenic pathways 
can indeed lead to clinical success is demonstrated by the inhibition of tyrosine kinases. 
Approaches based on other pathways as exemplified by farnesyl transferase inhibitors, TRAIL 
and GRADs, indicate that the scope of cancer-specific therapies can be greatly extended, 
hopefully culminating in efficacy and selectivity for different tumour types. Even though tumours 
share common alterations that can be targeted by a tumour-specific agent, it is unlikely that one 
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therapy, 'the magic bullet', will be effective against all tumour types for at least two reasons. First, 
tumour-type specific differences in achieving the different traits (genetic road-maps) render 
therapies based on a specific mutation rather than the outcome of the whole pathway suitable 
for only a subset of tumours. Second, the therapeutics are critically dependent on their 
pharmacokinetics and distribution efficiency in certain tissues. Thus, the development of multiple 
strategies remains necessary for the aim of treating all cancers, but the fact that these strategies 
can now be based on specific tumour characteristics will hopefully result in a complete arsenal 
of effective anti-tumour agents with dramatically reduced toxicities. 
The demonstration that tumour-specific treatment has a molecular basis and is in fact 
feasible has given a boost to research involving proteins with inherent tumour-selective killing 
abilities, which has in turn expanded our knowledge of the hallmarks of cancer and provided 
potential anticancer candidates. Examples have been given of depletion of tumour-essential 
proteins such as survivin or heat-shock proteins, or the introduction of apoptosis-inducing 
proteins such as cellular mda-7 and viral E4orf4. Another protein that induces tumour-selective 
apoptosis, called Apoptin (apoptosis-inducing protein), was described by Danen-van Oorschot 
et al. in 1997. The current data on the mechanism of action of Apoptin will be described below. 
Origin of Apoptin 
The chicken anaemia virus (CAV) belongs to the family of Gyroviridae. It has a single stranded 
genome of 2.3 kb that is transcribed into a single, polycistronic mRNA of 2.1 kb encoding three 
proteins, YP1, YP2 and Apoptin (VP3) (figure 6). The genes for these proteins are partially or 
completely overlapping but have distinct open reading frames, resulting in three different 
proteins without sequence similarity 220. No homologues in any other viruses or living organisms 
have been detected thus far. YP1 is 51.6 kD and thought to be the only capsid protein 221 . YP2 
(24.0 kD) has been implicated in virus assembly 222. A recent report describes YP2 to be a dual-
specific phosphatase, capable of removing phosphate groups from both tyrosine residues and 
serine/threonine residues in vitro 223 . If and how this function is important in CAY biology is not yet 
clear. The function of YP3 (13.6 kD) for the virus also remains to be clarified. Mutation of the last 
11 amino acids blocks CAY replication in vitro, suggesting that YP3 is essential for CAY 
replication (Noteborn, unpublished results). 
In young chickens, CAY mainly targets haemocytoblasts in the bone marrow and immature T 
cells in the thymus 224. Not much is known about the replication cycle of CAY or how it initiates 
the destruction of its target cells. Apoptotic bodies, however, were detected in thymus cells from 
CAY-infected chickens with electronic microscopy and in cultures of CAY-infected 
lymphoblastoid cell lines. Agarose gel electrophoresis of DNA extracted from thymuses of CAY-
infected chickens and from infected cell lines showed the characteristic pattern of apoptosis-
specific DNA laddering. Early after infection, Apoptin expressed by CAY shows a finely speckled 
distribution in the nucleus, co-localizing with chromatin. At the same time, it can be detected in 
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Figure 6. CAV genome. 
The double-stranded, circular replicative intermediate of CAY is represented by the double lines. The single line depicts 
the polycistronic mRNA. The three open-reading frames VP1, VP2 and Apoptin (VP3) are indicated by square boxes, 
with the numbers designating the nucleotide positions. 
perinuclear structures. During infection, Apoptin progressively concentrates into nuclear 
aggregates that partially co-localize with the apoptotic DNA 225• In transfection assays in vitro, the 
expression of Apoptin alone was found to be sufficient for induction of apoptotic morphology 
and DNA laddering of lymphoblastoid cell lines 226• Subsequently, Apoptin was shown to elicit 
apoptosis in a variety of human and rodent tumour cells as well 227• 
Apoptin characteristics in tumour and normal cells 
Apoptin is a protein of 121 amino acids that contains two nuclear localisation signals and a 
putative nuclear export signal (figure 7). The metazoan genome does not encode any proteins 
with homology to Apoptin. Because Apoptin is able to engage the apoptotic machinery in 
mammalian cells, probably via a functional interaction with cellular proteins, it is possible that 
analogues do exist. At present, these functional homologues are difficult to identify, as computer 
analysis of the Apoptin sequence predicts not much structure, a finding corroborated by circulair 
dichroism (CD) spectra 228 . Moreover, resolving the molecular structure of Apoptin by either 
nuclear magnetic resonance or crystallography has proved unsuccessful so far. 
Currently, over 50 different tumour cell lines have been tested in transient transfection assays 
and all were sensitive to apoptosis induction by Apoptin. Remarkably, primary cells were not 
killed by Apoptin. These include human fibroblasts, keratinocytes, hepatocytes, mesenchymal-
and CD34+ haemotopoietic stem cells, endothelial and smooth muscle cells (ref 229, 230 and 
Zhang, unpublished data). Analysis has been restricted by the limited life span and by the 
inefficiency of transduction of these primary cells in vitro. However, expression of Apoptin in a 
limited number of cultured cells could be achieved by transfection or microinjection of DNA or 
recombinant protein and, in all cases, there was no, apparent apoptosis in the time span wherein 
all tumour cells had already perished due to Apoptin expression. Moreover, the localisation of 
Apoptin strikingly differed between tumour and normal cells; whereas Apoptin was expressed 
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Figure 7. Amino acid sequence of Apoptin. 
Several slightly differing variants have been cloned worldwide; depicted is the one used in this thesis. Amino-acids 
1-121 of Apoptin are shown in single-letter code, the putative NES is indicated by a single line, the putative NLSs are 
underlined by bold lines. The phosphorylation-target threonine 1 08 is enlarged and bold. 
mainly in the nucleus of tumour cells it resided predominantly in the cytoplasm of normal cells. 
Redirecting Apoptin to the nucleus in normal cells, either by fusion to the SV40-NLS or direct 
microinjection of recombinant protein, did not result in apoptosis 231 , Danen-van Oorschot, in 
preparation). In tumour cells, truncation of the C-terminal 11 amino acids of Apoptin, containing 
one nuclear localisation signal (NLS), strongly reduced the activity of Apoptin, and also changed 
its localisation from mainly nuclear to more cytoplasmic 229•232. These data suggest that nuclear 
localisation of Apoptin is required for apoptosis induction, but is not sufficient 
Interestingly, microinjection of Apoptin into the nucleus of tumour cells resulted in delayed 
apoptosis, suggesting that Apoptin must go through the cytoplasm before entering the nucleus, 
possibly to target a cytoplasmic protein or acquire a necessary modification. In fact, it was 
recently demonstrated that Apoptin is post-translationally modified specifically in tumour cells. 
Metabolic 32P-orthophosphate labelling revealed phosphorylation of Apoptin after ectopic 
expression in a variety of transformed and tumour cells, while no detectable phosphorylation of 
Apoptin by their normal cell counterparts was observed 233. The phosphorylation was eventually 
determined to occur on threonine 108 (figure 7). A mutant Apoptin(T1 08E) was generated with a 
glutamic acid replacing threonine 108 to mimic constitutive phosphorylation and expressed in 
normal cells. The negatively charged amino acid at position 108 conferred both nuclear import 
and apoptosis induction in primary fibroblasts and mesenchymal stem cells. As expected, both 
wild-type Apoptin and a mutant Apoptin containing an alanine residue at position 108 (T1 08A) 
remained primarily in the cytoplasm and did not induce apoptosis in these cells 233• These data 
indicate that the machinery needed for Apoptin to induce apoptosis is present in both tumour 
and normal cells, but that the kinase responsible for the phosphorylation of Apoptin is 
specifically active in tumour cells. However, when non-phosphorylatable mutants were 
expressed in tumour cells, cell death was reduced but still occurred (Rohn, unpublished 
observation), suggesting that a phosphorylation-independent pathway exists that enables 
Apoptin to induce apoptosis. 
Indeed, mutational studies with Apoptin are also consistent with the idea that two separate 
death domains exist. Specifically, an Apoptin mutant consisting of the C-terminal amino acids 
80-121, containing both NLS sequences and the phosphorylation site, localised to the nucleus 
and was capable of inducing apoptosis in tumour cells. In contrast, amino acids 1-69 of Apoptin 
displayed a cytoplasmic localisation when expressed in tumour cells and had mild apoptotic 
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activity. However, when fused to an SV40-derived nuclear localisation signal, the N-terminal 
domain of Apoptin induced robust apoptosis 231 and Danen-van Oorschot, in preparation). This 
domain could be responsible for the cell death observed with the non-phosphorylatable mutant 
of Apoptin. Indeed, when the N-terminus is deleted, the apoptosis induction by the C-terminal 
half of Apoptin is completely abrogated when the threonine residue is replaced by an alanine 
(Rohn, unpublished data). 
The fact that normal cells are refractory to Apoptin, whereas Apoptin is capable of triggering 
apoptosis in all tumour cell types tested so far, suggests that a tumour-specific pathway allows 
the apoptosis induction by Apoptin. Which pathway this is remains to be established. It was 
shown that two to three days after transient expression of the SV40 large T antigen in primary 
fibroblasts or mesenchymal stem cells, Apoptin translocated to the nucleus and induced 
apoptosis, indicating that Apoptin responds to early changes in transformation and not to 
genetic alterations acquired later on. However, these experiments do not implicate which tumour 
hallmark pathway is responsible for Apoptin activation, as the activation could be a result of the 
inactivation of the RB pathway, the p53 pathway, or by any of the other functions of large T. The 
fact that CAV can induce apoptosis in normal chicken cells suggests that it could be a pathway 
employed under certain circumstances in normal cells as well, although further experiments are 
needed to determine whether Apoptin itself is actually responsible for the apoptosis observed in 
the context of the whole virus and whether viral infection exposes proteins/pathways that are not 
normally accessible in healthy cells. Intriguingly, CAV infection is frequently found concomitantly 
with transforming viruses such as Marek's disease 234, which may suggest that normal chicken 
cells are rendered more susceptible to CAV upon transformation. 
Apoptosis induction by Apoptin 
To obtain further insights in the downstream effects of Apoptin once it is activated, components 
of the cellular apoptotic machinery were inspected. Downstream caspases, like caspase-3, are 
activated during Apoptin-mediated apoptosis, but upstream caspases (1 and 8) do not seem to 
play a major role 235 (figure 8). In addition, Apoptin induces a slower form of cell death with 
atypical morphological changes in MCF? cells (Noteborn, unpublished results), which lack 
caspase-3, suggesting that caspase-3 helps to execute a fast apoptotic death, but is not 
obligatory for Apoptin to be able to induce death. Thus, Apoptin seems to feed into the apoptotic 
pathway at the level of the downstream caspases, but how they are activated is still unclear. 
As discussed earlier, most if not all tumours have a defective p53 pathway. However, some 
still possess wild-type p53 but have acquired mutations up- or downstream, allowing the 
activation of p53 by other mechanisms. Apoptosis induction by Apoptin, however, was not 
dependent on actions exerted by p53 because Apoptin also induces efficient apoptosis in 
tumour cells containing mutant p53 236. Additional studies indicated that Apoptin was not 
inhibited by overexpression of the anti-apoptotic proteins Bcl-2 and BAG-1 237•238. Remarkably, 
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Figure 8. Model for induction of apoptosis by Apoptin. 
Nuclear localisation of Apoptin seems to be required for its induction of apoptosis in tumour cells, but although its 
tumour-specific phosphorylation also conveys nuclear access, it is not certain if the essential apoptotic trigger is 
exerted in the cytoplasm or nucleus. Caspase activation and cytochrome c release are observed in Apoptin-induced 
apoptosis, albeit at a late stage, and as there is no inhibition by Bcl-2, Apoptin may also feed into the apoptotic 
pathway downstream of the mitochondria or activate a mitochondria-independent apoptosis pathway. Adapted from ref 
231. 
Bcl-2 even enhanced Apoptin-induced apoptosis at later time points 239. During apoptosis, Bcl-2 
can be cleaved into a pro-apoptotic fragment, which provides a positive feed-back loop but as a 
non-cleavable form of Bcl-2 was still capable of stimulating apoptosis by Apoptin, another 
mechanism must be involved 231 . 
Release of cytochrome c into the cytoplasm and loss of the mitochondrial membrane 
potential are observed only at a late stage in Apoptin-induced apoptosis, suggesting that these 
changes are the result, rather than the cause of cell death 235 . Together with the fact that Bcl-2 is 
unable to inhibit the Apoptin-induced apoptosis, this result suggests that initiation of cell death 
by Apoptin does not require the mitochondrial pathway. 
Electron microscopy revealed that early after transfection, Apoptin was localised 
predominantly in the endoplasmatic reticulum (ER) of tumour cells (Mommaas and Danen-van 
Oorschot, unpublished results). At later time points it also becomes abundant in the nucleus. 
Release of Ca2+ from the ER can result in apoptosis 40•240•24\ but it is unclear if this mechanism 
is involved in Apoptin-induced cell death. In fact, the ER-Iocalisation of Apoptin could be due 
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merely to accumulation of misfolded Apoptin protein that must be properly folded by chaperones 
before it can enter the nucleus. Apoptin is highly insoluble, due to aggregation and 'stickiness'. 
Only fusion of Apoptin to a hydrophilic protein twice its size (maltose binding protein, MBP) gave 
rise to a generally soluble recombinant protein, whereas attachment of a His-tag conferred 
solubility only in specific buffer conditions. Microinjection of MBP-Apoptin protein in tumour and 
normal cells shows a localisation comparable to that of transfected Apoptin and the induction of 
tumour-specific apoptosis 230 . The recombinant MBP-Apoptin is organised in a stable multimeric 
complex consisting of 30 to 40 monomeric subunits as determined by scanning force 
microscopy and dynamic light scattering 228• These complexes were found to specifically bind 
DNA in a cooperative fashion 242• Interestingly, in the nuclei of intact cells Apoptin co-localises 
with both heterochromatin and nucleoli. In tumour cells with apoptotic morphology Apoptin co-
localises with condensed DNA and ring-like structures in the nucleus, similar to the observations 
in CAV-infected transformed T cells. When MBP-Apoptin was co-injected with inhibitors of 
transcription and/or translation, apoptosis was still induced, indicating that Apoptin does not 
require de novo gene expression for its activity (Zhang, unpublished data). However, this does 
not rule out that repression of transcription is involved in Apoptin-induced apoptosis. 
Cellular proteins associating with Apoptin 
Apoptin also demonstrated different biochemical properties in tumour cells and their normal 
counterparts; the N-terminal epitope of Apoptin is readily accessible in tumour cells, whereas 
stringent lysis is required to detect it in normal cells 230 • Possibly, the N-terminus of Apoptin is 
bound to a cellular protein specifically in normal cells, or a different conformation of Apoptin 
shields this epitope in normal cells (see also chapter 6). 
To obtain further insight in the mechanism of Apoptin-induced apoptosis a yeast two-hybrid 
screen was performed to identify cellular proteins that interact directly with Apoptin. For this, a 
eDNA library derived from Epstein-Barr virus-transformed human lymphocytes was used. After 
validating clones that were identified in the yeast screen by immunoprecipitations from human 
tumour cells, four known and six unknown proteins were found to be bonafide Apoptin-
interacting proteins (Danen-van Oorschot, in preparation). One of the known proteins was 
DEDAF (death effector domain-associating factor) 243, a human protein found to associate with 
death effector domain (DED)-containing pro-apoptotic proteins. Its murine homologue RYBP has 
been shown to be a negative regulator of DNA transcription. DEDAF is expressed at low levels in 
a broad range of adult and fetal tissues, and has a strikingly high expression in placenta. Like 
RYBP, DEDAF was shown to bind the transcription factor YY1 and to repress transcription in a 
reporter assay. In overexpression studies, DEDAF localisation is predominantly nuclear, in both 
tumour and normal cells and its localisation is not altered when Apoptin is coexpressed. So in 
normal cells, where Apoptin resides in the cytoplasm, there is no co-localisation. However, in 
intact and apoptotic tumour cells partial co-localisation is observed, with distinct exclusion of 
DEDAF from nucleoli in contrast to Apoptin. Transient overexpression of DEDAF resulted in 
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apoptosis induction in various human tumour cell lines but not in primary cells. The tumour-
specific apoptosis induction of DEDAF was very similar to that of Apoptin, in that it was also not 
blocked by Bcl-2 or CrmA, but is inhibited by p35 Danen-van Oorschot). The importance of 
DEDAF and other Apoptin associating proteins for the tumour selectivity and induction of 
apoptosis by Apoptin is currently being evaluated. 
Scope of this thesis 
Since cancer remains an unmet medical need, the development of novel anticancer therapies 
continues to be necessary. There is a need for agents potent enough to eliminate chemo- or 
radiation resistant cancer cells and this potency is intimately linked with their dose-limiting 
toxicity, i.e. tumour-cell specificity. As highlighted in this chapter, molecular therapy of cancer 
has proven to be a promising strategy. The study presented in this thesis investigates the 
potential applicability of Apoptin as an anti-cancer agent. To address this, we focussed on 
two approaches; gene therapy and transgenic mice. After generating a replication-deficient 
adenovirus as a more efficient method to deliver Apoptin, we were able to investigate for the 
first time the effects of Apoptin in tumours in vivo. In chapter 2, the generation of the gene-
transfer vector is described. We demonstrate that this approach is technically feasible and 
that Apoptin remains tumour-selective when expressed by this vector, both in vitro and in 
vivo. Next, we examined short and long term effects of the Apoptin-adenovirus in human 
tumours xenografted on nude mice and show that it confers a significant survival benefit to 
the treated mice (chapter 3). Conventional cancer therapies fail to cure carcinomas of the bile 
duct, so in chapter 4 we analyzed whether Apoptin is potent enough to eradicate these 
therapy-resistant cancer cells. To obtain further insight in the potential toxicity of Apoptin in 
normal cells, especially after prolonged exposure and under different conditions, we 
generated Apoptin-transgenic mice (chapter 5). After characterisation of the expression 
patterns of Apoptin in these mice, we determined the effects of Apoptin in the cells with the 
highest expression, namely the lymphocytes. In addition, the biochemical properties of 
Apoptin in these mice hint at a possible (additional) mechanism for its tumour selectivity. 
Altogether, this thesis provides the first data on the effects of Apoptin in vivo and identifies 
directions for further development of Apoptin in tumour-specific therapy. 
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Abstract 
Specificity is an essential prerequisite for cancer gene therapy. Recently we described that 
Apoptin, a protein of 121 amino acids which is derived from the Chicken Anemia Virus, 
induces programmed cell death or apoptosis in transformed and malignant cells, but not in 
normal, diploid cells (Danen-van Oorschot AAAM et at., Proc Nat! Acad Sci USA 1997; 94: 
5843-5847). This protein has an intrinsic specificity that allows it to selectively kill tumor cells, 
irrespective of the p53 or Bcl-2 status of these cells. Hence, it is attractive to explore the use 
of the Apoptin gene for therapeutic applications, viz. cancer gene therapy. 
In this paper, we describe the generation and characterization of an adenovirus vector, 
AdMLPvp3, for the expression of Apoptin. Despite the fact that Apoptin ultimately induces 
apoptosis in the helper cells, which are transformed by the Adenovirus type 5 early region 1 
(E1), the propagation kinetics and yields of AdMLPvp3 are similar to those of control vectors. 
Infection with AdMLPvp3 of normal rat hepatocytes in cell culture did not increase the 
frequency of apoptosis. In contrast, in the hepatoma cell lines HepG2 and Hep3b, infection 
with AdMLPvp3, but not with control vectors, led to a rapid induction of programmed cell 
death. 
Experiments in rats demonstrated that AdMLPvp3 could be safely administered by intra-
peritoneal, subcutaneous or intravenous injection. Repeated intravenous doses of AdMLPvp3 
were also well tolerated, indicating that the Apoptin-expressing virus can be administered 
without severe adverse effects. In a preliminary experiment, a single intratumoral injection of 
AdMLPvp3 into a xenogeneic tumor (HepG2 cells in Balb/C""1"" mice) resulted in a significant 
reduction of tumor growth. 
Taken together, our data demonstrate that adenovirus vectors for the expression of the 
Apoptin gene may constitute a powerful tool for the treatment of solid tumors. 
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The applicability of cancer therapies is not only determined by their efficiency in eliminating 
tumor cells. Their specificity is equally important. Tumor-cell specificity allows the dose of the 
anti-cancer agent to be increased, thereby enhancing efficacy. Recently, in-vitro studies with the 
chicken anemia virus-derived protein Apoptin, demonstrated that this '12'1-amino-acid protein 
has an intrinsic tumor-cell specificity. It induces programmed cell death in immortalized and 
transformed cells, but not in normal, diploid cells. In-vitro studies have demonstrated that 
Apoptin induces apoptosis in a large panel of human transformed and malignant cells1-3. Many 
of the malignant cells exhibit alterations in their expression of proto-oncogenes and tumor-
suppressor genes, e.g. Bc/-24 or p535 , a phenomenon often associated with a poor response to 
chemotherapeutic agents4· s-a. Remarkably, Apoptin-induced apoptosis is not dependent on 
functional p539 , is not inhibited by Bcr-Abl expression and is even stimulated by overexpression 
of the apoptosis inhibitor Bc/-210 . An attractive feature of Apoptin is that it does not induce 
apoptosis in normal cells3. This is correlated with the subcellular localization of the protein. In 
normal cells, Apoptin is in the cytoplasm whereas, in tumor cells, it is found in the nucleus3. This 
suggests that Apoptin may be used as an agent that selectively eliminates malignant cells, 
provided that it can be delivered to target cells in vivo in sufficient amounts. One obvious 
strategy to reach this goal would be the application of the Apoptin gene, rather than the protein 
itself. 
At present the most efficient system to achieve this makes use of adenoviral vectors. These 
vectors have several advantages that make them particularly suitable for in-vivo gene transfer. 
Recombinant adenoviral vectors (rAdVs) can be grown to high titers, have the capacity to 
transduce non-mitotic cells, and do not integrate their genomes into host-cell DNA. Moreover, 
adenovirus vectors have already been applied for clinical gene-therapy trials. 
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Figure 1. Apoptosis induction by Apoptin in 
adenovirus helper cell lines. 
Cultures of 293 (square), 911 (diamant) and PER.C6 
(triangle) cells were transfected with pCMV-vp3 
expressing Apoptin (black) or with pCMV-desmin 
(open) as a control plasmid. The cells were fixed at 
several timepoints after transfection and analysed by 
indirect immunofluorescence. The percentage of 
cells that stained abnormally with DAPI was used as 
a relative indicator of apoptosis. Results are shown 
as the mean of at least three independent 
experiments, the error bars indicate the standard 
deviation. In each experiment at least 1 00 cells 
expressing Apoptin or desmin were examined. 
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In this paper, we describe the generation and characterization of an Apoptin-expressing 
adenoviral vector. We demonstrate that Apoptin maintains its specificity for tumor cells when 
introduced and expressed by an adenoviral vector. The intrinsic specificity and the inherent low 
toxicity make Apoptin adenovirus vectors promising tools for the treatment of solid tumors. 
Results 
The effect of Apoptin on helper cell lines 
Most adenovirus vectors are E1-deleted and are therefore replication-defective. It is necessary to 
propagate them in Ad5E1-transformed helper cell lines, such as 29311 , 911 12 and PER.C613 . This 
entails a potential problem, since Apoptin induces apoptosis in transformed cells. One can, 
therefore, envisage that the helper cell line undergoes apoptosis due to the action of Apoptin, 
and that this may interfere with the formation of progeny vector particles. For this reason, the 
sensitivity of three helper cell lines to Apoptin-induced apoptosis was determined. Cell lines 293, 
91 I and PER.C6 were transfected with pCMV-vp3, an expression plasmid encoding the Apoptin 
gene1 . At various time-points after transfection the cells were fixed, and the Apoptin protein was 
visualized by indirect immunofluorescence. To identify apoptotic cells, the cells were also stained 
with DAPI, which stains normal nuclei strongly, but apoptotic nuclei weakly and/or irregularly14. 
Apoptin induces apoptosis with equal kinetics in the three cell lines. The percentage of apoptotic 
cells reaches up to 80% after 5 days. However, 48 hours after transfection, about 25% of the cells 
expressing Apoptin were apoptotic (figure 1). This is just above the background level of apoptosis 
observed after transfection of pCMV-desmin, which encodes desmin as a non-apoptosis-inducing 
control3. In the following days, the frequency of apoptosis increased, just as observed for other 
transformed cells tested in transient transfection assays2•3. Since the lytic cycle of rAdVs is ap-
proximately 2 days, it is conceivable that an adenoviral vector expressing Apoptin can be generated 
in all of these helper cell lines. 
Generation of a recombinant adenoviral vector expressing Apoptin 
Recombinant adenoviral vectors are generated by co-transfection of an adaptor plasmid 
containing the gene of interest with a plasmid containing a cloned copy of a partial adenovirus 
(Ad) type 5 genome into helper cells. Upon homologous recombination between sequences 
present in the adaptor and in the adenovirus plasmids, an Ad genome is generated in which the 
Ad f1-region is replaced by the gene of interest. This f1-deleted vector can replicate in the 
helper cells by virtue of the El proteins provided in trans by the helper cells. The gene encoding 
Apoptin (vp3) was cloned in the Ad adaptor vector pMad515. The resulting construct (pMad-vp3) 
is depicted in figure 2A. Similarly, Apoptin was inserted in the reverse orientation resulting in 
pMad-as, in order to generate a control virus that can be used in animal experiments to 
distinguish between the effects of the Ad vector and those of Apoptin. Since the minus strand of 
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Figure 2. Characterisation of the adenoviral vector expressing Apoptin (AdMLPvp3). 
DAPI 
(A) Schematic representation of the adenovirus vector. The backbone adenoviral sequences are derived from an £3· 
deleted adenovirus serotype 5, with a bacterial insert in the E1 region. Following recombination, the E1 region is 
replaced by the Apoptin coding sequences under the regulation of the Major Late Promoter (MLP) either in the sense 
orientation, e.g. AdMLPvp3 encoding Apoptin, or in the antisense orientation, e.g. the control virus AdMLPas. ITR: 
inversed terminal repeat, tpl: tripartite leader, piX: structural protein of the adenovirus, pA: polyadenylation signal. 
(B) PER.C6 cells producing AdMLPvp3 (upper paneQ or mock infected (lower panel) were stained for Apoptin 
expression 24 hours after infection. Apoptin was stained with anti-Apoptin mAb 85.1 (Fitc) and the DNA was stained 
with DAPI (DAPI). 
the chicken anemia virus is noncoding 16 , no proteins will be expressed from the transgene of this 
control vector. 
The recombinant adenoviral vector expressing Apoptin (AdMLPvp3) and the control viral vector 
(AdMLPas) were generated by cotransfecting 911 helper cells with the linearized Ad adaptor 
constructs (pMad-vp3 and pMad-as) and pJM1717, containing an Ad5 genome lacking the E1 and 
E3 regions. The resulting plaques were isolated and after three rounds of plaque purification 
transferred to PER.C6 cells. These cells contain the E1 region regulated by a heterologous promoter 
which, combined with matched adaptor plasm ids, eliminates the generation of replication-competent 
adenoviruses (RCA) by homologous recombination12. All batches of AdMLPvp3 were tested for 
Apoptin expression by indirect immunofluorescence (figure 28) and for the presence of RCA by a 
PCR assay, using primers directed to the E1 region giving rise to a band of 615 bp when RCA occurs 
(as described in the Materials and Method section). As expected, the AdMLPas control vector 
originating from pMad-as did not express Apoptin. All the virus batches used passed an RCA test 
detecting 1 pfu of an E1-containing adenovirus amidst 107 pfu of an f1-deleted vector. 
To investigate whether the expression of Apoptin influences the virus yields, PER.C6 cells 
were infected with either AdMLPvp3 or AdCMV\acZ. The cells were harvested with 8-hour 
intervals. The growth curves of AdMLPvp3 and AdCMVIacZ are similar, indicating that Apoptin 
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Figure 2(Cl Yield of the recombinant 
adenoviral vectors. 
PER.C6 cells were infected with AdMLPvp3 (moi 1.5, 
open circles) or AdCMVIacZ (moi 0.6, black circles). 
The cells and medium were collected at 8-hour 
intervals after infection and after 3 times 
freeze/thawing the virus titer was determined by 
plaque assay. The results are shown as the 
percentage of virus (pfu) in the cell pellet at a given 
time point relative to the highest amount of virus 
(pfu) found during the experiment 
expression does not influence the vector yield (figure 2C). In all subsequent experiments, a 
harvest time of 48 hours was used. 
Characterization of AdMLPvp3 
To determine whether Apoptin maintains its tumor cell specificity also after adenovirus-mediated 
gene transfer, normal and transformed cells were infected with AdMLPvp3 and AdCMVIacZ. In 
view of the hepatotropic nature of human adenovirus type 5 after systemic delivery18'19 , we were 
particularly interested in the effect of Apoptin on liver cells, and liver-derived tumor cells. 
Therefore, HepG2 and Hep3b human hepatoma cells (with and without functional p53, 
respectively) were infected with AdMLPvp3 and after 24 hours expression of Apoptin was 
determined (figure 3A). After 24 hours, already 70-80% of the hepatoma cells expressing Apoptin 
are undergoing cell death (figure 38). The background level of cell death is determined in 
parallel infections of the cells with AdCMVIacZ. The ability of AdMLPvp3 to induce cell death in 
these transformed cells is equal to that of pCMVvp3 (not shown). 
So far, all normal cell types have been found to resist Apoptin-induced apoptosis. The cell types 
that have been tested by transfection of an expression plasmid include normal keratinocytes, 
fibroblasts, endothelial cells, smooth muscle cells and T cells3. To study what the effect of the 
Apoptin gene would be in normal cells when introduced by an adenoviral vector, primary rat 
hepatocytes were infected (figure 3A). After two days no difference was observed in the percentage 
of dead cells whether they expressed Apoptin, or /acZ, or after mock infection (figure 38). These 
observations indicate that, in hepatocytes, the adenoviral vector does not influence the specificity of 
Apoptin. 
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Figure 3. The effect of Apoptin on primary and malignant hepatocytes. 
Primary rat hepatocytes and human hepatoma (HepG2 and Hep3b) cells were infected with AdMLPvp3 or AdCMVIacZ. 
For the hepatocytes a multiplicity of infection (moi) of 5 was used, the hepatoma cells were infected with moi 20 . 
(A) Forty-eight hours after infection the cells were fixed and analysed by indirect immunofluorescence (panel A). 
Apoptin was stained with mAb 85.1 (FitC) and the DNA was stained with DAPI (DAPI). (B) HepG2, Hep3b and primary 
rat hepatocyte cells were fixed 24 hours after infection. The percentage of cells that stained abnormally with DAPI was 
used as a relative indicator of cell death. The percentages are given for cells expressing Apoptin (black bars), 
13-galactosidase (grey bars) and non-infected cells. In each experiment at least 100 cells expressing Apoptin or 
13-galactosidase were examined. 
The data also show that Apoptin maintains its characteristic localization after adenoviral 
transduction: nuclear in transformed cells and cytoplasmic in normal diploid cells (figure 3A). 
Moreover, transformed cells remain sensitive to Apoptin-induced apoptosis, whereas normal 
cells are not. 
To further characterize the nature of AdMLPvp3-induced cell death we visualized the 
presence of DNA strand breaks with the aid of the enzyme terminal deoxynucleotidyl transferase 
and Fitc-labeled dUTP (fUNEL assay). HepG2 cells were infected either with AdMLPvp3 or with 
AdCMVIacZ and after 20 hours stained for the transgene to confirm similarity in transduction 
efficiencies (figure 4). After 40 hours, parallel-infected dishes were subjected to the TUNEL 
assay. Even though approximately 15% of the HepG2 cells were expressing J3-galactosidase, 
only occasionally a single cell exhibited DNA breaks that could be detected by the TUNEL assay. 
However, the frequency of TUNEL-positive cells 40 hours after AdMLPvp3 infection appeared to 
be in the same range as the frequency of Apoptin positive cells 20 hours after infection. 
The anti-tumor cell activity of AdMLPvp3 is also demonstrated in-vitro by the clearance of a 
dish HepG2 cells 48 hours after infection at a moi of 50. Giemsa staining visualises the number 
of remaining cells attached to the dish, compared to the number of cells after infection with 
AdCMVIacZ (figure 5). lnspite of a slight toxic effect of the adenoviral vector itself, as observed in 
the difference in cell density between the mock and AdCMVIacZ infected cells, these data 
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Figure 4. Apoptosis induction by AdMLPvp3. Figure 5. Effect of AdMLPvp3 on viability of 
Parallel dishes of HepG2 were infected with AdMLPvp3 and HepG2 cells. 
AdCMVIacZ. After 20 hours immunofluorescence was HepG2 cells were mock-infected (left dishes) or 
performed to detect the number of cells expressing Apoptin, infected with AdMLPvp3 and AdCMVIacZ (moi 50). 
and 13-galactosidase assay was performed on the AdCMVIacZ After 48 hours, one dish was stained with Giemsa 
infected cells to confirm comparable transduction efficiencies and the other dish was used for a 13-galactosidase 
(10-15%). After 40 hours a TUNEL assay was performed on assay. 
parallel dishes, using Fitc-labeled nucleotides. 
confirm the potency of Apoptin in killing tumor cells. Thus, in vitro, the HepG2 cells are killed via 
apoptosis within 48 hours after infection with AdMLPvp3. 
Anti-tumor effect of AdMLPvp3 on human hepatoma cells in vivo 
To investigate the anti-tumor effect of Apoptin in vivo, 18 nude mice were injected with 1 *1 07 
HepG2 cells subcutaneously in both flanks. After 22 days, when the mean tumor dimensions 
were 50 mm2 (n=35), a single dose (equaling 8*1 09 pfu in a total volume of 40 Jll) of either 
AdMLPvp3 (n=12), AdMLPas (n=12), AdCMVLacZ (n=3) or saline (n=8) was injected 
intratumorally. In the following days, the tumor sizes were determined up to the nearest 0.5 mm 
with microcalipers and all animals were sacrificed at day 7. 
To obtain an impression of the efficiency of virus distribution and tumor cell transduction after 
an intratumoral injection with an adenoviral vector, we performed a 13-galactosidase staining on 
tissue sections obtained from AdCMVLacZ injected HepG2 tumors (figure 6). Since the tumors 
were isolated at the same time point (7 days after injection), the original percentage of infected 
cells must have been even higher. Due to the lobular growth of HepG2 tumors, it is difficult to 
obtain an even distribution of the virus throughout the tumor, which is also demonstrated by the 
lacZ staining patterns. 
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Figure 6. Transduction of HepG2 tumors after 
a single intratumoral injection with AdCMV-
IacZ. 
Paraffin sections of a HepG2 tumor 7 days after 
injection with 8*1 O' pfu AdCMVIacZ, were stained 
with a polyclonal antibody directed to 
J3-galactosidase. 
Tumors treated with AdMLPvp3 showed markedly reduced growth, whereas tumors injected with 
the control virus or saline did not (figure 7A). Growth rate was significantly lower in the 
AdMLPvp3-treated group than that in the buffer-treated (p<0.05) and the AdMLPas-treated 
groups (p<0.02), as determined with a multiple comparisons test. The gene transfer into the 
tumors was confirmed by Southern blot analysis with the radioactively labeled Apoptin gene as a 
probe (figure 7C). 
Visually, the HepG2 tumors injected with a single dose of AdMLPvp3 differed from the 
control tumors: the treated tumors had a pale appearance and seemed to contain vesicle-like 
structures (figure 78). Histological examination of AdMLPvp3-treated tumors revealed relatively 
hypovascularised tumor tissue, when compared to tumors treated with AdMLPas or saline. It 
seems possible that the reduction of vascularization is due to an indirect effect, i.e. caused by a 
reduced production of factors stimulating angiogenesis due to the Apoptin induced cell death. 
Toxicity of AdMLPvp3 
To evaluate the possible toxic effects of AdMLPvp3, we injected 2*1 09 pfu of virus (AdMLPvp3, 
AdCMVIuc or saline) in healthy rats in three different manners: subcutaneously, intraperitoneally 
and intravenously. 
Since body weight is generally a good indicator of health status within age-matched groups, 
we used this parameter as a criterion of well being. It can be seen in figure SA that, after an initial 
drop in weight after injection, all groups gained weight similar to control animals (range within 
I 0%). After one week, all animals were sacrificed. 
To confirm efficient transduction of the cells of the liver parenchyma, DNA was isolated from 
the livers of all of three groups, and used for Southern analysis (figure 88). These data revealed 
efficient transduction after i.v. administration (approximately 0.25 genome equivalent per cell was 
detected 7 days post infection), and, as expected, far less after i.p. and s.c. administration (less 
than 0.02 genome equivalents). 
We previously observed an induction of a proliferative response of the liverparenchyma after 
systemic delivery of adenoviral vectors carrying different transgenes. We analyzed livers from 
animals intravenously injected with either saline, AdCMVluc or AdMLPvp3. 8rdU labeling indices 
in liver parenchymal cells were similarly increased in both AdMLPvp3 and AdCMVluc treated rats 
compared to saline controls. This increase in 8rdU incorporation was paralleled by a similar 
small increase in the frequency of apoptotic cells in both virus-treated groups (table 1). 
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Figure 7. Anti-tumor effect of Apoptin. 
Results 
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Human hepatoma (HepG2) cells were subcutaneously injected at both flanks of 16 athymic nude mice (1*107cells/site). 
After 22 days the tumors were injected with a single dose (8*109 pfu) of AdMLPvp3 (n=12), AdMLPas (n=12) or saline 
(n=8). After 7 days the mice were sacrificed and the tumors harvested. (a) The rate of tumor growth is depicted relative 
to the initial size of tumors treated with AdMLPvp3 (black triangles), AdMLPas (open squares) or saline (open circles). 
The error bars indicate the standard error of the mean. (b) Treated tumors with the Apoptin expressing adenovirus 
vector (upper panel) harboured a less pronounced vascular bed compared to tumors treated with AdMLPas (lower 
panel) or saline (not shown). (c) Confirmation of gene transfer by Southern blot analysis with ' 2P-Iabeled Apoptin gene. 
Lanes 1 and 2 contain DNA isolated from saline treated tumors, and lanes 3 and 4 DNA from tumors treated with 
AdMLPvp3. Lanes 5 and 6 contain DNA isolated from tumors treated with AdMLPas. In the AdMLPas the Apoptin gene 
is present in the reverse orientation. As a result also the DNA isolated from the tumors treated with this control virus 
yield a hybridizing signal. 
Table 1 
Kinetics of liver parenchyma cells were analysed for 6 rats, 8 days after iv injection with 2*1 09 pfu of viral vector or PBS. 
Treatment Apoptotic cells Mitotic cells BrdU positive cells 
PBS 0 0 18 
PBS 0 22 
AdCMV-Iuc 65 7 267 
AdCMV-Iuc 6 2 78 
AdMLP-vp3 90 3 195 
AdMLP-vp3 37 0 263 
The data are shown for the individual animals. Numbers represent the total number of BrdU-positive, apoptotic or 
mitotic cells in 100 randomly distributed areas, containing approximately 1 00 liver parenchymal cells each. 
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Figure 8. Toxicity of AdMLPvp3 in rats. 
Healthy rats were injected with 2*10' pfu AdMLPvp3 (n=6, open symbols) or AdCMVluc (n=6, black symbols) via three 
administration routes; subcutaneously (circles), intraperitoneally (triangles) or intraveneously (penis vein, squares). 
Each administration group contained two rats. As an additional control 2 rats were intravenously injected with saline 
(black diamond). (a) Body weight of rats, measured on alternating days for one week after viral injections. (b) Viral 
infections were validated by Southern Blot analysis, using 32P-Iabeled Apoptin gene as a probe. Lane 1-3 contain Bam 
HI digested pCMV-vp3 (5, 1 and 0.1 ng). Lane 4-7 contain liver-derived DNA from rats intravenously injected with 
AdMLPvp3 (lanes 4 and 5) or AdCMVIuc (lanes 6 and 7). Exposure time for lanes 4-7 was approximately 10 times 
longer than for the control fragments. 
For all administration routes also heart, lung, spleen, kidney, skin, testis and muscle samples 
were isolated for macroscopic evaluation and histological examination. No overt pathology was 
noted in these tissues, except for a slight increase in the mean spleen weight. 
Also rats receiving a total of 8*1 09 pfu AdMLPvp3 intravenously in 4 doses administered on two 
consecutive days, revealed no toxicity after 5 weeks (data not shown). The general parameters 
measured (including the weights of total body, spleen and liver), were similar to those of the control 
groups at the end of the experiment. From these data we conclude that significant amounts of the 
AdMLPvp3 adenovirus vector can be administered without acute fatal toxicity. 
Discussion 
This report describes the generation of a recombinant adenoviral vector expressing Apoptin and 
its effects on normal and on transformed cells. Our previous in-vitro studies2• 3 have shown that 
Apoptin induces apoptosis in a range of human and rodent transformed and malignant cell lines, 
irrespective of p53, Bcl-2 or Bcr-abl status. We expected, therefore, that the generation and 
production of an adenovirus vector expressing the Apoptin gene might be hampered by the 
transformed nature of the helper cell lines. However, Apoptin-induced apoptosis in helper cells 
did not impede virus production. We previously showed that the 21-kD Ad-E1 B protein20•21 
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partially inhibits Apoptin-induced apoptosis. Possibly, this protein somewhat delays the onset of 
apoptosis and therefore may facilitate propagation of adenovirus vectors that carry the Apoptin 
gene. 
We report here that, after adenovirus mediated transfer of the Apoptin gene, human hepatoma 
cells are susceptible to Apoptin, whereas primary hepatocytes are not. Similar results with the vp3-
containing vector were found for other combinations of cells, e.g. keratinocytes versus squamous 
cell carcinoma. In transformed cells, Apoptin is located in the nucleus and may interact with 
nucleic acids through its basic character. Due to its high proline content, the presence of 
Apoptin in the chromatin structure, may disturb the supercoiled organization resulting in DNA 
condensation and fragmentation. An alternative explanation might be that the basic and proline-
rich character of the Apoptin protein enables it to act as a transcriptional regulator resulting in the 
induction of genes mediating apoptosis22. 
It appears that infection of HepG2 cells with an adenoviral vector encoding Apoptin leads to 
apoptosis faster than transfection with an expression vector. After DNA transfection, it takes 
approximately 3-4 days before 80% of the Apoptin-expressing transformed cells become 
apoptotic. In contrast, after adenovirus-mediated transfer of the Apoptin gene, this percentage is 
already reached after 24 hours (figure 3). Apparently, the adenoviral infection somehow 
stimulates Apoptin-induced apoptosis due to changes induced by the adenoviral infection, or, 
alternatively, the effective intracellular level of Apoptin is higher after viral infection than after 
transfection. Viral transduction does not, however, render normal cells sensitive to Apoptin. 
The animal studies presented in this paper demonstrate a low toxicity of Apoptin in vivo, 
confirming and extending the results of the in-vitro studies. Rats intravenously injected with either 
the Apoptin- or luciferase encoding virus vectors showed a comparable increase of proliferating 
hepatocytes (an indirect measurement for liver damage). Also previous experiments with other 
adenoviral vectors studies revealed some increase in BrdU incorporation and the occurrence of 
apoptosis in these livers could be a response to the induction of the proliferative activity rather 
than a consequence of the transgene, especially since no difference is obseNed between the 
effects of the Apoptin- and the control vector. 
In a first test for anti-tumor activity, AdMLPvp3 was injected into tumors arising from human 
hepatoma cells transplanted into nude mice. We obseNed a significant anti-tumor effect by 
Apoptin after a single intratumoral injection, despite the fact that this approach leads to 
transduction of only a part of the tumor. Given the finding that, in vitro, Apoptin-containing 
HepG2 cells are killed within a few days it may not be surprising that we do not find a high 
apoptotic activity in AdMLPvp3-treated tumors when evaluated 7 days after treatment. However, 
in (pre)clinical studies nowadays, repeated doses of a vector, e.g. Ad-p53, are administered 23-25. 
It is therefore reasonable to anticipate that with AdMLPvp3, too, repeated injections will be even 
more effective. 
In addition, Soruri et al. (1998) have shown that apoptotic tumor cells can trigger dendritic 
cells to process and present responding T lymphocytes, which will result in acquired cytotoxic 
responsive inducing apoptosis in the non-affected cells tumor cells26. If this mechanism also 
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holds true for Apoptin-induced apoptosis, its anti-tumor effect will be more pronounced in 
immune competent animals. 
Southern blot analysis of the tumor material one week after injection with AdMLPvp3 showed 
that the viral DNA carrying the Apoptin gene was still detectable. The presence of the Apoptin 
gene after one week (figure 7C) may be due to infection of normal cells, e.g. stroma or 
endothelial cells. 
The intrinsic tumor specificity of the Apoptin gene makes it a promising new tool for cancer 
gene-therapy. So far, attempts by others to obtain tumor-eel\ specificity rely on targeting the 
vector specifically to malignant cells, on tumor-specific expression of the transgene, or on local 
administration of the gene-transfer vehicle. To date, the applicability of the available systems is 
limited by their relatively low efficiency, or by lack of specificity27-29• Promising results have been 
obtained with the HSV-TK!gancyclovir combination in brain tumors30 , but applicability of this 
system outside the central nervous system (brain) is hampered by toxic effects for certain normal 
tissues, e.g. the cells of the liver parenchyma31 ·32. Another approach is based on the introduction of 
tumor-suppressor genes such as p53 or the retinoblastoma protein (RB) into tumor cells in which the 
endogenous counterparts are affected33•34. 
The p53 approach combines two important features for cancer therapy: efficacy and specificity. 
For instance, studies with Ad-p53 show that re-expression of p53 in established tumors can induce 
apoptosis and tumor regression in vivo35. Both preclinical and clinical studies suggest a low toxicity 
for non-transformed cells when they are forced to express exogenous p53 at levels sufficient for 
tumor-cell killing23· 36•37. However, the expression of wild-type p53 is most effective in cells lacking 
functional p53. Tumor cells expressing wild-type p53 are only marginally affected35. In vitro, at least, 
Apoptin does not seem to discriminate between p53- and p53+ cells2. 
The tumor-cell specificity of Apoptin makes it a valuable new addition to the list of approaches 
that can be explored for cancer gene therapy. Although our preliminary in-vivo studies with 
AdMLPvp3 are promising, its potency and the more general applicability in other tumor cell types 
needs to be demonstrated. 
Materials and Methods 
Cells and cell culture 
Ad5-E1 (nt 459-3510)-transformed human embryonic retina (PER.C6) 13 , Ad5- E1 (nt 79-5789)-transformed human 
embryonic retina (911) 12 , AdS-transformed human embryonic kidney (293)11 and human hepatoma (HepG238 and 
Hep3b39)cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal-calf 
serum (FCS) in a 5% CO, atmosphere at 37 oc. For immunofluorescence, cells were grown on glass microscope 
slides. 
Primary rat hepatocytes were cultured in Williams E medium (Gibco Life Technologies, Grand Island, NY, USA) 
supplemented with insulin (2mU/ml) and dexamethasone (1 mM). The cells were grown on collagen-coated culture 
slides (Micronic, Lelystad, the Netherlands). 
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Plasmids and transfection 
Expression plasmid pCMV-vp3 contains CAV DNA sequences encoding Apoptin (nt 427-868) under control of the 
cytomegalovirus promoter. pCMV-desmin encodes desmin, a component of type II intermediate filaments, and was 
used as a negative control for the induction of apoptosis4ll. 
Plasmid pMad5i5 contains the E1A enhancer linked to the Major Late promoter (MLP) to drive expression of the 
transgene. Downstream of the transgene, the region of the Ad5 genome comprising nt 3328-8914 is located and is 
used for recombination with homologous sequences in pJM1717• After a BamHI site was introduced into pMad5 to 
generate pMAD5/BamHI, the coding region of Apoptin (nt 427-868) was inserted as a BamHI fragment, in both 
orientations. The resulting plasmids were named pMad-vp3 and pMad-as. Plasmid DNA was purified by 
centrifugation in a CsCI gradient and column chromatography in Sephacryl S500 (Pharmacia, Uppsala, Sweden). 
All transfections were performed by means of the calcium-phosphate precipitation procedure as described by 
Graham and Vander Eb41 • Briefly, 2 hours prior to transfection the medium of 80% confluent monolayers of PER.C6, 
911 or 293 was replaced by fresh medium. DNA-calcium-phosphate precipitates were incubated for 30 min at room 
temperature, and subsequently added to the medium. The cells were washed twice with phosphate-buffered saline 
(PBS) after 24 hours and fresh medium was added. 
Immunofluorescence and DAPI staining 
Indirect immunofluorescence was performed as described previously42• To demonstrate the presence of Apoptin and 
establish its cellular localization in transfected or infected cells, the cells were fixed with 80% acetone. The indirect 
immunofluorescence assay (I FA) was performed with a 1 00-fold dilution of the mouse monoclonal antibody (mAb) 
CVI-CAV-85.1 (85.1) for Apoptin1, mAb 33 (Monosan, Uden, The Netherlands) for desmin and mAb lacZ (Boehringer 
Mannheim, The Netherlands) for B-galactosidase. Fluorescein-isothiocyanate-labeled goat anti-mouse antibody 
(Jackson lmmunoresearch Laboratories Inc., West Grove PA, USA) was used as second antibody. Nuclear DNA was 
stained with 1 ,Ug/ml 2,4-diamino-2-phenylindole (DAPI) in 2% 1, 4 diazabicyclo-[2,2,2]-octane in glycerol/0.1 M 
TrisHCI pH 8.014• 
Viruses and virus techniques 
The recombinant adenoviral vector AdCMVIacZ carries the E. coli LacZ gene for ~-galactosidase under control of the 
Cytomegalovirus enhancer/promoter. AdCMVIuc contains the firefly luciferase gene under control of the CMV 
enhancer/promoter. 
A recombinant adenoviral vector expressing Apoptin and a control vector were generated by cotransfecting near-
confluent monolayers of 911 cells with equal amounts of pJM17" and pMad-vp3 or pMad-as (linearized by Xmnl 
digestion). After 24 hrs the medium was removed and the cells were washed twice with PBS. F15 minimal essential 
medium (MEM) containing 0.85% agarose (Sigma, USA), 20 mM HEPES pH 7.4, 12.3 mM MgC12, 0.0025% L-
glutamine, and 2% horse serum (HS) (heat-inactivated at 56°C for 30 min), was added. After 8-10 days, plaques were 
extracted and subjected to three rounds of plaque purification. The recombinant adenoviruses (rAdvs) were 
subsequently transferred to PER.C6 cells by a limited dilution assay. 
Large-scale production of adenovirus was performed according to Fallaux et al. 12 Briefly, near-confluent PER.C6 
monolayers in 600-ml flasks were infected with approximately 5 plaque-forming units per cell, in 8 ml DMEM 
containing 2% HS. After 2 hours at 37"C/5% C02, 12 ml DMEM/10%FCS was added to each flask. After 48 hr, the 
detaching cells were harvested and collected in PBS/2% HS. Virus was isolated from the producer cells by three 
cycles of freeze/thawing. The lysates were cleared by centrifugation at 2600 g for 5 min, and after dialysis against a 
sucrose-containing buffer, stored at -80°C. 
Plaque assays were performed essentially as described by Graham and Prevec43• Briefly, adenovirus stocks 
were serially diluted in 1 ml DMEM/2% HS and added to near-confluent 911 cells in six-well plates. After 2 hours of 
incubation at 37"C/5% C02 , the medium was replaced by agar-containing culture medium. 
Quality control of rAdv batches 
The expression of Apoptin by the adenoviral vectors after infection of helper cells was tested by indirect 
immunofluorescence as described. The rAdV stocks were screened for the presence of replication-competent 
adenoviruses (RCA) by a polymerase chain reaction (PCR) assay. A 615-bp region was amplified with one 
oligonucleotide directed to the ITR of the adenoviral DNA (5'GGGTGGAGTTTGTGACGTG-3') present in the Ad 
vector, and one to the region coding for the E1A protein (5'TCGTGAAGGGTAGGTGGTTC-3'), which is not present in 
the vector. The presence of the 615 bp product is indicative for the presence of RCA. 
In brief, adenovirus supernatant (3* freezed/thawed) was degraded by digestion with proteinase K . After boiling, 
5,111 of the inactivated virus was added to 45,111 of 50 rnM KCI, 10 mM TrisHCI (pH 8.4), 0.1 mg/ml gelatine, 0.05% 
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Tween20, 1.75 mM MgCI2 , 0.1 mM of each deoxyribonucleotide, 20 pmol forward primer, 20 pmol reverse primer, 250 
ng tRNA and 3 U of AmpliTaq DNA polymerase (Perkin-Elmer, Norwalk, USA). PCR is performed for 30 cycles (94 oc 
1 min, 63 oc 2 min, 72 oc 3 min) in an automated DNA Thermal Cycler (Perkin-Elmer Cetus). DNA isolated from 911 
cells infected with a pseudo-wild-type adenovirus (d/7001) served as a positive control. The assay has been optimised 
and detects 1 pfu of an f1-containing adenovirus amidst 10'pfu of f1-deleted vector (Van den Wollenberg & Hoeben, 
unpublished results). 
TUNELassay 
Tdt-mediated dUTP nick end labeling (TUNEL) was performed with the use of the in situ cell death detection kit, 
fluorescein (Boehringer Mannheim). Forty hours after transfection cells were washed with PBS and fixed with 4% 
paraformaldehyde in PBS (pH 7.4), for 30 minutes at room temperature. After permeabilisation (0.1% Triton X-100, 
0.1% sodium citrate, 2 minutes at 4°C) cells were incubated with the TUNEL reaction mixture (containing fluorescein 
labeled nucleotide polymers and terminal deoxynucleotidyl transferase) for one hour at 3r C. After washing with PBS, 
the cells were analysed by fluorescence microscopy. 
Giemsa staining and (3-galactosidase assays 
For detection of the number of attached cells, cells were washed twice with PBS and fixed in methanol/acetic acid 
(3:1) for 15 minutes at room temperature. For 30 minutes, cells were incubated with Giemsa solution (3% Giemsa 
(Merck, Darmstad, Germany) in 1 mM Na2HP04 , pH 7.0) at room temperature. After staining, the cells were washed 
four times with deionized water and allowed to dry by air. 
For detection of LacZ-encoded (3-galactosidase activity, cells in tissue culture were fixed 48 hours after infection 
in ice-cold 2% paraformaldehyde/0.2% glutaraldehyde solution, washed in ice-cold PBS (containing 2 mM MgCI 2), 
and incubated in 3 ml of reaction mix (1 mg/ml X-Gal (Boehringer, Mannheim, Germany), 5 mM potassium 
ferrocyanide, 5 mM potassium ferricyanide, 2 mM MgCI2 in PBS) at 37° C for 4-16 hours44 • 
Animals 
Male Balb/c""1"" mice, aged 7-8 weeks, and male Wag/Rij rats, weighing 180-210 g were obtained from Harlan (Zeist, 
The Netherlands). Animals were kept at standard laboratory conditions of alternating 12-h periods of light and 
darkness and a standard laboratory diet. The animal experiments were approved by the Leiden University Anirnal 
Welfare Committee. 
Histology 
Tissue sections were fixed in 4% buffered formalin. After paraffin-embedding, sectioning (ca 4 micron) and mounting 
on slides, tissue sections were routinely stained with hematoxylin-eosin (HE). 
In the toxicity experiment, rats were injected intraperitoneally with 50 mg/kg bromodeoxyuridine (BrdU, Sigma) in 
saline, two hours prior to sacrifice. DNA-incorporated BrdU, as a measurement for cellular DNA replication, was detected 
immunohistochemically by a three-step imrnunoperoxidase staining with the anti-BrdU rnonoclonal antibody IU4 45• Sections 
were counterstained with haematoxylin. Both HE and BrdU/H stained rat liver sections were analysed using a Zeiss 
Axioplot microscope (Dena, Germany) and a 40x objective. In HE stained sections both apoptotic cells -
characterized by dense, often fragmented, nuclei, eosinophilic cytoplasm and reduced contact with neighbour cells-
and mitotic cells -defined by the absence of nuclear morphology, but the appearance of chromosomes in meta-, 
ana- or telophase- were counted. In anti-BrdU sections we discriminated BrdU-positive liver parenchymal cells 
(relatively large round nuclei) from (all) other cell types in the liver. For each parameter, 100 randomly distributed 
areas were scored in each liver section (mostly containing 3-4 lobes) and each area contained approximately 150 
nuclei. 
For detection of AdCMVIacZ encoded !3-galactosidase, paraffin sections were stained with the polyclonal rabbit 
antibody 55978 (Cappel, Aurora, Ohio, USA). After deparaffinisation, slides were incubated with the anti-!3 
galactosidase antibody (55978, 1 :2000) for 1 hour at room temperature. As a second antibody biotinylated swine anti-
rabbit (Dako, 1 :300) was used, followed by streptavidine-conjugated peroxidase. Cells were rinsed with Trizma 
(Sigma) and positive cells were revealed by 15 minute exposure to Dab solution in Trizma. 
Southern-blot analysis 
DNA was isolated from isopentane-fixed tissue and digested with BamHI. Southern" analyses were performed, by 
DNA fractionation on a 1% agarose gel and blotting onto Hybond+ (Amersham, UK). The blots were hybridized with 
randomly primed 32P-Iabeled DNA fragment encoding Apoptin. In all assays Bam HI digested pCMV-vp3 plasmid DNA 
was used as a control. The signals were quantitated by phosphor imaging. 
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Abstract 
The Chicken Anaemia Virus (CAV)-derived Apoptin protein shows remarkable specificity; 
namely, it induces apoptosis in tumour cells, but not in normal diploid cells. We have 
exploited the Apoptin gene for use in cancer gene therapy. Here we demonstrate that 
adenovirus-mediated intratumoural transfer and expression of the Apoptin gene results in 
regression or complete remission of human hepatomas grown as xenografts in immune-
deficient mice, and significantly increases their survival long-term. Early after intratumoural 
injection, Apoptin could be detected in significant quantities by Western-blot analyses and 
immunohistochemistry. Furthermore, cell death and disruption of the tumour integrity were 
apparent in the transduced regions. This experimental gene therapeutic strategy constitutes 
a unique example of specific anti-tumour activity using a virus-derived gene with broad-
spectrum applicability. 
Introduction 
Current anti-cancer therapies are limited by toxicity to normal tissue and the occurrence of 
therapy-resistant tumour cells. The Apoptin protein, encoded by the Chicken Anaemia Virus 
(CAV), shows unexpected specificity and potency towards human tumour cells. In young 
chickens, CAV infection leads to a depletion of the thymus caused by extensive apoptosisY In 
transfection studies, Apoptin was shown to induce apoptosis in a large panel of transformed and 
malignant cells of avian, murine, and human origin including carcinomas, sarcomas, melanoma, 
lymphoma and leukaemia.3.4 
Remarkably, Apoptin did not induce apoptosis in 'normal', diploid cells.4 However, 
transformation of diploid human fibroblasts or keratinocytes by expression of SV40 large-T 
antigen rendered these cells sensitive to Apoptin-induced apoptosis.5 The apoptosis-inducing 
activity correlates with the subcellular localisation of the protein. Specifically, in normal cells 
Apoptin resides predominantly in the cytoplasm, whereas in transformed cells, it localises to the 
nucleus.3 
67 
Chapter 3: Tumor therapy with Apoptin 
Intriguingly, although Apoptin-induced apoptosis involves caspase-3, it bypasses most of the 
upstream components of the apoptotic pathway, making it resistant to mutations in this 
pathway.6 Moreover, Apoptin-induced apoptosis is not affected by loss of functional p53, or by 
over-expression of either Bcl-2 or Bcr-abl, conditions that often frustrate conventional therapies 
such as chemotherapy and radiation. Indeed, it is even stimulated by Bcl-2 overexpression.7 
Thus, in addition to its intrinsic specificity, which allows selective action against transformed 
cells, Apoptin may also work in cases when chemotherapy and radiation have failed. Although 
the mechanism by which Apoptin distinguishes malignant cells from their 'normal' primary 
counterparts has not yet been fully elucidated, it is attractive to exploit these abilities for cancer 
gene therapy. 
To examine the anti-tumour effect of Apoptin, we generated a replication-deficient 
adenovirus containing the Apoptin gene (AdMLPvp3, further referred to as AdMLP.Apoptin). We 
showed that adenoviral expression of Apoptin both in vitro and in vivo did not change its 
specificity; namely, it still induced apoptosis in tumour cells and had no deleterious effects on 
normal cells. The first, short-term pilot experiment, which comprised a single intratumoural 
injection of AdMLP.Apoptin, the adenovirus vector that carries the Apoptin gene, in 
subcutaneous human hepatoma in nude mice, showed a significant decrease in tumour growth.8 
Because we noticed that a single intratumoural injection only reaches a fraction of the tumour 
cells, we designed a regimen using multiple injections to determine whether AdMLP.Apoptin can 
cause actual tumour regression. A parallel experiment was carried out to follow the effects of 
AdMLP.Apoptin at the cellular level. 
In this study we show the induction of apoptosis by AdMLP.Apoptin in HepG2 (human 
hepatoma) tumours similar to that observed for CAVin transformed chicken cells.9 Furthermore, 
multiple injections of the adenovirus vector with the Apoptin gene resulted in partial or complete 
regression of the established tumours in the majority of the recipient mice. Our data show for the 
first time that treatment with Apoptin significantly improves long-term survival of tumour-bearing 
animals. 
A B 
Figure 1. Apoptin expression after injection of 
AdMLP.Apoptin in HepG2 tumours. 
Two days after intratumoural injection of buffer (lane 
A) or AdMLP.Apoptin (lane B), HepG2 tumours were 
lysed and the protein fractions were subjected to 
immunoprecipitation with a polyclonal rabbit antibody 
specific for the C.terminus of Apoptin. After blotting, 
the proteins were immunoprobed with mAb 111.3, 
which is directed against the N-terminus of Apoptin. 
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To investigate the effects of the adenovirus expressing Apoptin on a cellular level in vivo, HepG2 
tumour-bearing mice were injected once intratumourally with AdMLP.Apoptin or with 
AdCMV.LacZ or virus dilution buffer as a control, and were sacrificed 2,3,4,5 and 6 days post-
injection. To ascertain the presence of Apoptin, protein extracts from the tumours two days post 
injection were subjected to immunoprecipitation with an antibody against Apoptin and the 
protein was detected by Western Blot analysis (fig 1). Additionally, the Apoptin protein could be 
readily detected in HepG2 tumour tissue sections by immunohistochemistry using the polyclonal 
antibody anti-VP3C (fig 2A,a). In contrast, no Apoptin signal was detected in the AdCMV.LacZ or 
buffer control (fig 2A,b,c). All stainings were performed on serial sections to determine the areas 
of the tumour transduced with adenovirus. 
Tumour areas expressing Apoptin exhibited aberrant morphology characterised by loss of 
tissue integrity, increase in interstitial space and visible remnants of disintegrated cells. These 
disrupted areas showed loss of cell-cell contact and tumour cells containing hypodense 
cytoplasms and condensed dark nuclei (fig 2A,d). Such morphological aberrations were not 
found in the ~-galactosidase-positive fields of the HepG2 tumours treated with AdCMV.LacZ (fig 
2A,e,f). These data demonstrate an Apoptin-induced anti-tumour effect at a cellular level in vivo. 
To determine the viability of the infected areas in the tumours, the mice were administered 
BrdU prior to sacrifice. The number of cells containing actively-replicating DNA was found to be 
reduced in most of the disrupted areas of the Apoptin-treated tumours (fig 2A,g,h,i) but not in the 
~-galactosidase-positive areas (~-galactosidase staining not shown). This suggests that 
Apoptin-transduced areas are repressed in their outgrowth. 
Over time, the number of Apoptin-positive cells decreased within the HepG2 tumours. Two 
days post-injection, several areas of the tumours showed up to 40% Apoptin-positive cells, as 
determined by immunohistochemistry (fig 2B,a). On subsequent days, however, the number of 
Apoptin-positive cells decreased to less than 1% (fig 2B,b,c). Between day 2 and 6, the Apoptin 
pattern distinctly changed: from a mixture of cells with homogeneously distributed nuclear and 
some cytoplasmic staining, to exclusively condensed nuclear staining. After six days, the 
Apoptin-positive cells had almost completely disappeared and only sporadic fragments of 
positive cells were found (fig 2B,c). B-galactosidase-expressing cells in tumours injected with 
AdCMV.LacZ, however, were still abundant after six days. In contrast to Apoptin-positive cells, 
virus-infected cells expressing B-galactosidase appeared histologically normal (fig 2B,d,e,f), 
indicating a toxic effect of Apoptin, but not B-galactosidase, on the HepG2 cells. 
Light-microscopic evaluation of individual Apoptin-positive cells at high magnification 
revealed a typical pattern of the Apoptin distribution within the nuclei. Two days after infection, 
the distribution was faint and finely granular. Later the granules increased in size, and gradually 
accumulated into "doughnut" shaped structures (fig 3a). Strikingly, these distribution patterns of 
Apoptin within the tumour cell nuclei closely resembled those observed for CAV-infected 
transformed chicken lymphoblastoid cells (fig 3b).9 Apparently, the effects of Apoptin are very 
similar when delivered by an adenovirus or by its natural vector, the chicken anaemia virus. 
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Figure 2 , Effects of Apoptin gene therapy on HepG2 tumours at the cellular level. 
A Tumour-bearing mice were treated with a single intratumoural injection of 5*109 pfu AdMLP.Apoptin, AdCMV.LacZ or 
were injected with virus dilution buffer. At day 2,3,4,5 and 6 after treatment, four mice per treatment group were 
sacrificed and tumours were processed for immunohistological analyses. Depicted are paraffin sections of tumours 
fixed two days after treatment. a, b,c, Sections were incubated with an Apoptin-specific antibody and labelled with 
peroxidase-coupled second antibody. Cells expressing Apoptin are visualised by DAB signal. The Apoptin protein was 
readily and exclusively detected in AdMLP.Apoptin-treated animals (a). In buffer (b) and AdCMV.LacZ-treated animals 
(c), no Apoptin was detected. d, e, f, Haematoxylin/eosin staining of sequential sections of a, b and c. (d) At the tumour 
sites infected with AdMLP.Apoptin, tumour cell integrity was disrupted with decreased cell-cell contact (~ ), containing 
enlarged hypodense cells with dark shrunken nuclei. Scattered throughout these areas, fragments of disintegrated 
cells (*) and apoptotic cells (11>-) were observed. In contrast, tumours treated with buffer (e) and AdCMV.LacZ (f) 
showed a uniform and regular structure. Additionally, frequent mitotic figures were present (arrows). g, h, i, Mice were 
injected with BrdU prior to sacrifice, to determine the number of DNA-replicating cells in the HepG2 tumours. (g) Anti-
BrdU-staining in areas of Apoptin expression (sequential sections) revealed predominantly low incorporation of label. 
In contrast, areas expressing B-galactosidase (h) or injected with buffer (i) showed persistent BrdU-incorporation. 
Figure 2 B, Effects of Apoptin gene therapy on HepG2 tumours at the cellular level. 
B, Transgene expression over time after recombinant adenovirus injection: sections of HepG2 tumours growing in 
nude mice. The animals were sacrificed 2, 4 or 6 days after a single virus injection (AdMLP.Apoptin or AdCMV.LacZ). 
Upper panel: Apoptin staining as described under fig2A. Lower panel; B-galactosidase expression in AdCMV.LacZ-
treated tumours was determined by labelling with a specific antibody, visualised by DAB oxidation. 
a, b, c, high expression of Apoptin is detected in tumours two days after intratumoural AdMLP.Apoptin injection. After 
four days the number of Apoptin-positive cells decreases and after six days only sporadic Apoptin expression is found. 
Furthermore, the structure of Apoptin staining in the cells also changes over time. Early after virus-infection the tumour 
cells show both cytoplasmic and nuclear localised Apoptin (a). Later, mostly nuclei are stained positive (b, c). Six days 
after injection, predominantly fragments of stained tumour cells and few intact stained tumour cells are detected (c). d, 
e, f, The number of B-galactosidase-expressing cells in AdCMV.LacZ-injected tumours remains constant over time. Two 
days after infection a high number of positive cells was detected (d). In contrast to the Apoptin expression in Apoptin-
treated animals, B-galactosidase is still present in a high percentage of cells four (e) and six (f) days after virus 
injection. 
Figure 3 lmmunoperoxidase staining of Apoptin. 
A, B, C, Staining on paraffin sections of xenografted human HepG2 tumours infected with adenovirus expressing the 
Apoptin protein with Apoptin-specific antibody 111.3. The tissue sections were fixed and stained 2 days after infection; 
three representative images are shown (original magnification: x 1 ,250). Typically, early after infection, the distribution 
was faint and finely granular (A). Later the granules increased in size (B), and gradually accumulated into "doughnut" 
A. B C shaped structures (C). Strikingly, these distribution 
D E F 
patterns of Apoptin within the tumour cell nuclei 
closely resembled those observed for CAV-infected 
transformed chicken lymphoblastoid cells '. 
D, E, F, For comparison purpose, indirect 
immunoperoxidase staining of CAV-infected chicken 
lymphoblastoid T cells is shown from Noteborn et a/ 
(1994)9• In this experiment the apoptin-specific 
antibody 85.1 was used and the cells were fixed and 
stained 76 hours after infection. 
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Figure 4 Human hepatomas (HepG2l in nude mice 
before and after Apoptin gene therapy treatment. 
Subcutanously grown HepG2 tumours were injected five 
times on alternating days with 3*10' pfu AdMLP.Apoptin, 
3*1 O' pfu AdCMV.LacZ or buffer. Hereafter, tumour growth 
was measured regularly. (a) and (b), examples of HepG2 
tumours at the start of treatment. The criteria to start virus-
treatment were met at this point a tumour volume > 250 mm3 
and tumour height of 3,0 mm. (c) and (d), examples of HepG2 
tumours treated with LacZ or buffer at the point when the 
criteria were met to end the experiment. The end-criteria 
were: a tumour volume of > 1800 mm3 and a tumour height of 
9 mm. (e) and (f), tumour regression upon AdMLP.Apoptin 
treatment. Examples of partial and complete remission (e, f) 
of HepG2 tumours achieved after Apoptin-gene therapy. 
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Figure SA Long-term effect of Apoptin gene 
therapy in vivo. Tumour growth kinetics after 
treatment 
Nude mice (nu/nu) were implanted subcutaneously 
with HepG2 cells and tumour growth was 
determined every other day. Each individual mouse 
was monitored until the criteria were met to enter the 
experiment. At that point each mouse was randomly 
divided for multiple injections either with 
AdMLP.Apoptin (a), AdCMV.LacZ (b) or buffer (c). In 
the following weeks each tumour was measured until 
its size reached the end-criteria at which point the 
mouse was sacrificed. 
To further evaluate the potential of Apoptin gene therapy, we designed an experiment to study 
the long-term effects and survival benefit of treating tumour-bearing mice with AdMLP.Apoptin. 
Based on previous observations that the percentage of transduced tumour cells is limited after 
one intratumoural injection, we attempted to achieve overall transduction of the tumour by using 
an improved treatment protocol. This protocol consisted of five intratumoural injections per 
tumour every other day, each injection comprising 3*1 09 pfu AdMLP.Apoptin, 3*1 09 pfu 
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Figure 5B Long-term effect of Apoptin gene therapy in vivo. Survival analvsis 
Mice treated with AdMLP.Apoptin survived longer than the mice in the other two groups (p<0.01). One hundred days 
after the beginning of the treatment still 60% of the animals treated with AdMLP.Apoptin (straight line) were alive, 
whereas at that point 90% of AdCMV.LacZ (dashed grey line) and 100% of buffer-treated (dotted black line) mice had 
met the end-criteria and were sacrificed by the experimentator. Insert Mean survival after Apoptin gene therapy. 
Tumour-bearing mice treated with buffer had a mean survival of 27 days (standard error of the mean = 2.4). The mean 
survival for AdCMV.LacZ was 41 days (sem = 3.7). The mean survival of Apoptin-treated animals was almost twice as 
long compared to LacZ and three times longer than the buffer-treated mice. 
AdCMV.LacZ or sucrose buffer. At the time of treatment the tumours had a volume of minimally 
250 mm3 and a tumour height of at least 3 mm (fig 4a,b). Each tumour was measured four times 
weekly. The virus-injected tumours showed a pale appearance during the I 0-day treatment 
period. In order to optimise the treatment, the inoculation was administered to the areas of the 
tumour that appeared most viable, as judged by the dark-red colour of non-treated HepG2 
tumours. After the treatment period, the AdCMV.LacZ-treated tumours gradually regained this 
dark-red colour, whereas Apoptin-treated tumours remained pale. 
The growth kinetics of the tumours following treatment are shown in figure SA During treatment, 
the tumours in both virus groups were delayed in growth, but soon after the end of treatment, the 
LacZ-treated tumours resumed growing (fig 5A,b) whereas most of the Apoptin-treated tumours 
did not (fig 5A,a). The majority of the mice treated with AdMLP.Apoptin showed partial or 
complete response to treatment (fig 4e,f). However, there were also several non-responders to 
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the Apoptin-treatment, which had to be sacrificed early in the experiment along with animals 
from the buffer- and AdCMV.LacZ treated groups (fig 5A a,b,c). Animals were sacrificed when 
their tumour had reached a minimal size of 1800 mm3 and a height of at least 8 mm (fig 4c,d). 
Between 8 and 28 days after intratumoral injection, all buffer-injected animals had to be 
sacrificed. After 60 days, only 1 of 12 of the AdCMV.LacZ-treated mice survived, whereas at that 
point 7/12 of Apoptin-treated animals were still alive (fig 58). To comply with the standard criteria 
for normal distribution, one outlier from the LacZ-treated group was excluded from statistical 
analysis. This results in a mean survival of LacZ-treated mice of 41 days, compared to a mean 
survival of buffer-treated mice of 27 days (fig 5B). Tumour-bearing mice treated with 
AdMLP.Apoptin, however, survived much longer than the mice in both other groups (mean 
survival 102 days; p<0.01). Six months after treatment, 30% of Apoptin-treated animals were 
completely tumour-free. These results demonstrate that Ad-Apoptin can confer significant 
survival benefits and tumour reduction when used in vivo. 
Discussion 
Here, we describe an unconventional approach for cancer gene therapy that is based on the 
tumour-specific activity of Apoptin. We initially observed that adenoviral transfer of Apoptin into 
subcutaneous HepG2 tumours in nude mice had a negative effect on tumour growth.8 To further 
investigate the therapeutic benefit of AdMLP.Apoptin for these tumours, we now treated well-
established tumours with multiple injections over a period of 1 0 days. With this approach we 
were able to achieve complete regression of tumours treated with AdMLP.Apoptin, thus 
providing proof of principle that Apoptin can be used as an anti-cancer agent. 
Regarded in more detail, the Apoptin-treated tumours can be divided into three distinct 
groups: those with a complete response, those with a significant delay in tumour growth, and 
those with tumour growth kinetics similar to tumours treated with AdCMV.LacZ. Because no 
replicating virus is produced, any tumour cell that escapes viral infection during the course of the 
five treatments will continue to proliferate, provided that there is not too much surrounding 
damage. Thus, differences in response to Apoptin treatment are probably an effect of adenoviral 
dispersion through the tumour. Indeed, the characteristic architecture of HepG2 tumours, with 
their partitioned lobular structure, does not allow an even distribution throughout the tumour after 
a single injection.8 Thus, it is plausible that complete regression occurred only in tumours in 
which all lobes received sufficient adenovirus. The partially responding tumours were most likely 
only transduced in certain areas; although substantial tumour cell death and disruption of tissue 
integrity contributed to a delayed outgrowth of these HepG2 tumours, there was not enough viral 
dispersion to completely eliminate the tumour. In the case of the non-responders, probably only 
a minor percentage of tumour cells were infected, resulting in a rapid outgrowth of the non-
transduced cells. Nevertheless, this in vivo experiment shows a significant survival benefit for 
tumour-bearing mice treated with AdMLP.Apoptin, provided that a substantial percentage of 
tumour cells can be transduced with Apoptin. 
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Investigation of the anti-tumour effect of Apoptin at the cellular level shows that a single 
AdMLP.Apoptin injection causes substantial damage to HepG2 tumours. In contrast, control-
treated tumours showed normal morphology and high proliferation, as determined by BrdU 
labelling. The areas of AdMLP.Apoptin-treated tumours containing Apoptin-positive cells, 
however, showed extensive aberrant morphology and a substantial decrease in proliferating 
cells, already detectable at two days after injection. The extent of damage to the tumour 
architecture surpassed that which would be expected based on the number of positive cells that 
was detected. This observation likely indicates a deleterious effect of dying Apoptin-positive cells 
on surrounding, non-infected cells. Thus, in addition to specific tumour cell-killing by Apoptin, it 
is possible that a critical threshold of apoptosis in tissue can lead to a bystander effect on non-
transduced cells, thereby increasing the overall efficacy. 
There are several pieces of evidence suggesting that AdMLP.Apoptin induced apoptosis in 
the treated tumours. Firstly, Apoptin accumulates in HepG2 tumours in similar structures that 
arise when apoptosis is induced by CAV in chicken lymphoblastoid cells. Secondly, Apoptin 
induces rapid apoptosis in HepG2 cells in vitro. 8 Finally, in contrast to LacZ-transduced tumours, 
Apoptin-positive cells are nearly depleted 6 days after injection. Taken together, these findings 
strongly suggest that the damage observed in these HepG2 tumours is a consequence of 
Apoptin-induced apoptosis. Although Haematoxylin and Eosin staining showed a trend towards 
increased apoptosis in tumours treated with AdMLP.Apoptin, examination of DNA fragmentation 
by TUNEL staining could not confirm this observation (data not shown). This difficulty in 
detecting apoptosis in vivo has been described for several in vivo apoptosis systems; for 
instance, the complete involution of islets of Langerhans in myc-transgenic mice10 or the 
disappearance of the prostate in castrated rats11 . In these cases, the apoptotic process 
combined with phagocytosis occur in such a short time span 12-14, that only occasional apoptotic 
cells are detected. Nevertheless, the entire tissue eventually disappears. 
Gene therapy with Apoptin offers unique advantages over current approaches for cancer 
therapy. For example, resistance to cancer therapies is often caused by the inactivation of 
apoptotic pathways, which has occurred in the majority of tumours. 15-17 Gene therapeutic 
approaches based on restoring part of the apoptotic pathway, for instance transduction of p53, 
p16, Bax and Bcl-x, are expected to be successful in a limited subset of tumours, depending on 
the particular mutations in their apoptotic machinery. The fact that Apoptin does not need a 
functional p53 pathway, is not hindered by common blockage of apoptosis by Bcl-2 or Bcr-abl 
expression and apparently acts downstream of most decision factors, suggest it will be 
applicable to a wide range of tumours. In vitro, Apoptin induces apoptosis in every cancer cell 
type of the extensive panel that has been tested.18 
In addition to therapy-resistance, toxicity to normal tissues often hampers cancer therapies 
such as chemotherapy and radiation. Moreover, most conventional gene therapeutic 
approaches suffer from insufficient tumour cell specificity, as illustrated by reports on toxic 
effects in healthy tissues· due to the use of the Herpes Simplex Virus Thymidine Kinase (HSV-
TK).19·20 Attempts to increase selectivity further include the use of tumour-specific promoters (e.g. 
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CEA, AFP) or targeted vectors. Even if the desired specificity does not abolish the necessary 
potency, these strategies, again, are likely to be applicable to only a subset of tumour types. In 
marked contrast, extensive in vitro data show that Apoptin has unparalleled specificity; despite 
its potency towards tumour cells, no normal cell type tested thus far has ever shown sensitivity to 
Apoptin.3•4·18 Consistent with this, during the in vivo experiments described here, we did not 
observe any toxic effects of AdMLP.Apoptin treatment, corroborating the data of a more 
extensive toxicity study after intravenous injection of AdMLP.Apoptin in healthy rats. 8 
The combination of potency and specificity residing in a single molecule provides new 
possibilities for cancer therapy. So far, the therapeutic use of Apoptin seems to be 
predominantly limited by factors in common with most gene therapy strategies; namely, the 
ability to transduce all target cells. New delivery methods are being developed to increase 
efficacy of spread throughout solid tumors and throughout the body. The Apoptin gene is 
exquisitely suited tor inclusion in technologies such as conditionally replicative viruses21 ·22 or non-
viral transduction methods due to its potency and small size. However, these new delivery 
strategies still have to be validated. At this time, the marked anti-tumour effect and survival 
benefits of Ad-Apoptin as we have shown in this paper already warrant its evaluation tor human 
clinical trials in the near future. 
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Methods 
Cells and cell culture. 
Human hepatoma cells (HepG2) (obtained from ATCC, USA), mycoplasm free and negative in Mouse antibody 
Production (MAP) test, were grown in Dulbeco's modified Eagle's medium (DMEM) C02 (GIBCO laboratories, Grand 
Island, NY, USA) supplemented with 10% fetal calf serum (FCS) at 37"C/5%. The cells were harvested by 
trypsinization, resuspended in cold Hanks (13.6 mM NaCI, 530 ,LIM KCI, 81 ,LIM MgS04 , 44 ,LIM KH2P04 and 34 ,LIM 
N~HP04) containing 2% horse serum and the viable cell number was determined by trypan blue exclusion and 
adjusted to 5*107 cells/ml in serum-free Hanks. Within one hour of harvesting, the cells were injected subcutaneously 
in the flanks of nude mice, depositing 200 ,LII cell suspension per flank with a 25-gauge needle. The cells were kept on 
ice during the time between harvest and injection. 
Viruses and virus techniques. 
The recombinant adenovirus vector expressing Apoptin (Ad.MLP.vp3, further referred to as AdMLP.Apoptin) was 
generated as described previously.• Briefly, 911 helper cells were cotransfected with the linearized Ad adapter 
construct, pMad-vp3, and pJM17. After homologous recombination, this results in an Ad5 genome lacking the E1 and 
E3 regions, containing the transgene under control of the adenovirus major late promoter (MLP). Plaques were 
isolated and after three rounds of plaque purification transferred to PER.c6 cells. These cells contain the E1 region 
regulated by a heterologous promoter which, combined with matched adaptor plasmids, eliminates the generation of 
RCA by heterologous recombination.23 All batches of AdMLP.Apoptin were tested for Apoptin expression by indirect 
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immunofluorescence 24 and for the presence of RCA by a PCR assay.' All virus batches used passed the RCA test 
detecting 1 pfu of an E1-containing adenovirus amidst 107 pfu of an E1-deleted vector. Construction of the 
recombinant adenovirus vector AdCMV.LacZ under the control of the cytomegalovirus enhancer/promoter has been 
reported previously.25 Recombinant viruses were propagated on PER.c6 cells and purified by double CsCI density 
centrifugation. Titers of the viral stocks were determined both by plaque assay on 911 cells.26 Virus was alliquotted 
and stored in sucrose buffer (140 mM NaCI, 5 mM Na,HP04 , 1.5 mM KH2P04 , 20 mM MgCI2 and 5% sucrose) at 
- 80°C. 
lmmunoblot. 
After sacrifice, tumours were dissected and half of each tumour was fixed in 4% formaldehyde for 
immunohistochemistry and half was flash-frozen in -80 °C cold isopentane. Frozen samples were subsequently 
grinded with a microdismembrator, resuspended in 1mllysis buffer (50 mM Tris pH 7.5, 250 mM NaCI, 0.1% Triton 
and protease inhibitors) and incubated on ice for one hour. The lysate was cleared by centrifugation and 
immunoprecipitated with protA beads (Santa Cruz biotechnology, Santa Cruz, California, USA) coupled to a 
polyclonal rabbit antibody recognising the C-terminus of Apoptin, aVP3C. The immunoprecipitates were washed three 
times with cold lysis buffer and boiled for 5 min in Laemli sample buffer. Samples were subjected to electrophoresis 
on a 12.5% polyacrylamide SDS gel, followed by transfer to lmmobilon P membranes (Millipore, Bedford, 
Massachusetts, USA). After blocking in milk buffer (5% milk in Tris-buffered saline with 0.2% Tween (TBST)) the 
membranes were incubated with the mouse monoclonal antibody 111.3 against the N-terminus of Apoptin in milk 
buffer overnight at 4 °C. The membranes were washed with TBST, and proteins were detected with horseradish 
peroxidase-conjugated goat anti-mouse lgG (Sigma-Aldrich, Zwijndrecht, The Netherlands) secondary antibody, 
followed by enhanced chemiluminescence according to the manufacturer's instructions (Amersham, Piscataway, New 
Jersey, USA). 
Animals. 
Male Balb/c nu/nu mice, aged 7-8 weeks (Harlan, The Netherlands) were kept in filtertop cages under Oil-safety 
conditions following Dutch government guide lines. Animals were fed sterilised laboratory chow and water ad libitum 
and were kept at alternating 12-hour periods of light and darkness. All experiments were approved in advance by the 
Dutch animal welfare committee. 
Evaluation of cellular effects after a single intratumoral injection of HepG2 tumours with AdMLP.Apoptin. 
Mice were injected subcutaneously (s.c.) in both flanks with 1 *1 07 HepG2 cells suspended in 200111 serum-free 
Hanks. The mice were checked daily for tumour growth. Once a tumour became detectable by eye, registration of 
tumour growth started by measuring tumour length, width and height using microcalipers and tumour volume was 
calculated every other day. Calculation of tumour volume was done using the following formula: [smallest 
diameter]*[largest diameter]/2. Three weeks after tumour cell injection, when tumours had reached an average 
volume of 350mm', the mice were randomised for one of the three treatment groups (AdMLP.Apoptin, AdCMV.LacZ 
or virus dilution buffer), and each tumour received an intratumoural injection with 5*1 09 pfu virus or control buffer in a 
total volume of 1 00 111. Each following day all mice were weighed and tumours were measured and examined for 
changes in colour or morphology. At day 2, 3, 4, 5 and 6 days after intratumoural injection a group of mice was 
sacrificed, comprising of 3-4 tumours of each treatment group. At sacrifice, blood was collected, and after removal, 
the tumours, liver and spleen were weighed and stored partly in 3,7% formalin or were flash-frozen in liquid nitrogen 
for the prospective measurements. One hour prior to sacrifice each mouse was injected intraperitoneally with 
50mg/kg BrdU (5-Bromo-2'-deoxy-uridine, Boehringer Mannheim, GmbH, Mannheim, Germany). 
Long term analysis of multiple intratumoural injections in HepG2 tumours. 
Mice were injected s.c. in the left flank with 1 *1 07 HepG2 cells suspended in 200111 serum-free Hanks. Every other day 
following tumour cell injection the mice were checked for tumour growth. Once a tumour became detectable by eye, 
registration of tumour growth started as described in the previous section. Calculation of tumour volume was done 
using the following formula: [smallest diameterf*[largest diameter]/2. Height was evaluated separately. Each tumour 
was allowed to grow upto a minimum volume of 250mm3 and a minimal height of 3 mm. When a tumour met both 
these criteria, the mouse entered the experiment and was randomly designated to one of the three treatment groups 
(AdMLP.Apoptin, AdCMV.LacZ or virus dilution buffer). The same day, the first virus injection was given 
intratumourally, followed by four intratumoural injections on alternating days. The injections were given on alternating 
days to allow for resorption of the injected volume prior to the next injection. For each injection 3*1 O' pfu in 50 111 virus 
in virus dilution buffer or virus dilution buffer alone was injected into the tumour tissue that looked most viable (as 
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judged by colour). The tumour was measured every other day until the end-criteria were reached (>1800 mm3 and/or 
> 8 mm in height). At that time the mouse was sacrificed, blood was collected and the tumour was excised, weighed 
and fixed for further examination. 
Histopathological analysis. 
Paraffin-embedded sections were prepared by routine methods and stained with haematoxylin and eosin. 
Additionally, sections (5f1m) were stained for Apoptin and S-galactosidase expression by a three-step 
immunoperoxidase staining using the aVP3C antibody (produced by EurogenTec, Seraing, Belgium), and an anti-S-
galactosidase antibody (DAKO, Glostrup, Denmark). Briefly, slides were deparaffinated, washed and endogenous 
peroxidase activity was blocked for 20' with methanoi/H20 2 0,3%. After rehydration, antigen retrieval was performed by 
a 10' incubation in boiling citrate buffer (0,01 M citric acid/0,01 M sodiumcitrate, pH=6.0). After cooling, slides were 
washed in PBS and incubated overnight with the antibodies anti-VP3C and anti-S-Galactosidase in PBS/BSA1% 
(1 :2000 for both). After washing the slides were incubated with biotinylated anti-rabbit lg (1 :400, 30'). Next, after 
washing, the slides were incubated with biotinylated HRP/streptavidine complex (DAKO, Glostrup, Denmark), washed 
with PBS and developed in di-amino carbazole (DAB). Staining of Apoptin and S-galactosidase was scored 
semiquantitatively by two independent observers and expressed as percentage of positive tumour cells within a 
tumour. DNA-incorporated BrdU was detected by a three-step immunoperoxidase staining with the anti-BrdU 
monoclonal antibody IU4 (Hycult bv, Uden, The Netherlands)." 
Statistics. 
Log rank tests were used for survival analysis. One AdMLP.Apoptin-treated mouse died 67 days after the start of 
treatment for no apparent reason. Since this mouse had been tumour-free for over a month, it was censored in the 
analysis. Based on normal probability plots one outlier (in the LacZ group) was excluded from the log rank test. All 
animals (including outlier) are shown in the Kaplan Meier plot (fig 5). Results were considered statistically significant 
at P < 0.01. In all cases, the investigator responsible for treatment and measurement was 'blinded' to the 
experimental status of the mouse. 
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Abstract 
Biliary tract cancer, or cholangiocarcinoma, has a poor prognosis. Resection is the only 
curative treatment available at the moment, but only a minority of patients is eligible. 
Chemotherapy and y-irradiation are merely palliative, as they are unable to remove the 
malignancy completely. Therefore a more potent therapy is warranted. The chicken anemia 
virus-derived protein Apoptin induces apoptosis in a wide range of human tumor cells. It is 
not hindered by mutations inactivating p53 nor by overexpression of Bcl-2, lesions both 
known to frustrate chemo- and radiation therapy. Thus, we were interested whether Apoptin 
could be effective against cholangiocarcinoma. After overexpression, Apoptin caused 
extensive cell death in three independent cholangiocarcinoma cell lines, CC-LP, CC-SW and 
Mz-ChA-1, regardless of their oncogenic mutations, which included inactivated p16 and p53. 
Moreover, co-expression of the caspase inhibitor p35 with Apoptin delayed the induced cell 
death, but changes in nuclear morphology still occurred early after transfection and nuclei 
eventually disintegrated, suggesting that Apoptin-induced cell death is not blocked by 
mutations in either the initiation or execution phase of apoptosis. Furthermore, we show that 
delivery by an adenoviral vector is an efficient method to express Apoptin in 
cholangiocarcinoma cells and to eradicate them. The fact that all healthy cell types tested to 
date are refractory to Apoptin, combined with its efficient induction of cell death in 
cholangiocarcinoma cell lines, makes Apoptin an attractive candidate for molecular therapy 
of biliary tract cancer. 
Introduction 
Malignancies of the bile duct give rise to high morbidity and mortality. These 
cholangiocarcinomas can be cured by surgery, but only in a minority of cases. Resection is 
particularly difficult due to dissemination of the tumor into different bile ducts 1. At the time of 
diagnosis, only half of the patients are resectable, but even then the 5-year survival rate is only 
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around 25% 2-4. Palliating the effects of biliary obstruction by endoscopic stenting is therefore 
often the only therapeutic possibility 5, especially since chemotherapy and y-irradiation are not 
effective against cho\angiocarcinoma 3'6.7, probably due to molecular alterations of these cells a-
10. During carcinogenesis cells acquire traits that enable them to continue proliferation. Among 
others, this comprises disabling fail-safe mechanisms that normal cells have against 
uncontrolled growth, one of which is the induction of apoptosis 11 . Paradoxically, it is precisely 
this suicide program that cancer therapies such as chemotherapy and radiation employ to 
induce cell death. Thus, when tumor cells have obtained anti-apoptotic lesions they usually 
become resistant to therapy 8·12•13. 
Therefore, successful treatment of cho\angiocarcinoma should be based on an agent that is 
not hindered by these features. In addition, it is important that this agent shows selectivity in 
killing tumor cells and not healthy cells. Cholangiocarcinoma are surrounded by highly 
proliferating cholangiocytes that will be sensitive to treatments targeting cell division. In addition, 
cholangiocarcinomas are located near to or within the liver, which is often particularly sensitive to 
cytotoxic therapies because of its detoxifying function. The sensitivity of these adjacent tissues to 
the anticancer agent limits the therapeutic dose that can be administered and thus should be as 
low as possible 6•14. 
Currently, several innovative strategies are being examined tor treatment of 
cholangiocarcinoma. One such approach uses the combination of radiation therapy with novel 
radiosensitizers such as topoisomerase inhibitors, taxanes and nucleoside analogs 6• In addition, 
other approaches have been designed to target specific tumor properties by inhibiting growth 
factor receptors, cyc\ooxygenases and angiogenesis 15-18. Moreover, therapies based on gene 
delivery use prodrug-enzyme combinations like 5-f\uorouraci\ and cytosine deaminase or the 
expression of specific membrane receptors to enhance tumor uptake of radiolabeled peptides 
19
•
20
. Although many approaches show encouraging results in cell culture and preclinical studies, 
no clinical benefits have yet been reported. 
In this study, we investigated whether the viral protein Apoptin could be a potential anti-tumor 
agent tor cholangiocarcinoma. Apoptin, one of three proteins encoded by the chicken anemia 
virus (CAV), efficiently kills a wide range of human tumor cells, including osteosarcoma, breast 
carcinoma, lymphoma and hepatoma 21 . It was shown that cell death induced by Apoptin 
displays the characteristics of apoptosis. Namely, nuclei condense and eventually show typical 
DNA laddering and the proteases involved in execution of the suicide program, called caspases, 
are activated 22. Interestingly, there are no known mutations in tumor cells that inhibit Apoptin-
induced apoptosis. For instance, non-functional p53 or overexpression of Bc\-2, characteristics 
known to inhibit apoptosis induced by chemotherapy, do not inactivate Apoptin 23-26. Given that 
chemotherapy and radiation are not effective in treating cholangiocarcinoma, Apoptin could be 
an attractive alternative. 
In addition to its potent pro-apoptotic properties, Apoptin exhibits remarkable tumor-
specificity. When Apoptin is over-expressed in non-transformed, primary cells, no adverse effects 
can be detected 27• Moreover, primary fibroblasts stably transtected with Apoptin continue to 
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proliferate up to the same number of passages as their control counterparts (B. Klein and M. 
Noteborn, unpublished data). In addition, Apoptin was nontoxic in human keratinocytes, 
thymocytes, smooth muscle cells, endothelial cells, mesenchymal stem cells and hepatocytes 
when tested in vitro 27·28. This tumor-selectivity renders Apoptin suitable for non-targeted or 
systemic therapy. As a first step to determine whether Apoptin might be useful against 
cholangiocarcinoma, we analyzed whether biliary tract cancer cells are indeed sensitive to 
Apoptin. In this study we show that Apoptin induces robust apoptosis in several 
cholangiocarcinoma cell lines in vitro, and moreover, that replication-deficient adenoviruses 
expressing Apoptin constitute an effective means to kill these cells. 
Results 
Apoptin induces cell death in cholangiocarcinoma cell lines 
To determine whether cholangiocarcinoma-derived cell lines are sensitive to apoptosis induction 
by Apoptin, we analyzed three cell lines CC-SW 29 , CC-LP 29 and Mz-ChA-i 30. CC-SW and CC-
LP both are moderately differentiated adenocarcinoma originating from bile duct epithelium. CC-
SW was derived from a patient without treatment prior to resection and CC-LP was isolated from 
a patient who underwent chemotherapy with 5-fluorouracil and leucovorin prior to surgery. Mz-
ChA-1 was cultured from a gall bladder adenocarcinoma metastasis. Several oncogenic 
mutations have been described for these cell lines, including hypermethylation of the pi 6 
promoter in CC-LP 38 and the disruption of the transforming growth factor beta (TGF-13) signaling 
pathway in Mz-Cha-1 39. In addition, we observed overexpression of p53, indicative of non-
functional p53 protein, in CC-SW and Mz-Cha-i, and a complete absence of p53 protein in CC-
LP cells (data not shown). In general, p53 mutations are frequently found in cholangiocarcinoma 
38
.4°.42 , as well as overexpression of Bcl-xL 43 and HER-2/neu 17. 
The three cholangiocarcinoma cell lines were transfected with plasmids encoding Apoptin or 
desmin, the structural protein of muscle cells, as a non-apoptosis inducing negative control. On 
several days after transfection cells were fixed and analyzed by indirect immunofluorescence 
using specific antibodies for either Apoptin or desmin. Positive cells were judged for nuclear 
morphology based on DNA staining with DAPI, which stains intact DNA strongly, apoptotic DNA 
weakly and allows detection of DNA fragmentation (figure 1 a). Two days after transfection, the 
percentage of apoptotic nuclei among Apoptin positive cells was already considerable higher 
compared to desmin-positive cells (figure i b). Several days later, Apoptin induced cell death up 
to 80-90% in all three lines. These data demonstrate that regardless of the molecular alterations 
that characterize these tumor cell lines, they are nevertheless sensitive to induction of apoptosis 
by Apoptin. 
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Figure 1A. Apoptin induces cell death in three cholangiocarcinoma cell lines. Plasmids encoding Apoptin 
and desmin were transfected into CC-LP, CC-SW and Mz-ChA-1 cells. Expression was visualized by indirect 
immunofluorescence. Representative images are shown from CC-SW cells expressing Apoptin and desmin, but results 
were similar in CC-LP and Mz-ChA-1 cells. Apoptotic morphology was determined by DAPI staining. 
Figure 1 B Apoptin induces cell death in three 
cholangiocarcinoma cell lines. Percentage of 
apoptotic nuclei in Apoptin- (grey bars) or desmin-
(black bars) transfected cholangiocarcinoma cell lines 
(CC-SW: filled, CC-LP: horizontal stripes and Mz-ChA-
1: diagonal stripes) measured on several days after 
transfection. In each experiment at least 100 cells 
expressing Apoptin or desmin were examined and the 
values are the mean of three independent experiments 
for CC-SW and CC-LP and of two independent 
experiments for Mz-ChA-1. 
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Results 
Apoptin-induced cell death is delayed but not abrogated by inhibition of caspases 
Since conventional chemo- and radiation therapy are thwarted by mutations in the apoptotic 
pathway, we investigated whether a block downstream in the apoptosis pathway would inhibit 
the anti-tumor activity of Apoptin in cholangiocarcinoma cell lines. To this end, caspase inhibitor 
p35, a gene derived from baculovirus whose product blocks both initiator and execution 
caspases 44, was co-expressed with Apoptin in CC-LP cells. Again desmin was used as negative 
control. Death of CC-LP cells induced by Apoptin was significantly delayed when p35 was co-
expressed (figure 2a). This indicates that cell death caused by Apoptin in cholangiocarcinoma 
occurs at least in part via the activation of caspases, and thus uses components of the apoptotic 
machinery of the cell as it does in osteosarcoma 22. However, coexpression of p35 with Apoptin 
did not lead to a decrease in cells with abnormal nuclei compared to expression of Apoptin 
alone. In fact, although typical apoptotic morphology was absent, these cells displayed slight 
changes in nuclear morphology that were not observed in cells coexpressing p35 and desmin 
(figure 2b). Furthermore, four days after transfection, the percentage of dead cells expressing 
Apoptin increased substantially above background. Thus, under these conditions, caspase 
inhibition seems to delay Apoptin-induced death rather than blocking it completely. 
Anti-tumor effect of Apoptin expressed by an adenoviral vector 
Because Apoptin is not endogenously present, it will have to be introduced into tumor cells. One 
of the most efficient delivery methods available at the moment is the adenoviral vector system. 
To explore the possibility whether gene therapy with Apoptin might be effective against 
cholangiocarcinoma, we used a replication-deficient adenovirus vector expressing Apoptin or 
the LacZ gene as a negative control. Three days after infection, the number of CC-LP cells 
dramatically decreased with increasing dose of viral vectors expressing Apoptin until no cells 
were left, while with the same or even higher doses of control virus, the cells remained unharmed 
(figure 3). Similar results were obtained in cell viability assays using the WST-1 method (data not 
shown). These data provide a proof of principle that when Apoptin is efficiently transduced to 
tumor cells, they can all be eliminated. 
Figure 2A. Effects of the caspase inhibitor p35 
on Apoptin-induced cell death. Induction of 
apoptosis by Apoptin (grey bars) in CC-LP cells is 
delayed by coexpression of p35 (striped bars). Desmin 
(black bars) constitutes a non-apoptosis inducing 
control and thus represents transfection toxicity. Values 
represent the mean of three independent experiments 
in which at least 1 00 positive cells were examined 
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IFA DAPI 
Figure 2 B Effects of the caspase inhibitor p35 on Apoptin-induced cell death (cont.) Co-expression of 
desmin and p35 does not lead to altered nuclear morphology (a+b). When Apoptin is co-expressed with p35, the 
overall number of apoptotic cells is reduced but the non-apoptotic cells show changes in nuclear morphology (c+d 
and e+f). Approximately half of the cells expressing Apoptin and p35 still undergo apoptosis four days after 
transfection (g+h). 
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Figure 3. Expression of Apoptin by adenovirus vectors efficiently kills CC-LP cells. CC-LP cells were 
infected with an increasing number of viral particles per cell (m.o.i.) from a replication-deficient adenoviral vector 
expressing Apoptin (Ad-Apoptin) or marker protein 13-galactosidase (Ad-LacZ). Remaining cells were visualized by 
Giemsa staining 
Discussion 
The study described here shows that Apoptin could be a candidate for treatment of 
cholangiocarcinoma. We first showed that cholangiocarcinoma cells can be effectively killed by 
Apoptin. Cholangiocarcinomas have been shown to harbour multiple anti-apoptotic mutations, 
including p53 mutations and upregulated Bci-XL 38•43 , lesions that can lead to drug resistance 8·12 . 
Importantly, the three independent cholangiocarcinoma cell lines tested here were equally 
sensitive to Apoptin-induced apoptosis, including CC-LP cells which failed to respond to 
chemotherapy in vivo. Even when caspases were blocked by a broad-spectrum inhibitor such as 
p35, the cells still died, although the process was delayed. Probably cell death is more efficient 
when caspases cleave crucial substrates such as PARP, Bid and DNase, subsequently disabling 
several components of the cell simultaneously, including those involved in metabolism and DNA 
integrity 45 . The residual apoptosis induced by Apoptin could be explained by incomplete 
inhibition by p35 under these transient coexpression conditions. However, the effect of p35 is 
detectable by the nuclear changes that occur in approximately all non-apoptotic Apoptin-
expressing cells, which are absent when p35 is not co-expressed. Eventually, the nuclei 
disintegrate completely in a considerable percentage of these cells with altered nuclear 
morphology, suggesting Apoptin causes such damage that the cells are no longer viable. 
Significantly, the delay of cell death rather than inhibition of Apoptin-induced apoptosis by p35 
has been observed previously in osteosarcoma cells 22, and several groups have reported that 
caspase inhibition after an apoptotic insult leads to loss of clonogenicity 46.47 . Thus, also in 
cholangiocarcinoma, mutations in both the decision and execution phase of apoptosis are not 
likely to confer resistance to Apoptin. 
The therapeutic window of an anticancer agent is not only determined by its potency, but also by 
its toxicity to healthy surrounding tissues. Notably, it was demonstrated that human hepatocytes 
are refractory to Apoptin when injected as a recombinant protein in vitro 28 . In addition, no 
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hepatotoxicity was observed after intravenous administration of an adenoviral vector expressing 
Apoptin in rats 35. In the future, the sensitivity of cho\angiocytes to Apoptin will need to be 
assessed. Due to technical difficulties with obtaining sufficient cholangiocytes and their limited 
culture time, this question can be best addressed in vivo. In order to achieve this, an efficient 
delivery method is required. As described below, several approaches are being pursued at the 
moment. If Apoptin indeed shows the same specificity for cholangiocarcinoma compared to 
cholangiocytes as has been demonstrated, for instance, in tumorigenic fibroblasts and 
keratinocytes compared to their normal counterparts 27 , Apoptin may be applicable in diagnosis 
of cholangiocarcinoma as well. At the moment diagnosis is frequently based on suspicion 
because endoscopic brush cytology and/or biopsies and imaging studies are often negative for 
malignancy 48•49 • 
The tumor-selectivity of Apoptin renders it suitable for systemic therapy, which in the case of 
non-resectable cholangiocarcinoma would be preferable. Alternatively, semi-regional treatment 
by occlusion of the bile ducts would also be a possibility. In any case, the major prerequisite at 
the moment is a suitable vector to deliver the Apoptin gene. In this study, we show that 
adenoviral transduction of Apoptin is an effective method of introducing Apoptin into 
cholangiocarcinoma cells in vitro, a procedure that subsequently causes the elimination of all 
tumor cells. Others have also reported that cholangiocarcinoma cells can be efficiently 
transduced by adenovirus 19·50, indicating that the receptor is present. We have shown that 
replication-deficient adenovirus vectors expressing Apoptin have significant anti-tumor effects 
against xenografted hepatoma, in some cases leading to complete regression 36 • However, 
these effects were depended on efficient penetration and transduction, which was only achieved 
in a fraction of the tumors. Therefore, it is not likely that replication-deficient adenoviral vectors 
will be very effective in delivering Apoptin to all cells within a cholangiocarcinoma, especially with 
its difficult topology. A promising strategy would be to use conditionally replicating adenoviruses 
(CRADs)51 that would nevertheless require retrograde injections into the cho\angiocarcinoma 
tumor mass, but would then be able to spread to deeper layers and more distal bile ducts. 
Inclusion of Apoptin into these vectors could in theory add essential potency and specificity to 
these vectors. Previous studies have already shown that the production of adenoviral particles is 
completed prior to the induction of cell death by Apoptin 35 , rendering this a technical feasible 
approach. Alternatively, fusion of Apoptin to a peptide that confers the ability to cross cell 
membranes to the protein would eliminate the need for intra-tumoral injections. Efficient 
transduction by proteins fused to the TAT-peptide of virtually all tissues in a living mouse has 
been described 52, and the selectivity of Apoptin renders it suitable to such a systemic approach. 
In conclusion, the lack of efficient treatment for cholangiocarcinoma warrants the evaluation 
of alternative treatments. We propose that Apoptin could be a potential candidate, as it is highly 
effective in killing several cholangiocarcinoma cell lines, in spite of their molecular alterations. 
The selectivity of Apoptin observed so far implies a large therapeutic window, although this 
needs further experimentation for cholangiocarcinoma. The development of an efficient delivery 
method for Apoptin could potentially provide a new treatment modality for this incurable tumor. 
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Cells and cell culture 
The cholangiocarcinoma cell lines CC-LP ", CC-SW 2' and Mz-ChA-1 30 and adenovirus producer cell lines PER.C6 31 
and 911 32 were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 100 
U/ml penicillin and 100 ,ug/ml streptomycin (Life Technologies, Rockville, Md) in a 5% C02 atmosphere at 37°C. For 
immunofluorescence, cells were grown on glass microscope slides. 
Plasmids and transfection 
Expression plasmid pCMV-vp3 contains CAV DNA sequences encoding Apoptin (nt 427-868) under control of the 
cytomegalovirus (CMV) enhancer/promoter 26 . pCMV-desmin encodes desmin, a component of type II intermediate 
filaments, and was used as a negative control for the induction of apoptosis 33, pCMV-neo is the empty vector control 
26
• The subcloning of the eDNA of p35 in pCMV has been described previously 22. pAdApt-vp3 was generated by 
ligation of the Apoptin-BamH1 fragment from pCMV-vp3 into the adenoviral transfer vector pAdApt constructed by 
lntrogene (now Crucell Holland BV). 
Plasmid DNA was purified by centrifugation in a CsCI gradient and transfection was carried out by complexing 
with FuGENE 6 Transfection Reagent according to the manufacturer's protocol (Boehringer Mannheim, Almere, The 
Netherlands). In co-transfections, pCMV-p35 or pCMV-neo was used in three-fold excess to the plasmid encoding the 
protein that was stained by immune fluorescence (Apoptin or desmin). The DNA:Fugene ratio was 1:3 in all cases. 
Indirect immunofluorescence and DAPI staining 
Indirect immunofluorescence was performed as described previously 34• To demonstrate the presence of Apoptin and 
establish its cellular localization in transfected cells, the cells were fixed with 80% acetone. The indirect 
immunofluorescence assay (IFA) was performed with hybridoma culture supernatant containing the mouse 
monoclonal antibody (rnAb) 111.3 for Apoptin and with a 1 00-fold dilution of mAb 33 (Monosan, Uden, The 
Netherlands) for desmin. Fluorescein-isothiocyanate-labeled goat anti-mouse antibody (Jackson lmmunoresearch 
Laboratories Inc., West Grove PA, USA) was used as second antibody. Nuclear DNA was stained with 1 ,ug/rnl 2,4-
diamino-2-phenylindole (DAPI) in 2% 1, 4 diazabicyclo-[2,2,2]-octane in glycerol/0.1 M TrisHCI pH 8.0. 
Adenovirus production and infection 
A replication-deficient adenoviral vector lacking the E1 region and expressing Apoptin under the regulation of the 
CMV promoter was generated by cotransfecting near-confluent monolayers of PER.C6 cells with the A/m-ITR fragment 
of adenovirus type 5 and pAdApt-vp3. When cytopathogenic effects occurred, cells were harvested and lysed by 
freeze-thawing and the subsequent viral supernatant was serially diluted on PER.C6 cells. Individual clones were 
tested for Apoptin expression by immunofluorescence and for the absence of replication-competent adenovirus by 
PCR as described 35• The recombinant adenoviral vector AdCMVIacZ carries the E. coli LacZ gene expressing ~­
galactosidase under control of the CMV promoter 36• Large-scale production of adenovirus was performed according 
to Fallaux et al. 32 • Briefly, PER.C6 helper cells were infected with approximately 5 plaque-forming units per cell, in a 
small volume of DMEM containing 2% horse serum (HS) (heat-inactivated at 56°C for 30 min). After a 2-hour 
incubation, DMEM/1 O%FCS was added to each flask. Forty-eight hours later, the detaching cells were harvested and 
collected in PBS/2% HS. Viruses were isolated from the producer cells by freeze/thawing, purified by cesium-chloride 
gradient centrifugation and dialysis against a sucrose-containing buffer. Viral titers were determined by plaque assays 
essentially as described by Graham and Prevec 37• Briefly, adenovirus stocks were serially diluted in DMEM/2% HS 
and added to near-confluent 911 cells in six-well plates. After 2 hours of incubation at 3JOC/5% C02, the medium was 
replaced by agar-containing culture medium. Plaques were scored on day 5-7 after infection. 
Cholangiocarcinoma cells were counted and plated four to six hours prior to infection. At the time of infection, the 
appropriate number of infectious viral particles per cell (multiplicity of infection, m.o.i.) was added in a small volume of 
DMEM/2%HS. After a 2-hour incubation, the volume was increased to regular levels with DMEM/1 O%FCS. This virus-
containing medium was replaced the following morning with DMEM/10%FCS. 
Giemsa staining 
For detection of the number of attached cells, CC-LP cells were washed twice with PBS three days after infection and 
air-dried. Cells were subsequently fixed in methanol/acetic acid (3:1) for 15 minutes at room temperature. Cells were 
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incubated with Giemsa solution (3% Giemsa (Merck, Darmstad, Germany) for 30 minutes in 1 mM Na2HP04 , pH 7.0). 
After staining, the cells were washed four times with deionized water and allowed to air-dry. 
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Abstract 
Apoptin is one of few cytocidal proteins endowed with tumor-specificity. This protein is 
activated and induces apoptosis in a wide variety of tumor cells but leaves non-transformed 
cells unharmed. Currently, systemic therapies are hindered by toxicity to rapidly dividing 
tissues, including the immune system. Apoptin is therefore an attractive candidate for 
systemic cancer therapy. To investigate whether Apoptin remains inert in normal 
lymphocytes, even during development, activation and proliferation of these cells, we 
generated transgenic mice expressing Apoptin under the regulation of the H2-J<I' promoter. 
The Apoptin-transgenic mice were born with the expected Mendelian distribution and 
exhibited normal development. Robust Apoptin RNA expression was detected in thymus and 
spleen. Apoptin protein, however, could be detected only after concentration by 
immunoprecipitation. In addition, we show that the amount of Apoptin protein detected in 
transgenic splenocytes was significantly increased by inhibition of the proteasome. This 
instability of Apoptin in normal cells could be part of the explanation for its lack of activity in 
normal cells. 
Importantly, there was no difference in B, helper T-or cytotoxic T cell numbers derived 
from transgenic spleens compared to spleens from wild-type littermates, suggesting that 
none of these cell types is sensitive to Apoptin expression during any of their developmental 
stages. Moreover, stimulation of B cells with LPS or stimulation ofT cells with IL-2 and conA 
did not result in a growth disadvantage for the transgenic lymphocytes, nor did it lead to 
increased cell death. These data show that normal lymphocytes tolerate the expression of 
Apoptin during both activation and proliferation, eliminating a first hurdle for the development 
of systemic therapy with Apoptin. 
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Introduction 
Chickens infected with the chicken anaemia virus (CAV) not only suffer from anaemia, but also 
from a depletion of thymocytes 1•2. Thymuses isolated from CAY-infected chickens showed DNA-
Iaddering typical of apoptosis 3 . This was also observed after expression of the viral genome in 
transformed chicken T cells, and when one of the three proteins encoded by CAV was expressed 
separately 4 . This protein was therefore named Apoptin. Subsequent studies revealed that 
Apoptin induced apoptosis in cells from human and rodent origin as well 5. Strikingly, the ability 
to induce apoptosis is restricted to tumor and transformed cells. In these cells, Apoptin localizes 
to the nucleus and causes cell death. Expression of Apoptin in 'normal' diploid cells on the other 
hand shows a sequestration of Apoptin in the cytoplasm, sometimes appearing in vesicular 
structures, and the cells remain viable without any signs of apoptosis 6. 
At this moment it is not clear what element of the 'transformed nature' of a cell is responsible 
for the activation of Apoptin that renders it capable of inducing apoptosis. However, already the 
selective tumor-cell killing of Apoptin offers an excellent opportunity for the development of new 
therapies for cancer. Current cancer therapies are, among other things, limited by their toxicity to 
normal tissues 7. Innovative strategies designed to circumvent this problem aim at tumor-specific 
delivery of a toxic substance, or alternatively, at systemic delivery of a tumor-specific 
substance 8. Apoptin is one of few proteins that may be suited for the latter approach. 
In previous studies, we have shown that transfer of the Apoptin gene by replication-deficient 
adenoviruses to subcutaneous human hepatoma grafted on nude mice resulted in considerable 
demise of tumor cells 9 . Moreover, the Apoptin treatment conferred a significant survival benefit 
to the mice 10 . In addition to the absence of adverse effects of the treatment for the mice, primary 
rat hepatocytes remained unscathed by adenovirally expressed Apoptin, both in vitro and in vivo. 
These data confirm that Apoptin is capable of eradicating tumor cells in vivo. Nevertheless, the 
studies with the replication-deficient adenovirus expressing Apoptin emphasized the main curb 
of gene therapy at this moment, namely the efficiency of transduction. Virus spread through solid 
tumors is severely limited, so only a small percentage of the entire tumor mass can be infected. 
Thus, new treatment modalities need to be developed that more efficiently transduce Apoptin to 
all tumor cells. Based on the unique properties of Apoptin, these strategies will be focussed on 
systemic delivery, such as insertion of the Apoptin gene into replicating vectors, or modification 
of Apoptin protein so it can pass cell membranes. 
One of the normal tissues affected by systemic anticancer therapies is the immune system 7. 
Given that CAV causes apoptosis in chicken thymocytes, we wanted to know if problems can be 
expected in the lymphoid department of the body when Apoptin is employed for systemic 
therapy. To include all stages of differentiation and proliferation of lymphocytes, a transgenic 
approach was taken to answer this question. 
We found that transgenic mice expressing Apoptin under the regulation of the H2-Kb 
promoter are viable, express Apoptin mainly in the lymphoid organs, and have normal B and T 
cell populations. In addition, the biochemical properties of Apoptin in these transgenic mice 
provide a possible explanation for the tumor-specificity of Apoptin, namely its short half-life in 
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normal cells. The observation that even during stimulation of B and T cells Apoptin does not 
become active offers great promise for systemic therapy with Apoptin. 
Results 
. ;;; 
% 
0 g. 
"' 
Apoptin-transgenic mice are viable 
To obtain insight in the effects of prolonged expression of Apoptin during differentiation and 
proliferation of lymphoid cells, Apoptin-transgenic mice were generated. Because we were not 
initially interested in the effects of Apoptin on the embryonic development a promoter was 
chosen that starts protein expression late in embryogenesis. This promoter is the H-2Kb 
promoter, the murine homologue of human MHC class I. Transgenic mice have been generated 
previously using the same construct 11 . Expression of the transgene was hardly detectable 
during the first 11 days of embryogenesis, after which it rapidly increased. Due to a partial 
promoter region and positional effects at the site of integration 12, expression does not occur in 
all tissues as would be expected from a general gene product like MHC class I. Rather, 
expression in adult mice was high in spleen, lymph nodes, lung and liver which makes this 
construct suitable to test our hypothesis on the effects of Apoptin in lymphocytes. 
The Apoptin gene was inserted in the first exon of the H-2Kb promoter. To test whether 
Apoptin expressed by this construct is capable of inducing apoptosis, we transiently transfected 
it into cultured Saos-2 osteosarcoma cells. Apoptin expressed by the H-2Kb promoter induced 
apoptosis to a similar extent as when expressed from a CMV promoter (fig. 1 a), demonstrating 
that Apoptin is functional. 
After pronuclear injection seven transgenic founders were born among 51 pups. H-2Kb-
Apoptin mice are born in the expected Mendelian ratios, are fertile, and do not show any gross 
morphological or behavioural abnormalities (data not shown). The presence of the Apoptin gene 
was confirmed by Southern blotting (fig. 1 b) and PCR analysis (fig. 1 c). Sequence analysis 
revealed an intact Apoptin gene in different founders (data not shown). 
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Figure 1A Induction of apoptosis by 
pH2-Kb-Apoptin. 
Osteosarcoma (Saos-2) cells were transiently 
transfected with pH2-Kb-Apoptin (filled 
diamond), pCMV-Apoptin (open square) or 
pCMV-desmin (filled triangle). Cells positive for 
the transfected protein as judged by 
immunofluorescence were scored for apoptosis 
based on nuclear morphology on day 3, 4 and 5 
after transfection. 
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Figure 1 B Characterization of H2- Kb-Apoptin 
mice by Southern and PCR analysis. 
(B) H2-Kb-Apoptin transgenic mice were identified by 
hybridising Xbal-digested DNA with a 32P-Iabeled 
Apoptin probe on Southern blot. 
(C) Additionally, a PCR method was developed that 
also specifically detects H2-Kb-Apoptin DNA. (+) 
indicates H2-Kb-Apoptin founders and (-) wild-type 
littermates. 
Apoptin is primarily expressed in lymphoid tissues 
To determine Apoptin expression in different tissues, cytoplasmic RNA was isolated from 
different organs and hybridised with a 32P-Iabeled Apoptin probe. Apoptin mRNA could easily be 
detected in thymus, spleen and lung (fig. 2a). A more detailed insight in what cell types express 
Apoptin was obtained by RNA in situ hybridization (fig. 2b). In spleen sections, double staining 
with an antibody against B cells demonstrated that virtually all B cells express Apoptin. T cells 
were stained with an antibody directed against CD3 in both spleen and thymus sections. 
Double-staining with RNA in situ hybridization revealed that a subset ofT cells express Apoptin 
(fig. 2b). 
Founder2 Founder6 
HT BKSULu H T M B K S U Lu 
28S 
18S 
Figure 2A. RNA expression profile of H2- Kb-Apoptin mice. 
Total RNA was isolated from heart (H), thymus (T), muscle (M), brain (B), kidney (K), spleen (S), liver (Li) and lung (Lu) 
from two H2-Kb-Apoptin mice and analysed by Northern blot using a 32P-Iabeled Apoptin probe. 
96 
Results 
RNA in situ only Anti-CD3 Anti-CD220 
Figure 28. RNA in situ expression in the spleen of H2-Kb-Apoptin mice. 
Sequential sections from the spleen of a H2-Kb-Apoptin mouse were hybridised with a dig-labelled RNA antisense 
probe to detect Apoptin mRNA (purple signal) and were co-stained with antibodies against CD3 and CD220 to identify 
T and B cells, respectively (brown signal). The upper panel shows images taken at a 20x magnification; the images of 
the lower panel are taken from the same sections but magnified 40x. RNA in situ hybridisations of spleen sections from 
wild-type mice with the anti-sense probe were negative, as were hybridisations of sections from H2-Kb-Apoptin mice 
with the sense probe (data not shown). 
Apoptin is unstable in transgenic tissues 
Although the Northern blot results (fig. 2a) show a robust expression of Apoptin in these mice, 
Apoptin protein could not be detected by immunohistochemistry on sections of transgenic 
tissues. This is not likely due to unavailability of the epitope, because in previous experiments 
Apoptin protein was detectable in tissue sections after adenovirus-transduction (ref. 10 and S. 
Rutjes, unpublished data), demonstrating that the antibody should be able to recognize Apoptin 
under these conditions. However, concentrating the amount of Apoptin protein by 
immunoprecipitation from freshly isolated spleen, lung or cultured splenocytes yielded a weak 
signal on Western blot, albeit with low reproducibility (fig. 3a). Since the combination of high RNA 
expression with hardly detectable protein expression points in the direction of an unstable 
protein, we tested if Apoptin could be stabilized to a detectable level in the transgenic 
lymphocytes by inhibition of protein degradation. Indeed, after inhibiting the proteasome with 
CBZ/LLL or lactacystin, a significant amount of Apoptin protein was detectable (fig. 3b), 
indicating that although the protein is expressed from the RNA it is unstable in these cells. 
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Figure 3. Apoptin protein expression in H2-Kb-Apoptin mice. 
(A) Freshly isolated splenocytes (S) or lung frozen in liquid nitrogen and pulverized (Lu) from three H2-Kb-Apoptin mice 
(Tm 1, 2 and 3) and one wild-type mouse were lysed and subjected to immunoprecipitation using an Apoptin-specific 
rabbit antibody. Samples are subsequently run on Western blot and stained with mouse monoclonal 111.3 directed 
against Apoptin. Lysate from Saos-2 cells tranfected with pCMV-Apoptin (A) serves as a positive control for Apoptin 
detection on Western blot. The arrows indicate the molecular weight of Apoptin (16 kD). 
(B) Splenocytes derived from two H2-Kb-Apoptin mice (Tm 1 and 2) and from 1 wild-type mouse were treated with 
proteasome inhibitor CBZ/LLL (3L), lnterferon-y (~ or not treated (n.t.) and subsequently lysed, immunoprecipitated 
and subjected to Western blot analysis as described in figure 3A. 
A separate set of experiments shows that Apoptin can in fact be ubiquitylated, a prerequisite for 
recognition by the proteasome. SV40-transformed fibroblasts were transfected with Apoptin and 
HA-tagged ubiquitin. After 48 hours a proteasomal inhibitor was added to facilitate detection by 
accumulating ubiquitylated proteins. Apoptin was immunoprecipitated from cell lysates and 
staining of HA-ubiquitin on Western blot revealed Apoptin-ubiquitin conjugates (fig. 4). Proteins 
known to be ubiquitylated and degraded by the proteasome, like p53 and c-myc, also portray a 
high molecular weight smear after proteasomal inhibition (fig. 4 and ref. 13). It represents the 
molecule targeted for degradation, in this case Apoptin, with ubiquitin chains of various lengths 
attached to it. 
Apoptin does not interfere with B and T cell development 
Given that the spleen has the highest expression of Apoptin RNA and protein in H2-Kb-Apoptin 
transgenic mice, we investigated whether Apoptin expression caused any deleterious effects in 
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Figure 4. Apoptin is ubiguitylated and 
degraded by the proteasome. 
SV40·transformed fibroblasts were cotransfected 
b. WCL 
with Apoptin (vp3) and HA-ubiquitin (ubi), Apoptin 
(vp3) alone, or p53 with HA-ubiquitin {ubi), in duple. 
After 48 hours proteasome inhibitor (CBZ/LLL) was 
added to one sample of each condition and 
incubated overnight. After lysis, part of the whole cell 
lysates (WCL) was saved as a control for transfection 
efficiency, the rest was subjected to 
immunoprecipitation (IP) with a-VP3C for samples 
transfected with Apoptin or D0-1 for samples 
transfected with p53. The western blot (WB) of the IP 
was stained with a-HA (a) and the blotted whole cell 
lysates with a-Apoptin and a-p53 (b). 
WB: a-Apoptin/p53 
-- :--lp53 
---
'Apoptin 
splenocytes. Since the bulk of spleen cells comprise B and T cells, and the deletion of any of 
these cells would not lead to an immediately apparent phenotype, we first looked with FACS 
analysis whether all major cell types were present. As can be seen in figure 5, no differences 
between transgenic and wild-type littermates were found in the numbers of B cells, helper- or 
cytotoxic T cells, demonstrating that Apoptin does not interfere with the development of these 
lymphocytes. 
Apoptin does not induce apoptosis in proliferating B and T cells 
Next, it was determined whether stimulation of these cells might activate Apoptin to cause 
apoptosis. B cells were magnetically selected from wild-type and transgenic spleens and 
stimulated with lipopolysaccharide (LPS). The growth curves in figure 6a show that proliferation 
of B cells is not hindered by Apoptin expression, since the transgenic cells multiply to the same 
extent as wild-type control cells. Moreover, although the cells gradually die in culture, Apoptin 
does not cause additional cell death in these stimulated B cells (fig. 6a). The same holds true for 
the concanavalin A and IL-2 activated T cells from B cell-depleted spleens. The growth kinetics 
of the T cells in culture varied significantly between experiments; therefore, the cultures from 
different spleens are depicted separately. Again, the transgenic cells proliferate with similar 
kinetics compared to cells from the wild-type littermate (fig. 6b). Despite the difference in growth 
kinetics, the increase in cell death due to cell culture is remarkably consistent between the T cell 
cultures. Evidently, cell death was not enhanced by expression of Apoptin. Taken together, these 
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CDS+ CD19+ 
Figure 5. Presence of different cell types in 
spleens derived from H2-K"-Apoptin and wild-
type mice. 
Splenocytes from three H2-K"-Apoptin (grey bars) 
and three wild-type littermates (black bars) were 
stained with labelled antibodies directed against 
CD3 (all T cells), CD4 (helper T cells), CDS (cytotoxic 
T cells) and CD19 (B cells) and analysed by FACS. 
The percentage of positive cells relative to the total 
cells counted is depicted 
data show that Apoptin expression does not interfere with the differentiation of lymphocytes and, 
importantly, that activation of B and T cells does not trigger Apoptin to induce apoptosis. 
Discussion 
The generation of transgenic mice expressing Apoptin allows us to address several important 
questions. Up to date, all studies on Apoptin have been performed by transient expression. This 
restricts the data to cell types that can be subjected to in vitro culture, which especially for 
primary cells is usually of short duration. Possibly, some normal cells will be sensitive to Apoptin 
after a longer expression period. Specifically, tumor cells do not often acquire entirely new traits 
but usually show simultaneous reactivation of different pathways. These pathways are present in 
normal cells but are usually carefully guarded and/or inhibited except for the short period when 
they are necessary, for instance to divide (sustain cell number), invade (immune cells) or acquire 
an extended lifespan (reproductive cells) 14. It is therefore conceivable that Apoptin might be 
activated during certain stages of proliferation or differentiation of normal cells in the body. For 
any future therapy based on Apoptin it is imperative to know if and where normal conditions exist 
that allow Apoptin activation, giving rise to toxic side effects of systemic treatment. This 
information can then be used to choose the best delivery system, thereby avoiding the cells that 
would be sensitive. Because the immune system is often adversely affected as a side effect of 
cancer therapy, we decided to study these cells first. 
In this study, we show that mice expressing Apoptin under the regulation of the H2-Kb 
promoter are viable and apparently healthy. As expected, the expression is highest in lymphoid 
organs. Interestingly, we observed that Apoptin protein is unstable in these cells. It is not likely 
that this is an artefact of these transgenic mice, since no mutations in the Apoptin gene were 
found in any of the founders. Additionally, the construct used to generate the mice induced 
significant apoptosis in tumor cells, indicating that Apoptin expressed by this promoter is 
functional. Furthermore, degradation via the proteasome is a highly regulated process. The fact 
that Apoptin is ubiquitylated shows that there is an E3 ligase present in cells that is able to 
recognize the protein and conjugate ubiquitin specifically to one or more lysine residues of 
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Figure GA+ B. Faith of B cells derived from H2-Kb-Apoptin and wild-type mice after in vitro stimulation 
with lipopolysaccharide (LPS). 
A: Growth curves of B cells from H2-Kb-Apoptin (open square) and wild-type (black diamant) mice after positive 
selection with CD19-microbeads and culture in medium supplemented with 5 ~g/ml LPS. 
B: Percentage of B cells from H2-Kb-Apoptin (open square) and wild-type (black diamant) mice undergoing cell death 
during culture. 
Figure GC+ D. Faith of T cells derived from H2-Kb-Apoptin and wild-type mice after in vitro stimulation 
with concanavalin A and IL-2. 
C: Growth curves of T cells from H2-Kb-Apoptin (open square) and wild-type (black diamant) mice in three separate 
experiments. Each symbol (diamant, circle or square) represents two littermates, one wild-type (closed symbol) and 
one Apoptin-transgenic (open symbol). Splenocytes were depleted from B cells with Goat-anti-mouse-beads and 
cultured in the presence of con A and IL-2. 
D: Percentage of T cells from H2-Kb-Apoptin (open square) and wild-type (black diamant) mice undergoing cell death 
during culture. 
Apoptin. In a separate study, microinjection of recombinant Apoptin protein also revealed 
increased degradation of Apoptin in normal fibroblasts compared to tumor cells (Zhang et a!, 
submitted). Taken together, these data indicate that instability of Apoptin may be a general 
phenomenon in normal cells. 
Recent data shows that Apoptin is differentially modified, namely phosphorylated specifically 
in tumor cells 15 . When constitutive phosphorylation is mimicked by inserting a glutamic acid at 
the site of phosphorylation, this mutant Apoptin is now able to induce apoptosis in normal cells 
as well. Consequently, tumor-specific activation of Apoptin could be the result of a kinase that is 
specifically upregulated in tumor cells. Alternatively, it is also possible that the Apoptin protein is 
not available for the kinase in normal cells due to binding to other molecules in the cell. 
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Nonetheless, it should be noted that a non-phosphorylatable mutant of Apoptin can still kill 
tumor cells and remains inactive in normal cells, indicating that phosphorylation is not the only 
determinant of the tumor-specificity of Apoptin. The instability of Apoptin in normal cells may 
contribute to the specificity as well. It will be interesting to see whether phosphorylation can 
prevent Apoptin from ubiquitylation, or reversely, whether ubiquitylation of Apoptin in normal cells 
prevents phosphorylation. It is even conceivable that both processes bestow specificity on the 
protein separately, further reducing the risk of Apoptin activation in normal cells at any stage of 
their development. 
As stated previously, the tumor-specificity of Apoptin makes it exquisitely suitable for 
systemic therapy. To determine whether continued expression of Apoptin in lymphocytes poses 
a problem for systemic therapy, different subsets of splenocytes from H2-Kb-Apoptin mice were 
evaluated. No deviation in B cells, helper-Tor cytotoxic T cell populations was found compared 
to wild-type mice, signifying that Apoptin was not activated during any stage of their 
differentiation. The next question was whether these cells can still react properly to activating 
stimuli. Both transgenic and wild-type lymphocytes responded equally well to stimulation, 
indicating that the transgenic mice should be able to mount a proper immune response. The fact 
that Apoptin does not become active upon activation of T cells corroborates previous findings 
where ectopically expressed Apoptin in human T cells did not cause apoptosis after stimulation 
with phytohemagglutinin 4 . Furthermore, lysates from IL-2/conA stimulated T cells do not 
phosphorylate recombinant Apoptin, in contrast to lysates derived from tumor and transformed 
cells (ref. 15 and data not shown). Apparently, the signal transduction pathways used in normal 
stimulation and proliferation ofT and B cells do not activate Apoptin. 
The data presented here, demonstrating that it was not possible to detect negative effects of 
continuous Apoptin expression in lymphocytes in vivo, on the contrary, the cells appear fully 
functional, are an important first step for the development of systemic therapy. In the future, it will 
also be important to generate mice with a broader expression spectrum, to assess the effects of 
Apoptin in other organs. Meanwhile, the mice described here can be used to answer other 
important questions regarding Apoptin. Based on data generated so far, it cannot be excluded 
that Apoptin is active in tumor cells only when they are adapted to tissue culture, which selects a 
subpopulation of cells from the original tumor. A clear anti-tumor effect of Apoptin in tumors 
arising in the H2-Kb-Apoptin mice would eliminate the possibility that Apoptin reacts specifically 
to culture-induced changes. For this, Apoptin-transgenic mice should be crossed with a mouse 
strain prone to lymphoma. Simultaneously, that experiment will provide valuable information 
regarding the turning point in carcinogenesis that renders cells sensitive to Apoptin. Mice 
contracting lymphoma because of a specified mutation are in this case more informative than 
lymphoma induced by an applied carcinogen, which leads to a multitude of uncharacterised 
mutations. Finally, when established, this model can be used not only to study the mechanism of 
Apoptin, but also for molecular mechanisms that are currently difficult to study because of 
sporadic tumor formation originating from one in a million cells. This is for instance the case for 
studying the effects of c-myc on B cell development in Ej.J-myc mice. In conclusion, we have 
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shown that it is feasible to generate Apoptin-transgenic mice. They are healthy and fertile, and 
the cells with the highest expression of Apoptin appear not to tolerate this well. The fact that the 
lymphocytes are not hindered in their development and function is an important prerequisite for 
systemic therapy with Apoptin. 
Experimental procedures 
Transgenic mice 
To generate Apoptin transgenic mice the Apoptin gene was cloned into the first exon of the mouse H-2Kb 
promoter. The 450 bp BamH1 fragment derived from pCMV-vp3 16 was inserted in the Not1 site of the pSB1 plasmid 
containing the Hindiii-Nrul fragment of the H-2Kb promoter 11 , with the help of Not-BamH1 linkers (p21 EcoA-vp3). 
Bacterial sequences were removed by EcoRI digestion and the 5.5 kb H-2Kb- Apoptin-EcoR1-restriction fragment 
was microinjected into the pronuclei of FVB fertilized eggs according to standard protocols 17• Eggs that survived 
microinjection were implanted into the oviducts of pseudo-pregnant BCBA foster mice. From 300 transferable eggs 
implanted in 15 foster mice, 51 pups were born, of which 7 were transgenic. Two of these founders (E2 and D10) 
were backcrossed eight times in the standard FVB strain and also in the C57BI/6 strain to exclude a strain-specific 
phenotype (Charles River, Lyon, France). 
Genotyping of Animals 
Southern analysis 18 was performed by fractionating BamH1-digested DNA on a 1% agarose gel and blotting on to 
Hybond+ (Amersham, UK). The blots were hybridised with randomly primed 32P-Iabeled DNA fragment encoding 
Apoptin and results were obtained by autoradiography. PCR analysis was performed with high molecular weight DNA 
extracted from mouse tails with Dneasy tissue kit (Qiagen, Hilden, Germany). A 462-bp region was amplified with one 
oligonucleotide directed to the region in the p21 EcoA plasmid prior to the Apoptin-start codon 
(5'ACCTGGGCCCAGCGGAGC-3') and one to the region after the Apoptin-stop codon 
(5'CGGATCCAACCCGGGTTGAA-3'). The presence of an amplified product indicates a transgenic genome. In brief, 
1 pi DNA was added to 49 pi of 50 mM KCI, 10 mM TrisHCI (pH 8.3), 0.2 mg/ml gelatine, 1.5 mM MgCI2 , 0.1 mM of 
each deoxyribonucleotide, 20 pmol forward primer, 20 pmol reverse primer and 3 U of AmpliTaq DNA polymerase 
(Perkin-Elmer, Norwalk, USA). PCR is performed for 30 cycles (94°C 30", 54°C 60", 72°C 60") in an automated DNA 
Thermal Cycler (Perkin-Elmer Cetus). Sequencing was performed by Baseclear (Leiden, the Netherlands) with a 
sequence kit for GC-rich sequences using the PCR primers. 
Cell culture and treatment 
Osteosarcoma cells (Saos-2) and SV40-transformed fibroblasts (VH/SV) were grown in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal-calf serum (FCS), 100 U/ml penicillin and 100 pg/ml streptomycin (1% 
pen/strep, Life Technologies, Rockville, Md., USA) in a 5% C02 atmosphere at 37 oc. For immunofluorescence, cells 
were grown on glass microscope slides. 
Splenocyte cultures were obtained by disaggregating spleen tissue aseptically through a 100 pm filter (Falcon, 
BD Biosciences) in complete DMEM medium. After centrifugation erythrocytes were lysed with NH4CI 8.4 g/1, KHCO, 
1 g/1, pH 7.4 (Pharmacy LUMC, Leiden, The Netherlands) and cells were resuspended in spleen medium to a 
concentration of 1*106 cells/mi. Spleen medium consisted of 39% RPMI 1640 and 30% AIMV (both Life 
Technologies), 15% Fetal Clone I (Hyclone), 10% rat T stim (Becton Dickinson, Mountain View, CA), 2mM glutamax 
(Life Technologies), 1 mM sodium pyruvate, 50 pM J3-mercaptoethanol, 1% pen/strep, 4 pg/ml concanavalin A (con A, 
Pharmacia) and 10 U/ml IL-2 (Roche Diagnostics)). The proteasome was inhibited by addition of 5 pM clasto-
lactacystin J3 lactone (Sigma, St. Louis, MO)) for 5 hours or 2 pM N-CBZ-Leu-Leu-Leu-al (Sigma) overnight to the 
medium. 
_ B cell cultures were obtained by positive selection with aCD19 Dynabeads (Dynal Biotech, Hamburg, Germany) 
of splenocytes cultures after lysis of erythrocytes. After 20 minutes incubation B cells were selectively retained on an 
autoMACS column and resuspended in RPM I 1640 medium supplemented with 10% FCS and 1% pen/strep at 5*1 05 
cells/mi. Cells were stimulated with lipopolysaccharide (LPS, Sigma) diluted to 5 pg/ml in the medium. 
T cell cultures were obtained by removing B cells with magnetic Goat-anti-Mouse beads (Miltenyi Biotec, 
Germany). After 20 minutes incubation the beads were precipitated with a Promega-magnete, which was repeated 
twice. The remaining cells were resuspended in spleen medium at 1 *1 06 cells/mi. 
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Plasmids and transfections 
Expression plasmid pCMV-vp3 contains CAV DNA sequences encoding Apoptin (nt 427-868) under control of the 
cytomegalovirus promoter 16• pCMV-desmin encodes desmin, a component of type II intermediate filaments, and was 
used as a negative control for the induction of apoptosis 19• pHA-ubiquitin was a kind gift from dr. H. Masselink, NKI, 
The Netherlands. The ubiquitin is tagged with an epitope of the influenza hemagglutinin protein (HA). 
Transfections were performed by means of the calcium-phosphate precipitation procedure as described by 
Graham and Van der Eb 20 Briefly, 2 hours prior to transfection the medium of 30% confluent monolayers of 
osteosarcoma cells (Saos-2) or SV40-transformed fibroblasts (VH/SV) was replaced by fresh medium. DNA-calcium-
phosphate precipitates were incubated for 30 min at room temperature, and subsequently added to the medium. The 
cells were washed twice with phosphate-buffered saline (PBS) after 24 hours and fresh medium was added. 
Immunofluorescence and DAPI staining 
Indirect immunofluorescence was performed as described previously 21 • To demonstrate the presence of Apoptin, 
cells were air dried and fixed with 80% acetone. The indirect immunofluorescence assay (IFA) was performed with 
hybridoma supernatant containing the mouse monoclonal antibody 111.3 ' directed against Apoptin or a 25-fold 
dilution of the mouse monoclonal antibody 33 directed against desmin (Monosan, Uden, The Netherlands). 
Fluorescein-isothiocyanate-labelled goat anti-mouse antibody (Jackson lmmunoresearch Laboratories, USA) was 
used as second antibody. Nuclear DNA was stained with 1 ,ug/ml 2,4-diamino-2-phenylindole (DAPI) in 2% 1,4 
diazabicyclo-[2,2,2]-octane in glycerol/0.1 M TrisHCI pH 8.0. 
Northern analysis 
Total RNA was isolated from heart, thymus, muscle, brain, kidney, spleen, liver and lung from two H2-Kb-Apoptin mice 
according to the acid-guanidinium-phenol-chloroform protocol as described 22 • Twenty microgram RNA was run on a 
1% agarose gel and blotted onto Hybond+ membrane (Amersham, UK). Apoptin mRNA (2.3 kb) was hybridized with 
a randomly primed 32P-Iabeled DNA fragment encoding Apoptin and visualized by autoradiography. 
RNA In situ Hybridisation 
Isolated organs were fixed overnight in 4% (w/v) formaldehyde in PBS. The organs were dehydrated in a graded 
ethanol series, paraffin-embedded, cut into sections, and mounted on aminoalkylsilane-coated slides. Serial sections 
were probed for the presence of Apoptin mRNA by in situ hybridization with a digoxigenin (dig) -labeled probe 
complementary to Apoptin mRNA. As a negative control, dig-labelled Apoptin mRNA was used. Probes were made 
according to the manufacturer's specifications (Roche, Mannheim, Germany). To obtain Apoptin RNA pobes (sense 
and antisense) the BamHI fragment of pCMV-VP3 was subcloned into pBiuescript II SK-, either in sense or antisense 
orientation. Dig-labelled RNAs were transcribed by T7 RNA polymerase after linearization with Xbal. 
Deparaffinated sections were washed twice with PBS and digested for 10 minutes at 37°C with 20 ,ug/ml 
proteinase K. After rinsing once with 0.2%glycine/PBS and twice with PBS, the sections were re-fixed for 20 min in 4% 
formaldehyde/0.2% glutaraldehyde dissolved in PBS and then washed twice with PBS. Sections were pre-hybridized 
for 1 hr and subsequently hybridized overnight at 70°C with approximately 300 ng/ml probe in 50% formamide, 5 x 
SSC, 1% block solution (Roche), 5 mM EDTA, 0.1% Tween-20, 0.1% Chaps (Sigma), 0.1 mg/ml heparin (Becton-
Dickinson), and 1 mg/ml yeast total RNA (Roche). Sections were subsequently rinsed in 2 x SSC, pH 4.5, washed 
twice at 65°C in 50% formamide/2 x SSC, pH 4.5, followed by three washes with PBS/0.2 %Tween. Probe bound to the 
section was detected using sheep anti-digoxigenin Fab fragment covalently coupled to alkaline phosphatase and 
NBT/BCIP as chromogenic substrate, according to the manufacturer's protocol (Roche). Sections were washed with 
double-distilled water, dehydrated in a graded ethanol series and xylene, and embedded in Entellan (Merck, 
Darmstadt, Germany). 
Immunohistochemistry 
Paraffin-embedded sections of spleen and thymus tissue obtained from H2-Kb-Apoptin mice and wild-type littermates 
were stained for Apoptin by a three-step immunoperoxidase staining using a polyclonal rabbit antibody recognising 
the C-terminus of Apoptin, aVP3C (produced by EurogenTec, Seraing, Belgium) as described10 • 
lmmunoprecipitation and western analysis 
Splenocytes were isolated as described earlier under 'cell culture and treatment'. Isolated lung was flash-frozen in 
liquid nitrogen and subsequently grinded with a microdismembrator. Live spleen cells or frozen lung powder were 
resuspended in lysis buffer (50 mM Tris pH 7.5, 250 mM NaCI, 0.1% Triton and protease inhibitors) and incubated on 
ice for one hour. The lysate was cleared by centrifugation and immunoprecipitated with Protein A-sepharose beads 
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(Sigma-Aldrich, Zwijndrecht, The Netherlands) coupled to a polyclonal rabbit antibody recognising the C-terminus of 
Apoptin, aVP3C or to the mouse monoclonal D0-1 recognizing p53 (Santa Cruz biotechnology, Santa Cruz, CA). The 
immunoprecipitates were washed three times with cold lysis buffer and boiled for 5 min in Laemli sample buffer. 
Samples were subjected to electrophoresis on a 12.5% polyacrylamide SDS gel, followed by transfer to lmmobilon P 
membranes (Millipore, Bedford, Massachusetts, USA). After blocking in milk buffer (5% milk in Tris-buffered saline 
with 0.2% Tween (TBST)) the membranes were incubated with the mouse monoclonal antibody 111 .3 against the N-
terminus of Apoptin, HA11 directed against the hemaglutin-tag on transfected ubiquitin (Babco, Berkeley, 
CA, USA) or D0-1 against p53 when appropriate. The membranes were washed with TBST, and proteins were 
detected with horseradish peroxidase-conjugated goat anti-mouse lgG (Sigma) secondary antibody, followed by 
enhanced chemiluminescence according to the manufacturer's instructions (Amersham, UK). 
Flow cytometry analysis 
Spleen tissue was disaggregated through a 100 11m filter (Falcon) in complete DMEM medium. After centrifugation for 
8 minutes at 800 rpm, single cell suspensions were washed in cold phosphate buffered saline (PBS) containing 0.5% 
BSA. 5*104 cells were directly labelled for 30 min using aCD19-Fitc, aCD3-Fitc, aCD4-APC, aCD8-APC antibodies 
(BD PharMingen, UK) to detect B cells, T cells, helper T cells and cy1otoxic T cells, respectively. Samples were 
analysed on a FACScalibur (BD Pharmingen). 
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Chapter 6. Summary + discussion 
The chicken anaemia virus was cloned in 1990 and analysis of its three proteins led to the 
serendipitous finding that viral protein 3, or Apoptin, induces apoptosis in many cultured 
human tumour cells but not in their normal counterparts. The ensuing question, whether the 
activity and specificity of Apoptin would also hold true in vivo, was addressed in the research 
described in this thesis. Besides preliminary confirmation of this concept, my studies have 
yielded some important guidelines for the development of an anticancer therapy based on 
Apoptin gene or protein therapy. Moreover, the full potential to use Apoptin as an anticancer 
agent is intimately linked with the unravelling of its mechanism of action. These data will have 
implications for the safe application of Apoptin, the feasibility of developing small molecular 
drugs, and the suitability for combination therapies, as will be discussed below. 
Apoptin as a therapeutic agent 
Adenovirus vectorology 
To exert its anti-tumour activities in humans, the chicken virus-derived Apoptin has to be 
introduced into cells in vivo. An efficient way to achieve this is by employing mammalian viruses 
as carriers. Chapter 2 describes the generation of a replication-deficient adenovirus expressing 
Apoptin. At the moment of generation, the safety issues of replication-competent viruses in gene 
therapy were still under heavy discussion, and since we were, to begin with, looking for a proof 
of principle of the in vivo anti-tumour activity of Apoptin itself, we chose this well-studied, non-
replicating virus as a delivery vector. 
Production of viral vectors containing genes toxic to packaging cells has proved difficult, 
illustrated by the problematic attempts to generate adenoviruses expressing Fasl and Bax 1·2. 
Fortunately, apoptosis induction by Apoptin is relatively slow and as the replication cycle of 
recombinant adenoviruses in vitro takes about 32-48 hours, we were able to demonstrate that 
the induction of apoptosis by Apoptin in the transformed helper cells occurred predominantly 
after these first two days, rendering the production of Ad-Apoptin technically feasible. 
Eventually, when preclinical data with an adenovirus expressing Apoptin would warrant 
clinical testing, the risk of co-injecting replication-competent viruses must be restricted to a 
minimum. Adenoviral vectors are rendered replication-deficient by deletion of the E1 region from 
their genome. Producer cell lines, such as 293, 911 and PER.C6, have the adenovirus E1 region 
integrated in their genome to allow the replication of E1-deleted adenoviral vectors. The first 
generation vector AdMLP.Apoptin contains a short stretch of adenovirus sequence that is also 
present in the producer cells. Potentially, replication-competent adenoviruses (RCA) could arise 
from non-replicating vectors through regaining the E1 sequence from the helper cells by 
homologous recombination 3 . Although all of the batches we produced were found negative for 
RCA with a PCR assay that detects one RCA particle among ten million E1-deleted particles, the 
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risk of RCA increases when the scale of production is enlarged. Therefore, two new adenoviral 
vectors expressing Apoptin have been generated by Ronald Vogels at lntrogene (presently 
Crucell, Leiden), called AdCLIP .Apoptin and AdApt.Apoptin, both expressing Apoptin under the 
regulation of the CMV promoter and with viral backbones that are perfectly matched to the 
PER.C6 cell line, thereby preventing the emergence of RCA through homologous recombination 
(chapter 4). 
Multiple large-scale batches (in 3-10 liter fermentors) of all three Apoptin-expressing 
adenoviruses have been produced by George Roth at Berlex Biosciences (Inc., Richmond, CA, 
USA), to be used in preclinical studies. Since large-scale production and standardization under 
GMP (good manufacturing practice) are prerequisites for clinical testing as well, these 
productions provide important information on the technical feasibility of an Apoptin-based 
medicine using these vectors. In small-scale productions, AdMLP.Apoptin exhibited similar 
kinetics and yields as control viruses (chapter 2). In addition, no differences were observed for 
AdMLP.Apoptin, the new vector AdCiip.Apoptin and their anti-sense counterparts when 
subjected to large-scale virus production. However, the second CMV-vector, AdApt-Apoptin, 
yielded fewer infectious particles than did AdMLP Apoptin, AdCiip.Apoptin or the control viruses. 
Nevertheless, AdApt.Apoptin cleared dishes of HepG2 and MDA breast cancer cells at a lower 
multiplicity of infection (m.o.i.) than did AdCiip.Apoptin (D. Henderson and G. Roth, personal 
communication). This led us to speculate that the expression of Apoptin by AdApt might be 
earlier or higher than that of the other constructs. If this increased expression would lead to cell 
death prior to virus particle formation in a higher percentage of the packaging cells, this could 
explain the apparently lower yield observed in the large-scale productions, as judged by total 
infectious particles (titer times volume). However, such premature cell death would consequently 
give rise to an underestimation of the titer (amount of infectious particles per millilitre), since 
some cells in the plaque assay would also perish before they could infect their surrounding cells, 
thus resulting in fewer plaques than actual infectious particles. This putative titer underestimation 
could explain the apparent lower virus dose of AdApt.Apoptin required to kill tumour cells, i.e. the 
actual dose would then have been comparable to the other constructs. 
To distinguish whether the effects of AdApt.Apoptin versus the control, non-expressing, 
AdApt.Antisense in preclinical studies are attributable to Apoptin, as opposed to differences in 
viral dose, a new assay for titration of adenoviral-vectors expressing Apoptin should be 
developed, one based solely on infection of cells and not on subsequent lysis and re-infection of 
neighbouring cells. Preliminary data based on DNA quantification suggest that the titer of 
AdApt.Apoptin may be underestimated by a factor of 5-1 0 (S. Rutjes, unpublished data). For 
Fas-expressing adenoviruses an underestimation of 2000-fold has been described 2 ; the less 
dramatic titration effect of Apoptin in the AdApt vector and the absence of detectable effects in 
the other vectors is most likely due to its relatively slow induction of apoptosis. To investigate 
further the differences in viral production and anti-tumour effects of the AdApt vector versus 
AdMLP and AdCLIP, the timing and levels of Apoptin expression by the different constructs in the 
packaging cell lines could be compared to the expression of early and late viral gene expression. 
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Fortunately, no difference in yield was observed between AdMLP Apoptin and control vectors, 
suggesting that in this context Apoptin did not affect the viral production to noticeable extent; 
therefore the conclusions that the anti-tumour effects described in chapter 2 and 3 with 
AdMLP.Apoptin are due to Apoptin remain the most plausible. Nevertheless, the findings with 
AdApt.Apoptin stress the importance of careful characterization of viral vectors expressing 
apoptotic genes, as this could have major implications for the interpretation of data generated 
with those. 
In addition to these considerations for the titration of viral vectors carrying toxic genes, it 
should be noted that large-scale productions of such vectors are at risk of generating non-
functional mutants. Specifically, even though the majority of virus particles is assembled prior to 
the toxic effects of Apoptin in transformed producer cells, a subset of cells (approximately 20%, 
see chapter 2) is killed by Apoptin prior to viral production, providing a window for negative 
selection against wild-type Apoptin. In fact, several rounds of propagation with successive virus 
batches (versus always starting from the initial mother stock) has resulted in an AdMLP Apoptin 
virus batch that expressed mutated Apoptin that was atypically distributed over the nucleus and 
cytoplasm and did not induce apoptosis in tumour cells (A. Pietersen and J. van Tongeren, 
unpublished results). Besides the fact that analysis of this mutant batch may provide valuable 
insights into the mechanism of Apoptin, this observation also indicates that caution should be 
taken with large-scale productions, as expanding the number of infected cells increases the 
chance of attenuating mutations. 
Recently, an innovative approach has been developed that provides a solution for the 
potential problems of lower yield and titer underestimation, as well as the risk of selecting 
mutants. Gu and coworkers make use of the Tet-Off system in a bicistronic adenoviral vector for 
the generation of a Bax-delivery method. The virus expresses a transcriptional transactivator 
(tTA), which can induce the synthetic promoter that regulates the Bax gene present in the same 
viral construct. However, when tetracycline is added to the medium of the viral packaging cells, 
the transactivator will be inhibited, thereby preventing Bax expression. Viral production can occur 
without Bax-mediated toxicity to the packaging cells, but when the viruses are used to infect 
tumour cells, the absence of tetracycline will result in robust Bax expression and subsequent 
tumour cell death 4 . Inclusion of the Apoptin gene in such a vector would exclude potential 
effects of Apoptin expression on the viral producer cells and it may therefore be advisable to use 
this system for large-scale productions of adenoviral vectors expressing Apoptin when clinical 
testing is pursued. 
Apoptin in other viral vectors 
Adenoviral vectors infect a broad range of cell types, but are not very effective in transducing 
haematopoietic cells. To test Apoptin as a therapeutic agent for haematopoietic malignancies, a 
vector that does infect these cells is required, such as certain recombinant retroviruses, like 
Moloney murine leukaemia virus (MoMLV) or human immunodeficiency virus (HIV). Several 
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attempts have been made to generate these RNA-based viral vectors expressing Apoptin, but so 
far these have not been successful (Oiijslagers and Rutjes, manuscript in preparation). In the 
case of the MoMLV-based vector, infection of tumour cells with supernatant derived from 
producer cell lines with stable integrated Apoptin constructs did not result in Apoptin expression 
in the malignant cells. Transient transfection of the constructs of either the MoMLV or the 
lentiviral system to generate Apoptin-expressing retroviruses in a batch-wise fashion, in contrast 
to the stable integration method, did not improve this. On one hand, it seems that Apoptin 
expression is detrimental for the generation of these vectors, as cotransfection of an Apoptin-
expressing plasmid with plasmids for the generation of a GFP-Ientivirus significantly reduced 
viral production, whereas this was not the case with an empty-control plasmid (S. Rutjes, 
personal communication). Because retrovirally-infected cells do not lyse, as they do with 
adenoviral infection, but particles are instead continuously exocytosed from the cytoplasm, it 
may be that the retroviral production is hindered by Apoptin-induced apoptosis in the 
transformed producer cells. It can also be that Apoptin directly interferes with the replication 
cycle of retroviruses. However, with the lentiviral approach, Apoptin-containing particles are 
formed, albeit at a lower level, and the lack of Apoptin expression following subsequent infection 
may be due to low expression levels by retroviruses. Since only one or a few viral particles may 
integrate and express Apoptin, the level of Apoptin protein per cell may remain under the 
detection limit of the antibodies used in Western Blot and immunofluorescence analysis. This 
theory is supported by preliminary experiments using proteasomal inhibitors that reveal the 
presence of some Apoptin protein after lentiviral infection of HeLa cells (S. Rutjes, personal 
communication). The Apoptin expression level may influence the suitability of delivery vectors, as 
is discussed below in the section 'Intracellular Apoptin levels'. 
A viral vector that is also capable of infecting haematopoietic cells, is the autonomous 
adena-associated virus called Parvovirus. This virus, which has a DNA genome, proved 
compatible with Apoptin expression and gave rise to high Apoptin protein levels. Parvoviruses 
already hold some intrinsic tumour-selectivity (see chapter 1), but are not always potent enough 
to cause eradication of all tumour cells. Incorporation of the Apoptin gene in the place of the 
genes encoding the capsid proteins, together with the tumour-selective expression of the toxic 
NS-1 protein of the parvovirus, extended the range of tumour cells sensitive to parvovirus in cell 
culture 5. If future experiments demonstrate that Apoptin is also compatible with replication-
competent parvoviruses, this parvoviral vector system would constitute an alternative approach 
for cancer gene therapy with Apoptin, although more knowledge on the biology of the parvovirus 
and its proteins would be desirable. 
Transduction in vivo 
The generation of the adenoviral vector expressing Apoptin enabled us for the first time to 
examine the effects of Apoptin in vivo. A pilot experiment described in chapter two showed a 
delay in tumour growth seven days after a single injection of AdMLP.Apoptin in xenografted 
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human hepatoma. We also noted that these tumours exhibited lobular growth and that a single 
injection was often confined to one such lobule, thereby impairing transduction of the rest of the 
tumour. To increase the transduction efficiency, we used a regimen of multiple injections over a 
period of several days in the large-scale, long-term experiment described in chapter 3. This 
approach resulted in a significant overall survival benefit for the Apoptin-treated mice and in 
some cases, complete regression of the established tumour. Our data demonstrating the in vivo 
anti-tumour effect of Apoptin have been corroborated by preclinical studies at Berlex 
Biosciences (Inc., Richmond, CA, USA, D. Henderson, H-L. Liu, G. Roth and M. Halks-Miller, 
unpublished data). There, nude mice bearing human breast carcinoma (MDA231 MT cells) were 
treated with eight injections of AdAptApoptin or AdApt.Antisense, compared to five doses of 
taxol. Twenty-one days after the start of the treatments, both the Apoptin gene therapy and the 
taxol chemotherapy had prevented tumour growth, whereas the tumours treated with vehicle or 
antisense-viral vector continued their exponential growth (figure 1). Even if the titer of 
AdAptApoptin had been underestimated, treatment with Apoptin proved as efficient as the 
lowest dose of taxol and had none or only minor effect on the weight of the treated mice, 
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Figure 1. Effect of AdApt.Apoptin and chemotherapy on human breast carcinomas xenografted on nude 
Animals bearing MDA2331-MT1 tumours received 2.1x109 plaque forming units (pfu) of AdAptApoptin or 
AdAptAntisense intratumourally every third day for a total of 8 doses starting 9 days after tumour implantation. Control 
animals received either vehicle or 5 doses of taxol at 14, 16, and 18 mg/kg intraperitoneally. Tumour volume was 
measured twice a week until the study was terminated at day 31. Apoptin expression was detectable in a small 
percentage of tumour cells at the end of the study as determined by immunohistochemistry. Experiments were 
performed at Berlex Biosciences. 
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Figure 2. Effect of AdApt.Apoptin and chemotherapy on the body weight of mice bearing MDA231-MT1 
tumours. 
Body weight of the mice (whose tumour volumes are depicted in figure 1) as a crude measure for toxicity of the 
treatment with taxol and the adenoviral vectors expressing Apoptin. Experiments were performed at Berlex 
Biosciences. 
whereas the chemotherapeutic regimen resulted in life-threatening weight loss (figure 2). The 
local administration of the Apoptin-adenovirus versus the systemic treatment with taxol precludes 
a comparison of toxicities, but it does demonstrate the effectiveness of Apoptin expression in 
vivo. 
With successful preclinical results achieved, it became necessary to choose an appropriate 
clinical model. Carcinoma of the bile duct formed an attractive candidate. This cancer is 
insensitive to conventional cancer therapy, probably because tissue-specific damage (e.g. bile 
salts) leads to potent blockage of the pathways utilized by chemotherapeutics and radiation. 
Strikingly, Apoptin was able to induce apoptosis in three independent cholangiocarcinoma cell 
lines irrespective of their individual mutations (chapter 4), further supporting the model that 
Apoptin acts downstream in the apoptotic pathway and indicating that current therapy-resistant 
tumours might benefit from an Apoptin-based therapy. However, clinicians disagree on the 
feasibility of using a replication-deficient vector for the treatment of cholangiocarcinoma. We 
already observed limited viral spread in our hepatome xenograft studies, and even after a 
regimen of multiple injections over several days, there was considerable variation in the 
response of individual tumours, probably due to differences in transduction. Biliary tract cancers 
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comprise several cell layers and can be located in bile ducts embedded in the liver, rendering 
them difficult to reach. Presumably, injection of replication-deficient adenoviruses into the bile 
duct would only transduce the outer layer of cholangiocarcinoma cells 6. Although it has been 
postulated that semi-local administration by occlusion of the bile ducts with dotter-like balloons, 
potentially accompanied by intratumoural injections, might improve the transduction efficiency, 
the predominant notion seems to be that gene therapy with a non-replicating vector transducing 
a therapeutic protein without bystander effect will be ineffective. Therefore, despite the promising 
potency of Apoptin in these therapy-resistant carcinomas, the non-replicating adenoviruses 
expressing Apoptin will not be tested in clinical trials for cholangiocarcinoma. 
Replicative-deficient viruses carrying transgenes such as p53 or HSV-TK have been useful in 
providing the first proofs of principle for gene therapy of cancer in the clinic, and although 
modest successes with these vectors have been reported, most attention is currently focussed 
on selectively-replicating vectors, as these have proved to be relatively safe, showed superior 
spread within the tumours and have yielded impressive results in phase Ill clinical trials (see 
introductory chapter). Similarly, the preclinical studies with replication-deficient adenoviruses 
expressing Apoptin have been essential to validate the concept of Apoptin as an anticancer 
agent. They have demonstrated that when Apoptin is expressed in a tumour cell in vivo it will kill 
it, and that under optimal delivery circumstances entire tumours can be eradicated. However, the 
data also demonstrate the current inefficiency of transduction, and therefore, improvement of the 
delivery and/or bystander effects of Apoptin are warranted before any clinical trial can be 
initiated. 
Enhancing transduction efficiency 
In cancer gene therapy, especially against disseminated disease, one of the largest problems 
constitutes the targeting of each and every tumour cell. As illustrated by the previous section, a 
therapy based on Apoptin is also dependent on the efficiency of transduction. Besides 
engineering more efficient delivery vehicles, evoking a 'bystander effect' could also substantially 
increase the efficacy of therapies based on toxic genes. The term 'bystander effect' was 
traditionally used to describe the effects of prodrug therapy, but it can be more broadly applied 
to processes that affect the non-transduced cells, such as anti-angiogenesis or protein 
transport. 
Presently, no clear bystander effect has been detected with Apoptin. The small scale 
experiment described in chapter 2 showed some remarkable effects on the vascularisation of 
certain tumours, which could be due to a direct effect on angiogenesis, or by an indirect effect of 
diminishing angiogenic factors caused by disappearance of tumour cells. However, the effect on 
tumour vasculature was much less pronounced in the study described in chapter 3. An 
experiment specifically designed to measure the effect of Apoptin on angiogenesis could 
provide further evidence and insight for the provocative initial observation. 
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In recent years, considerable effort has been put into approaches to actively endow a bystander 
effect on Apoptin. One approach was based on fusing Apoptin to the herpes simplex virus 
protein VP22. Others have shown that VP22 migrates from the initial transfected cells to 
surrounding cells, ultimately transducing an entire culture dish 7 . When a VP22-p53 fusion was 
transduced by an adenoviral vector, VP22 mediated intracellular transport of p53 into normal 
livers and liver tumours in mice, increasing the anti-tumour activity compared to a virus 
expressing p53 alone 8. Apoptin was fused to both the N- and C-terminus of VP22, but 
unfortunately the fusion proteins were not transported to neighbouring cells after transfection 
(Rutjes, in preparation). In fact, the VP22-Apoptin products seemed to reside in aggresome-like 
structures in transfected cells and were almost exclusively present in the insoluble fraction of cell 
lysates. Another protein transduction strategy is based on the HIV-derived TAT-peptide. When 
injected intravenously, TAT-fusion proteins transduced virtually all tissues of mice, even crossing 
the blood-brain barrier 9 . Again, the biochemical properties of Apoptin proved extremely 
unfavourable for the production of a TAT-Apoptin fusion protein, both in our lab (M. Voorhoeve 
and K. Kooistra, unpublished results), as well as in the lab that first developed the TAT peptide 
(S. Dowdy, personal communication). An attempt to optimise this process could comprise 
deleting the part of Apoptin that causes the insolubility. If such an approach would indeed be 
successful in transporting Apoptin, while retaining its tumour-specific activity, the resultant ability 
to deliver Apoptin systemically to all tissues would greatly enhance the potential of Apoptin for 
cancer therapy. 
Another option currently being explored to enhance the local delivery/intratumoural spread is 
the inclusion of Apoptin into conditionally-replicating viral vectors. This combination may ensure 
enhanced spread of Apoptin throughout the tumour, and Apoptin could add potency to these 
vectors, which for unclear reasons are not able to lyse an entire tumour on their own 10 . Apoptin 
may even function as an Adena Death Protein (ADP), improving viral release in a tumour-
selective fashion. Very late in the wild-type adenoviral replication cycle, when viral particles have 
formed in the cell nucleus, ADP is expressed to facilitate release of the adenoviral particles. Viral 
vectors selectively replicating in cells lacking RB are more cytolytic when they are genetically 
modified to overexpress ADP 11 . If apoptosis induced by Apoptin would be equally efficient in 
mediating viral release, it would add an additional safety feature in that viral spread would be 
enhanced only from tumour cells, and not from normal cells. In this way, systemically 
administered virus is predicted to have even lower side effects. Obviously, production of such 
viruses needs to be carefully monitored for effects of Apoptin on viral yield and titration assays to 
exclude the generation of mutants. Importantly, the kinetics of Apoptin-induced apoptosis may 
be too slow to have an effect on viral release, or the induction of cell death may even be 
incompatible with the viral burst mechanism, rendering the inclusion of Apoptin in these vectors 
ill-suited in both cases. Hence, appealing as the concept may be, experiments are required to 
demonstrate its feasibility. 
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Toxicity studies 
Toxicity to non-tumour cells represents a major determinant of the therapeutic window, and thus 
of treatment success, particularly in the case of systemic delivery. The fact that cell types 
damaged by classical cancer therapies, such as CD34 + stem cells and hepatocytes, are not 
sensitive to Apoptin in vitro is encouraging 12, Zhang, unpublished observations). 
Reassuringly, the inactivity of Apoptin in normal cells has been independently confirmed by 
Berlex Biosciences, in experiments in which they infected normal cell cultures of dermal 
fibroblasts, mammary epithelial cells and endothelial cells with AdApt.Apoptin or Ad CLIP Apoptin 
(H. Dinter, unpublished data). Of note, primary human fibroblasts or rat hepatocytes infected 
with AdApt.Apoptin in our lab exhibited nuclear expression of Apoptin, however, this did not lead 
to an increase in apoptosis (S. Rutjes, unpublished observations). Furthermore, transfection of 
primary, CD31 + cell-depleted fibroblast cultures with Apoptin-expressing plasmids in the 
research laboratories of Schering AG (Berlin, Germany) again corroborated our findings that 
Apoptin localises in the cytoplasm and does not induce apoptosis (D. Mumberg, personal 
communication). However, all in vitro studies are limited by the short life span of primary cells in 
culture, which obstructs any long-term evaluation of the effects of Apoptin in normal cells. Thus, 
because not all toxic effects can be predicted from in vitro studies, the validation of Apoptin as 
an anticancer agent relies heavily on preclinical studies. 
I have examined the effects of Apoptin in normal cells in vivo after adenoviral overexpression 
(chapter 2) and after continuous expression throughout development in transgenic mice (chapter 
5). The first in vivo toxicity experiment comprised the injection of AdMLP.Apoptin in rats and 
demonstrated that subcutaneous, intraperitoneal and even intravenous administration did not 
result in toxic effects. Later on it became apparent that the major late promoter may be less 
active in rodent cells than in human cells 13 . In cultured rat hepatocytes, Apoptin could be 
visualized by immunofluorescence after infection with AdMLP.Apoptin, showing clear 
cytoplasmic localisation and no induction of apoptosis during their limited life-span in culture 
(chapter 2). Unfortunately, at the time of the in vivo toxicity study, we had not yet solved the 
technical difficulty of detecting Apoptin protein in tissue sections. After publication, the detection 
of Apoptin in paraffin sections was enabled by a new antigen-retrieval protocol (chapter 3). 
Subsequent staining of the liver sections from our toxicity study failed to detect Apoptin 
expression, even though it was demonstrated that the livers of these rats were efficiently infected 
(as assessed by the detection of viral DNA in this tissue) and that in the same procedure HepG2 
tumour tissue infected with AdMLP.Apoptin was positive (S. Rutjes, unpublished observations). It 
could be that the MLP promoter of this vector was not active in vivo, or that the Apoptin levels 
remained below detection level due to a possible normal-specific instability (see section below 
on intracellular Apoptin levels). Both possibilities are contradictory to the in vitro experiments that 
suggest that substantial Apoptin protein levels can be achieved in rat hepatocytes after infection 
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with AdMLP.Apoptin. This discrepancy prevents definite conclusions over the absence of 
adverse effects. Therefore, the use of our newly generated adenoviral vectors that express 
Apoptin under the regulation of the CMV promoter, which should work equally well in rodent and 
human cells, should allow a more definitive in vivo toxicity study. 
Apoptin-transgenic mice 
Previous work on the tumour-specificity of Apoptin has understandably focussed on human 
cells. However, performing studies in rodents to obtain long-term toxicity data requires that 
Apoptin's behaviour is examined in rodent cell cultures as well. Importantly, Apoptin was shown 
to induce apoptosis in rat CC531 and mouse 816 tumour cells (A. Pietersen, unpublished 
results), but not in rat hepatocytes (in cell culture, where Apoptin expression was detectable) and 
most likely also not in mouse lymphocytes (chapter 2 and 5). These observations imply that 
Apoptin is also selectively active in rodent cells, in contrast to, for instance, E4orf4. Together with 
the absence of apoptosis when Apoptin is expressed in mouse embryo fibroblasts (Y-H Zhang, 
personal communication), these results render transgenic mice suitable preclinical models for 
Apoptin. 
As discussed in the introductory chapter, several approaches exist to deliver toxic genes to 
tumour cells. The more specific the gene, the less targeted the approach needs to be. For the 
development of Apoptin as an anticancer agent it is therefore of paramount importance to know 
whether there are any normal cell types that are sensitive to Apoptin at any time of their life-span. 
The identification of such populations could contribute to the choice of delivery vehicle so that 
these cells are not transduced and toxicity is kept to a minimum. If that delivery system does not 
exist or is incompatible with Apoptin, the information can be used to predict contra-indications 
and perhaps, what cancer types would be suitable for Apoptin treatment. 
The results from the H2-Kb-Apoptin mice appear promising for systemic treatment with 
Apoptin regarding the lack of effects on the immune system. Nevertheless, before any definite 
conclusions can be drawn, this model must be validated by assessing the activity of Apoptin in 
these cells when they transform into lymphoma. Probably the most straightforward way to test 
this is by crossing the Apoptin-transgenic mice with mice that have an increased incidence of 
lymphoma, for instance p53-null or E,u-myc, INK4N1· transgenic mice. If the level of Apoptin 
expression that we observed in transgenic lymphocytes (chapter 5) is capable of triggering 
apoptosis once these cells become transformed, the cancer-prone mice that also express 
Apoptin should exhibit a significant delay in occurrence of lymphoma. A complete protection 
against lymphoma is not to be expected, since there will be selection pressure against Apoptin 
expression. Specifically, the presence of the Apoptin-transgenic locus will force an additional 'hit' 
that needs to occur in addition to the acquisition of the other cancer hallmarks; therefore, the 
stochastic inactivation of Apoptin should add substantial time to the latency of the lymphoma. If 
this delay is indeed observed, the experiment shows that the Apoptin levels are sufficient and 
sanctions the conclusion that Apoptin is not toxic after prolonged expression in B and T cells in 
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vivo. After validation, the Apoptin-transgenic mice additionally constitute a mouse model that can 
be used to study the effects of proto-oncogenes on normal cell populations, something that is 
currently not possible. For example, the analysis of the effects of c-myc on the development of B 
cell compartment is obstructed by the rare emergence of a tumourigenic B cell that will rapidly 
populate the haematopoietic system and become lethal to the mouse. Crossing these mice with 
the H2-Kb-Apoptin mice could provide valuable information on the regulatory role of c-myc in 
normal cell processes because, due to elimination of the occasional transformed cell, the normal 
B cells can be studied for a longer period. 
Most importantly, however, validation of the Apoptin-transgenic mice would prove that 
Apoptin is also active in tumours that arise in vivo. The majority of tumours isolated from patients 
fail to proliferate when explanted in vitro; in fact, it has been estimated that less than 1% of 
tumours can be subjected to continuous cell culture. Due to technical constraints, we have not 
been able to test Apoptin in freshly isolated tumour biopsies; hence the activity of Apoptin has 
been tested solely in in vitro-transformed cells and in tumour cell lines that have been selected to 
grow in culture. Although it has been shown that freshly isolated biopsies exhibit increased 
Apoptin-kinase activity 14, it can not yet be excluded that Apoptin responds to changes induced 
by tissue culture in the tumour cells, in combination with their oncogenic phenotype. Therefore, 
demonstrating an anti-tumour effect of Apoptin in tumours arising in transgenic mice would be 
an important step toward clinical testing. 
Additionally, Apoptin-transgenic mice can be used to obtain insight into the circumstances 
that lead to the activation of Apoptin. By inducing tumorigenesis in these mice, one could identify 
the 'turning point' when a normal cell becomes sensitive to Apoptin. It has been shown that 
normal fibroblasts from cancer-prone individuals, e.g. carriers of germline tumour-suppressor 
mutations, are not sensitive to Apoptin. However, after a pulse of UV-radiation Apoptin does 
migrate to the nucleus and induces apoptosis, whereas fibroblasts from healthy individuals 
remain resistant to Apoptin even after UV exposure 15• These results suggest that loss of one p53 
allele or mutation of both p16 copies, which were the characteristics of two of the cancer-prone 
syndromes, are not sufficient to activate Apoptin. Crossings of Apoptin-transgenic mice with 
genetically-defined cancer-prone mice for instance overexpressing c-myc or Ras, lacking p53 or 
p16, or harbouring other tumorigenic alterations can elucidate whether Apoptin reacts to any of 
these cancer characteristics alone or in particular combination. Part of the question can be 
addressed in vitro, since transgenic mice allow the isolation of a primary cell culture that 
generally expresses Apoptin. Transduction of primary cells in vitro can be extremely inefficient; 
therefore, the transgenic cells constitute an attractive tool for biochemical studies on the effect of 
Apoptin in normal cells. 
Furthermore, the generation of an Apoptin-transgenic mouse with a strong, broad-range 
expression such as that directed by the actin promoter or the Rosa locus would constitute an 
effective means to study whether there are cell types besides the lymphoid compartment that are 
sensitive to Apoptin at any phase of their life-span. If some cells are indeed found to be sensitive 
to Apoptin, these data could provide additional clues for the mechanism of action of Apoptin. 
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High levels of Apoptin expression in colon or skin of these mice would allow analysis of well-
characterized models for carcinogenesis in these tissues. The spectrum of lesions found in 
Apoptin-transgenic mice may for instance be predominantly restricted to hyperplasia while 
neoplasia occurs frequently in their wild-type littermates. These studies could thus contribute 
further to determine at what stage of transformation Apoptin becomes activated. 
Intracellular Apoptin levels 
An important question that is currently being addressed is whether there is a difference in 
Apoptin's activities when it is overexpressed by, for instance, transient transfection or adenoviral 
infection compared to relatively low expression from a few integrated copies as is the case with 
transgenic mice and retroviral infections (8. Rutjes). If a considerable amount of Apoptin is 
necessary per cell to cause apoptosis, this requirement will restrict the choice of treatment 
modality for Apoptin. Experiments titrating down an Apoptin-expressing plasmid suggest that 
such a threshold level indeed exists (thesis Olijslagers), further emphasising the importance of 
validating that the H2-Kb-Apoptin mice express sufficient protein to exceed this threshold. 
An intriguing possibility is that the stability of Apoptin protein may be differentially regulated 
in normal versus malignant cells. Namely, the observation that Apoptin expressed in healthy 
transgenic cells is unstable is in keeping with data from microinjections of recombinant Apoptin 
in normal cells. Here, Zhang and colleagues showed that early after injection, the biochemical 
properties of Apoptin in normal cells differ from that in tumour cells with respect to the epitope 
for an Apoptin-specific antibody, which becomes inaccessible in normal cells only 12. After 
stringent lysis, this epitope is retrieved, indicating that the protein is still present. However, 
somewhat later, the recombinant Apoptin disappears from the normal cells. By then, all tumour 
cells have already undergone apoptosis, precluding a comparison of the half-life of Apoptin in 
tumour and normal cells. Experiments designed to compare the stability of Apoptin between 
tumour and normal cells are necessary to determine the relevance of the degradation of Apoptin 
in normal cells for its tumour-specific actions. This information may again be significant for 
choosing a suitable delivery vector. If Apoptin is indeed rapidly degraded in normal cells, this 
would have implications for the applicability of, for instance, the TAT-Apoptin fusion. In this 
system, the fusion protein will cross cell membranes until equilibrium is reached 9• If TAT-Apoptin 
is continuously degraded in normal cells, the entire body (excluding the tumour) would act as a 
'sink' that will probably prevent the delivery of sufficient amounts of the fusion protein to the 
tumour cells. In that case, additional modifications would be required, for example, adding a 
cleavage site for an intracellular enzyme that would remove the TAT-peptide from Apoptin after it 
has entered the cell, thereby preventing cell exit. 
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Triggering the immune system 
Significantly, the tumour-specific actions of proteins such as Apoptin, MDA-7 or E4orf4 render 
them amenable to systemic therapy, which is likely the only solution to treat (micro)metastasis. 
The benefit of employing a general delivery system, instead of a less potent tumour-targeted 
system, stands or falls with the effect these proteins exert when they end up in normal cells. 
Nevertheless, the probability and extent of a specific immune response against these transgenes 
is an important question that currently remains unanswered. So far, expression of Apoptin in vivo 
has been carried out in human tumour cells xenografted in immune-compromised mice, and in 
the immune-competent transgenic mice a low level of Apoptin is continuously present after 
approximately 13 days of gestation, a situation that should result in immune-tolerance. At Berlex 
Biosciences, lung colonies of B16 mouse melanoma cells in the syngeneic, immune-competent 
Black 6 strain were treated with an i.v. injection of an Apoptin-plasmid complexed to liposomes. 
After three weeks, the experiment was terminated and a significant anti-tumour effect by Apoptin 
was observed compared to the anti-sense control (D. Henderson, unpublished data). In this 
study, there was no indication of an activation of the immune system, however, the time-span 
was relatively short and specific assays to detect an immune response were not used. Therefore, 
none of these studies are informative about the antigenic nature of the viral protein Apoptin. As 
treatment with Apoptin will likely comprise overexpression in immune-competent patients, the 
investigation of the effects of Apoptin overexpression in immune-competent mice is warranted. 
Evidently, the design of such studies can be improved when the delivery method that will be 
used for Apoptin has been established. In general, if normal cells overexpressing Apoptin 
become targets for cytotoxic T cells, the immune response elicited by Apoptin will comprise an 
unwanted side-effect of Apoptin treatment by causing damage to healthy tissues. In that case 
temporary inhibition of the immune system may prove beneficial. Blocking the costimulatory 
molecules CD40L, CD80 and CD86 effectively inhibits both humoral and cellular immune 
responses against adenoviral vectors 16, rendering this an attractive approach to test for Apoptin 
if future experiments demonstrate that immune repression is required. 
Small molecular drugs based on Apoptin 
The difficulties surrounding the delivery of Apoptin, either as a protein or gene, can be avoided 
by the use of a small molecular drug that mimics Apoptin's tumour-specific cell killing. Small 
molecular drugs are also more easily amenable to standardized and large-scale productions, 
both of which are prerequisites for clinical use. However, such a drug should be as effective and 
specific as Apoptin is; i.e., it should be based on the mechanism of Apoptin. Obviously, for the 
development of such a drug, elucidation of this mechanism is crucial. The data generated on 
Apoptin so far have resulted in our current model, which is based on tumour-specific activation 
of Apoptin rather than a difference in response of tumour versus normal cells to an otherwise 
identical Apoptin molecule. 
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Tumour-specific activation of Apoptin 
The fact that Apoptin is active in all tumour cell types tested so far implies that Apoptin is 
activated by a cancer hallmark pathway, either by one of the hallmarks described in the 
Introduction, or by one that has yet to be identified. It could be that the breaching of checkpoints, 
the constitutive activation of a particular pathway, or the activation of several pathways 
simultaneously result in a molecular situation in tumour cells that never arises in normal cells, 
which may be responsible for the tumour-specific activation of Apoptin. On the other hand, it is 
also possible that the Apoptin-activating signal is occasionally present in normal cells, when a 
cancer hallmark pathway is employed for a physiological function, but that this activation is 
specifically prevented. This may be due to an unfavourable folding of Apoptin, to sequestration 
or shielding by an associating cellular protein or to enhanced degradation (figure 3). 
The most convincing argument that differential activation of Apoptin is indeed responsible for 
its specific induction of apoptosis is the finding that the mutant that mimics phosphorylated 
Apoptin is able to trigger cell death in normal cells. Apparently, phosphorylation not only allows 
Apoptin to enter the nucleus but also to find its appropriate target there, since targeting Apoptin 
to the nucleus of normal cells does not elicit apoptosis. 
Significantly, the kinase that phosphorylates Apoptin may be a crucial link in a hallmark cascade, 
and a small molecular drug designed to specifically inhibit this kinase could thus disrupt the 
tumour-essential pathway and subsequently impair malignant growth. Such inhibition does not 
automatically result in an apoptotic phenotype, as it depends on the characteristic endowed by 
the hallmark pathway. If the trait, for instance, would be forced progression through the cell 
cycle, the result of treatment with the Apoptin kinase-specific inhibitor could be growth arrest or 
perhaps differentiation. Depending on the localization of the tumour nodule(s), this therapy could 
still be effective in 'curing' cancer, as long as the remaining (arrested) cell mass did not hinder 
organ functions. However, an important consideration for an Apoptin kinase inhibitor is the 
possibility that activation of the Apoptin kinase is a side-effect of the cascade responsible for the 
tumour trait, e.g. when a kinase upstream of the Apoptin kinase activates a substrate crucial for 
the hallmark and the kinase for Apoptin in parallel (figure 3). In this case, activation of the 
Apoptin kinase would be a sensor for an active cancer hallmark pathway, but disrupting its 
activity will not lead to disruption of the hallmark pathway and therefore not be effective as an 
anticancer agent. 
Regardless of whether the Apoptin kinase is essential for malignancy or not, preliminary 
experiments suggest that Apoptin kinase activity may indeed have diagnostic value. In tissue 
sections from patient material, the Apoptin kinase was remarkably more active in the tumour 
tissue than in surrounding normal tissue 14. However, there was significant variation in the level of 
activity between tumours of different patients. Lower activity seemed to correlate with a lower 
percentage of actual tumour cells in the tested section; however, more observations are required 
to prove that upregulation of the Apoptin kinase indeed occurs in every tumour in vivo. It could 
also be that Apoptin is active in all tumour cells because it combines two death domains, so that 
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Figure 3. Model for the tumour-specific activation of Apoptin 
For an in-depth discussion, see text. Briefly, Apoptin is phosphorylated specifically in tumour cells (right hand side of 
the model), which results in its activation (triangular indent), and subsequent activation of its target (extruding triangle), 
with the end result of apoptosis. Phosphorylation of Apoptin could be caused by a kinase that is active as part of a 
cancer hallmark pathway (chapter 1). It could also be that a protein in the cancer hallmark pathway activates the 
Apoptin kinase in parallel (forked pathway). Possibly, Apoptin responds to two cancer hallmark pathways 
simultaneously, for instance, if a conformational change induced by heat-shock proteins (potential cancer hallmark) is 
required to allow phosphorylation. Alternatively, a distinct pathway may activate the N-terminal death domain of 
Apoptin. In normal cells (left hand side of the model), the cancer hallmark pathway that activates Apoptin may never 
occur (e.g. breaching of a check point), or only rarely (e.g. heat shock upregulation following stress), or may not be 
constitutively overactive (as it would be in a tumour cell, e.g. overexpression of Cyclin 01 or mutated Ras). 
Furthermore, Apoptin may be improperly folded or the activation site may be shielded by an associating protein (AAP) 
or a normal-cell specific modification. In addition, Apoptin may be unstable in normal cells. 
when one pathway is not active, e.g. the kinase, the other part, e.g. the pathway that activates 
the N-terminus, can still kill the cell. In that case, the kinase-inhibitor may not be effective in the 
tumours of patients with low kinase activity. Conversely, normal cells may crucially depend on 
small amounts of the Apoptin kinase and inhibiting it with a small molecular drug could be toxic. 
In conclusion, it is important to investigate all possibilities and pitfalls for a therapy based on 
the inhibition of the Apoptin kinase, as such studies may facilitate the identification of tumour 
types that are less or more suitable for such treatment and thereby ensure the design of a 
clinical trial that will be most potent in validating (or falsifying) the Apoptin kinase inhibitor for 
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cancer therapy. Nevertheless, the discovery of the tumour-selective phosphorylation of Apoptin 
has yielded important proof of the existence of a tumour-selective mechanism and represents 
the best chance of designing an Apoptin-based molecular drug generated by the Apoptin 
research so far. 
Normal-specific inhibition of Apoptin 
Our data support a model where the difference in sensitivity to Apoptin between tumour and 
normal cells arises from the fact that Apoptin is specifically activated in tumour cells, whereas 
this activational change does not occur in normal cells (figure 3). A possible explanation for the 
strict tumour specificity of Apoptin may be due to the fact that it is dependent on two conditions 
that (almost) never occur at the same time in normal cells. In light of this hypothesis, upregulated 
heat shock proteins, which could be a cancer hallmark (see chapter 1), might activate Apoptin 
by creating a conformational change that allows binding to another cellular protein, resulting in 
phosphorylation and subsequent nuclear localisation. Electron microscopy shows that Apoptin is 
present in the ER of tumour cells prior to its nuclear transport, even though the Apoptin 
sequence lacks an ER-retention signal. In fact, one of the cellular binding partners of Apoptin 
identified in the yeast-two-hybrid screen of a transformed 8-cell library was an ER-Iocalised 
chaperoning protein called BiP. The possibility that Apoptin is activated by a stress-induced 
upregulation of chaperones is in keeping with anecdotal observations that stress may 
compromise normal-cell resistance to Apoptin. To investigate whether tumour-specific 
upregulation of heat-shock proteins is a determining factor tor activation of Apoptin, normal cells 
expressing Apoptin could be subjected to heat to examine whether Apoptin is then also capable 
of inducing apoptosis in these normal cells. A negative result may indicate that Apoptin is 
regulated by multiple tumour-specific activities, and needs, tor instance, phosphorylation after its 
proper folding before it can induce apoptosis. Downregulation of HSPs in tumour cells by 
antisense methods 17 could have answered the question whether heat-shock proteins are 
required tor Apoptin-induced apoptosis, it this approach did not already induced cell death on its 
own. 
Alternatively, the differential activity of Apoptin could be due to a phosphatase that is active 
in normal cells but specifically downregulated in tumour cells. Because the in vitro kinase assays 
that demonstrate phosphorylation of recombinant Apoptin by cell lysates from tumour cells but 
not from normal cells are performed in the presence of a cocktail of diverse phosphatase 
inhibitors, this seems unlikely 14. Instead, phosphorylation may be prevented by association with 
a cellular protein specifically in normal cells which may or may not be determined by a normal 
cell-specific conformation of Apoptin. The biochemical studies demonstrating a shielded 
Apoptin-epitope in normal cells suggest that Apoptin may indeed be associated to a distinct 
cellular protein or differently folded than it is in tumour cells. Another putative inhibitory condition 
may be caused by covalent binding of ubiquitin moieties. Addition of one or more ubiquitin 
molecules to a protein can have a variety of effects, including conformational change, prevention 
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of phosphorylation, and targeting to lysosomes or proteasomes. Ubiquitylation of Apoptin occurs 
both in tumour and normal cells (chapter 5), indicating that an E3 ligase exists that can 
recognise Apoptin. Furthermore, studies demonstrating the disappearance of Apoptin 
recombinant protein in normal cells, as well as the stabilisation of Apoptin with proteasome 
inhibitors in Apoptin-transgenic cells, suggest that Apoptin may be unstable in normal cells. 
Therefore, ubiquitylation of Apoptin may have different effects on its stability in tumour versus 
normal cells. Whether the half-life of Apoptin is indeed significantly reduced in normal cells, 
comprising an additional safety feature for therapies with Apoptin, could be determined in pulse-
chase assays. 
Other drug targets 
If cellular proteins apart from the kinase play a crucial role in the activation of Apoptin in tumour 
cells, they represent potential tumour-specific drug targets. The yeast-two hybrid screen has 
yielded twelve potential candidates for Apoptin-binding proteins in transformed cells 18. However, 
the significance of these interactions for the activity of Apoptin must still be determined. A new 
technique has been developed that can facilitate the validation of these binding partners with 
regard to their role in Apoptin-induced apoptosis. By introducing small interfering RNAs, the 
expression of all candidates can be knocked down 19 , and the study of Apoptin-associating 
proteins can then be limited to those that abrogate Apoptin-induced apoptosis when their 
expression is sufficiently reduced. Subsequent studies should categorise these essential 
Apoptin-binding partners as activators of Apoptin, which are likely to be tumour-specific, versus 
its downstream effectors, which are probably present in both tumour and normal cells, as the 
phosphorylation-mimic is capable of inducing apoptosis in normal cells. Significantly, none of 
the Apoptin-associating proteins had a kinase domain or resembled a known kinase regulatory 
subunit such as a cyclin. This could be because only a subset of mammalian proteins is 
screened, namely those present in the library. Moreover, transient associations are not 
detectable in a yeast-two-hybrid assay and it is also possible that a crucial Apoptin-associating 
protein must be modified by mammalian cell components before it can functionally interact. An 
additional screen in a mammalian system could help identify the Apoptin kinase, or at least aid 
the construction of a model for Apoptin activity by confirming some of the proteins isolated with 
the yeast-two-hybrid screen and identifying novel, may be more relevant, cellular-interacting 
proteins. The mammalian protein-protein interaction trap (MAPPIT)-method constitutes an 
attractive approach 20, provided that Apoptin does not induce apoptosis in tumour cells when it is 
tethered to the cell membrane. 
If the upstream kinase cascade proves to be the major determinant of Apoptin's tumour-
specificity, the situation may be fortunate, as kinases have proved to be much easier to inhibit 
than for instance protein-protein interactions. The AlP-pockets of kinases are 'druggable', i.e. 
represent an amenable target for small molecular inhibitors. Molecular studies of cancer have 
yielded a plethora of tumour targets, but only a subset of these is pharmaceutically tractable. 
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Receptor-ligand interactions, such as the receptor for EGF, and kinase activities, such as Bcr-
abl, are good targets for drug development, as demonstrated by the success of therapeutic 
antibody lressa and the small molecular inhibitor Gleevec, respectively. There is strong evidence 
that disruption of Myc/Max dimerization or Ras/Raf binding would inhibit the function of pathways 
essential to certain tumour cells. However, although inhibitory peptides were developed, their 
conversion into small molecular drugs with suitable pharmaceutical properties has failed 21 . 
Novel techniques such as high-throughput screens of peptidomimetic libraries may greatly 
increase the potential of this approach, but in vivo success has not yet been achieved 22. 
Therefore, while awaiting validation of the Apoptin kinase as a tumour essential effector and 
considering the potential lack of additional druggable targets, small molecular drugs need to be 
developed side-by-side with gene and protein therapy, in the hope that at least one of these 
approaches will produce a successful anti-cancer agent based on Apoptin. 
Future of tumour-specific therapies 
The research described in this thesis is a first exploration of the potential of Apoptin as an 
anticancer agent. I showed that when a substantial percentage of a tumour in vivo is infected 
with an adenoviral vector expressing Apoptin, the tumour mass disappears. Importantly, no 
adverse effects were detected in normal tissues, not even after intravenous injection of healthy 
rats. The generation of transgenic mice provided further evidence for the lack of harmful activity 
of Apoptin in normal cells, as well as new research opportunities. Together, these findings 
support the potential of Apoptin for cancer therapy. At the same time, they revealed the 
inadequacy of replication-deficient vectors for this purpose. Development of alternative gene or 
protein delivery techniques for Apoptin is warranted, not only because of the clear anti-tumour 
effects achieved in vivo with the adenoviral transduction of Apoptin, but also because recent in 
vitro data further corroborate the potential of Apoptin as an anti-cancer agent. For instance, it has 
become clear that Apoptin acts downstream of most apoptosis regulators, rendering Apoptin a 
potent inducer of apoptosis regardless of the individual evasive mutations acquired by tumours 
(Danen, chapter 1 and 4). This could mean that Apoptin may be active in tumour cells that are 
resistant to certain other cancer therapies. In addition, Apoptin was shown not to harm primary 
human cell types that are highly sensitive to classical and certain novel cancer therapeutics, 
such as hepatocytes and CD34+ stem cells 12 and Zhang, personal communication). If the same 
holds true in vivo, Apoptin's selectivity would provide a therapeutic window that exceeds existing 
ones. Equally exciting is the observation that Apoptin is tumour-specifically modified, providing 
the first prospect for small molecular drug intervention. A small molecular drug approach would 
not be hindered by delivery problems, but it remains to be determined whether such an 
approach would lead to tumour-specific cell death or restraint, and whether the target is indeed 
'druggable'. Since the tumour-selective properties of Apoptin have already been demonstrated, 
it would be advisable to continue the development of delivery methods for Apoptin in parallel. 
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As discussed, it will be important to gain further knowledge about the mechanism of Apoptin 
activation and subsequent effects. Because Apoptin is active in all tumour cells tested to date, it 
is likely that it detects a tumour essential pathway, probably quite downstream. Systematic 
testing of all known cancer hallmark pathways for their activation of Apoptin should provide 
important information for the development of the Apoptin kinase-inhibitor, identification of new 
drug targets as well as for the design of combination therapies. If Apoptin is activated by one or 
more of the known cancer hallmark pathways, it may be that an inhibitor of this pathway already 
exists. In this case, the Apoptin research may induce the testing of this inhibitor as an anticancer 
agent. It may also be that inhibitors upstream in this pathway are not effective in all tumour cells, 
or cause side effects due to their involvement in other pathways, in which case a new inhibitor 
based on Apoptin, for instance inhibiting Apoptin kinase, may provide a more potent or selective 
alternative to target this particular pathway for cancer therapy. If Apoptin responds to a presently 
unknown cancer hallmark pathway, this could yield new targets for cancer treatment, as well as 
new insight in the process of carcinogenesis. Arguably, Glivec, Tarceva and lressa were 
developed in parallel with the elucidation of the relevant molecular defects. The lack of detailed 
understanding did not slow down the development of clinical candidates, and likewise the new 
understanding of molecular pathways involved had only a limited impact in accelerating the 
development process 21 , suggesting that the development of Apoptin applications may not be 
crucially dependent on elucidation of its mechanism. 
Nevertheless, it will be important to know what the mechanism of Apoptin is, as it will allow 
for rational combination with other cancer therapeutics. It currently seems clear that tumour cells 
must acquire a limited set of essential traits, as specified by the cancer hallmarks, and that this 
requirement allows the design of tumour-specific treatment modalities. However, this fact does 
not change the reality that each tumour has acquired a unique combination of mutations leading 
to the malignant phenotype. Considering the possibility that genetic instability in tumours can 
lead to therapy-resistant clones, the most effective cancer therapy will most likely be based on 
multiple agents targeting several tumour essential pathways simultaneously. Notwithstanding the 
recent successes of the molecular therapy of cancer, it is apparent that not all of the approaches 
are performing as well as anticipated. There is clearly a learning curve with respect to the best 
ways to use these new agents, just as has been the case in the development of traditional 
cytotoxic drugs. A number of toxicities have been encountered, some of which are mechanism-
based (EGF receptor inhibitors, FTis, MMPis) and some of which are caused by the chemical 
structure of drug in a manner that is unrelated to its mechanism of action (phosphothioate 
antisense oligonucleotides) 21 . Furthermore, several patients have in fact developed resistance to 
Gleevec, either by amplification of BCR-ABL or by selection for mutations affecting the ATP-
pocket, rendering a perturbation of drug binding that leaves ATP intact 2a Fortunately, Gleevec-
resistant clones can be eliminated either by a farnesyl transferase inhibitor or by the Hsp inhibitor 
17-AAG (see introduction, and refs 24•25), illustrating the power of targeting distinct tumour 
pathways simultaneously. 
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In the case of Apoptin, the effect of radiation or chemotherapy on tumour cells was shown to be 
significantly augmented by additional Apoptin treatment, both in vitro and in vivo. Specifically, 
when irradiation of mice bearing human prostate tumours was combined with the injection of a 
tumour-targeted liposome containing the Apoptin gene, the tumour growth was reduced an 
additional 6-fold compared to radiation alone (unpublished data, E. Chang). In addition, 
S. Olijslagers demonstrated that infection of breast or prostate cancer cells with AdApt.Apoptin 
significantly reduced the amount of taxanes required to kill these cells 26. Importantly, when the 
mechanism of Apoptin is elucidated, an Apoptin-based treatment can be rationally combined 
with tumour-specific therapies that target a distinct pathway. Ideally, such a combination would 
prevent the occurrence of therapy-resistant clones because the chance of the emergence of a 
tumour cell that has acquired two mutations in two separate pathways simultaneously is much 
smaller than the chance of generating resistance to an agent targeting only one pathway. 
Hopefully, the combination of several tumour-specific agents will be so potent that the required 
doses will be lower, subsequently limiting toxicity. 
Concluding remarks 
Taken together, the effects of Apoptin in vivo merit further investigation, of both its activity in 
naturally-arising tumours and its potential toxicity in normal tissues. The generation of a new 
Apoptin-transgenic mouse with a ubiquitously and highly active promoter would expand the 
technical possibilities to examine the effects of Apoptin in normal cells and simultaneously 
describe the window of opportunity for delivery methods. Protein transduction delivery via the 
TAT-peptide or conditionally-replicating adenoviral vectors may constitute more effective 
methods for the delivery of the Apoptin gene and protein. In addition, continuous research 
into the mechanism of Apoptin is important for the prediction of potential toxicities, the 
development of small molecular drugs and the design of combination therapies. 
Several decades ago, the application of chemo- and radiation therapy had a dramatic 
impact on the prospects of cancer patients. Since then, few advances have been made in 
cancer research that translated into actual clinical benefits. In recent years, however, the 
accumulating knowledge of the molecular biology of cancer has started to pay off. 
Eventually, after a scientific learning curve and feedback from clinical trials, molecularly 
based medicines should be able to afford more effective cancer therapies with diminished 
side effects. Exploring the remarkable tumour selectivity of Apoptin could make an important 
contribution to this field. Nevertheless, the outcome of numerous interesting experiments, 
some of which have been proposed in this discussion, will determine whether an Apoptin-
based medicine will be among the few that meet the clinical criteria. 
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Nederlandse samenvatting 
lnlefding 
Therapieen tegen kanker zijn tot nu toe gebaseerd op het feit dat tumorcellen over het algemeen 
sneller delen dan normale cellen. Zowel chemotherapie als bestraling veroorzaken zodanige 
schade in cellen dat zij ofwel onmiddellijk doodgaan, of dat doen op het moment dat zij 
proberen te delen voordat de schade hersteld is. Reparatie van schade gaat over het algemeen 
gepaard met een tijdelijke, en soms permanente, rem op de celdeling. In tumorcellen is deze 
inhibitie van de celdeling vaak uitgeschakeld, tumorcellen blijven zich immers per definitie 
vermeerderen. Dit leidt ertoe dat tumorcellen eerder doodgaan door chemotherapie of bestraling 
dan normale cellen die in sommige gevallen de schade kunnen herstellen. Dit neemt niet weg 
dat de bijwerkingen van deze behandelingen aanzienlijk zijn, doordat organen waarin veel 
celdelingen plaatsvinden ernstige schade oplopen. Weefsels die in hoog tempo cellen 
vervangen zijn bijvoorbeeld de darmen of het beenmerg dat nieuwe bloedcellen aanmaakt. De 
gevoeligheid van gezonde weefsels voor kankertherapieen bepaald in hoge mate het succes 
van de behandelingen; in veel gevallen zou een hogere dosis bestraling of chemo resterende 
tumorcellen kunnen doden, ware het niet dat de patient zo'n behandeling niet zou overleven. 
Nieuwe behandelingen voor kanker zullen dus bij voorkeur gericht moeten zijn tegen 
eigenschappen die specifiek zijn voor de tumorcellen, en die niet of nauwelijks voorkomen in 
gezonde cellen. 
Kankertherapie gericht op tumor-specifieke eigen-
schappen, in plaats van op celdeling in het algemeen 
Onderzoek naar de moleculaire verschillen tussen tumor- en normale cellen (wat maakt een 
tumorcel een tumorcel?) heeft Iaten zien dat tumorcellen niet slechts normale cellen zijn die 
teveel delen. Er blijken allerlei beschermingsmechanismen in normale cellen te bestaan die 
allemaal ge"inactiveerd zijn in tumorcellen. Die inactivatie gebeurd niet 'bewust', maar is een 
gevolg van het elke keer opnieuw kopieren van het genetische materiaal (de genen, opgebouwd 
uit DNA) op het moment dat een eel deelt. Dit is een heel nauwkeurig proces, maar het is niet 
perfect en er treden dus af en toe fouten, of mutaties, op. Vaak hebben deze mutaties geen 
effect, of leiden tot celdood, maar in een enkel geval zorgen ze ervoor dat een 
beschermingsmechanisme tegen ongebreidelde celgroei niet meer werkt. Zo'n eel heeft de kans 
om uit te groeien, te vergelijken met de 'survival of the fittest' van individuen in de natuur, maar 
dan als een individuele eel in een lichaam. Als een dergelijke eel kan blijven delen, heeft het 
vervolgens een hogere kans op een nieuwe mutatie tijdens een volgende celdeling. Die mutatie 
kan een nieuwe eigenschap opleveren die bijdraagt aan de ontwikkeling tot tumorcel. Maar de 
kans dat dit een ongunstige eigenschap voor de tumorontwikkeling is, is vele malen grater. Oat 
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is een van de verk\aringen voor het feit dat het vaak jaren duurt voordat mensen tumoren krijgen; 
rakers krijgen bijvoorbeeld pas na tien tot twintig jaar \ongkanker. Terug naar het begin van deze 
alinea: tumorcellen blijken dus tijdens een \angdurig proces geselecteerd te worden op het 
vergaren van mutaties die leiden tot tumor-specifieke eigenschappen, zoals bijvoorbeeld de 
inactivatie van een rem op de celdeling, het voorkomen van een zelfmoordprogramma dat wordt 
aangeschakeld a\s een eel een gevaar voor het lichaam dreigt te worden, de ongevoe\igheid 
voor signalen van buurcellen die een eel Iaten weten dat er genoeg gedeeld is, en nog een 
aantal andere. 
Het ontdekken en onderzoeken van deze tumor-specifieke eigenschappen heeft ertoe ge\eid 
dat nieuwe kankertherapieen ontwikkeld zijn die gericht zijn tegen een van deze eigenschappen, 
en dus minder bijwerkingen zouden moeten hebben en (daardoor) effectiever kunnen zijn dan 
de bestaande behande\ingen omdat norma\e cellen niet aangetast worden. Vee\ van deze 
nieuwe therapieen zijn nog in de ontwikke\ingsfase, maar een klein aantal zijn onlangs 
goedgekeurd a\s officieel medicijn, zoa\s bijvoorbee\d G\ivec tegen \eukemie of Herceptin tegen 
borstkanker. 
Onderzoek naar mogelijke tumor-specifieke therapieen gebeurt op basis van inmiddels 
bekende tumor-eigenschappen, het ontdekken van nieuwe tumor-eigenschappen, of op basis 
van mo\ecu\en waarvan bekend is dat ze tumor-specifiek zijn, maar waarvan de bijbehorende 
tumor-eigenschap onbekend is. Het onderzoek dat ik beschrijf in dit proefschrift is gebaseerd op 
de \aatst genoemde mogelijkheid. Het eiwit Apoptin veroorzaakt ce\dood in tumorcel\en en niet 
in normale cell en, maar we weten nog niet waarom. 
D it p roefsch rift 
Apoptin is een eiwit, en eiwitten zijn de producten van de genen die in een eel zitten en de 
uiteindelijke functies uitoefenen die nodig zijn voor een eel. Nu komt het gen dat Apoptin maakt 
niet voor in cellen, het is afkomstig van een virus. Virussen bevatten s\echts genen met een 
kapse\ eromheen, en hebben verder geen mogelijkheid om zelfstandig van deze genen de 
functione\e producten, of eiwitten, te maken. Op het moment dat een virus een eel binnenkomt 
('infecteert') gebruikt het de eiwitten van de eel om van zijn eigen genen viruseiwitten te Iaten 
maken. Dit leidt uiteindelijk tot vele nieuwe virusdee\tjes die de eel verlaten en weer nieuwe eel len 
kunnen infecteren. Het gen voor Apoptin komt van een virus en za\ dus waarschijnlijk bijdragen 
aan het proces van virusproduktie, maar ook daar is weinig over bekend. Wat wei bekend is, is 
dat als het gen voor Apoptin in tumorcellen van een mens (of muis) wordt gebracht, en dus het 
eiwit Apoptin wordt gemaakt ('tot expressie gebracht'), deze cellen na een aanta\ dagen hun 
ze\fmoordprogramma aanschakelen en vervolgens doodgaan. Wanneer dit gen in normale 
cel\en tot expressie wordt gebracht, lijken deze cel\en er totaa\ geen last van te hebben. Het lijkt 
niet uit te maken wat voor ce\type het is, Apoptin heeft bijvoorbee\d geen effect in huidcellen, 
b\oedcellen of \evercellen, maar we\ in de tumorcellen die uit deze weefse\s kunnen ontstaan. 
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Deze proeven zijn allemaal gedaan met gekweekte cellen, dus cellen die uit het lichaam zijn 
gehaald en in schaaltjes in Ieven worden gehouden. Het Apoptin gen is in deze cellen gebracht 
met een techniek die aileen op cellen in schaaltjes werkt en niet erg efficient is; slechts een deel 
van de cellen neemt het gen open brengt Apoptin tot expressie. Toen ik began aan mijn AIO-
periode waren wij benieuwd of Apoptin ook echt te gebruiken zou zijn als kankertherapie. Om 
dat te kunnen testen, moest er een andere techniek gebruikt worden, waarmee Apoptin efficient 
in cellen gebracht kon worden, niet aileen in een schaaltje maar ook in een echte tumor in een 
Jevend organisme (uiteindelijk misschien ooit in de mens, maar in eerste instantie in de muis). 
Aangezien virussen geevolueerd zijn om hun genen zo efficient mogelijk in eel len te krijgen zodat 
er nieuwe virusdeeltjes gemaakt kunnen worden (de virussen die dat niet kunnen verdwijnen 
vanzelf), heb ik het gen voor Apoptin in een virus gezet dat heel efficient een groat aantal 
celtypes kan infecteren en dat vaak voor dit soort studies wordt gebruikt. Dit virus is gebaseerd 
op een humaan verkoudsheidvirus, het Adenovirus genaamd, maar er zijn een aantal genen 
uitgehaald waardoor het geen nieuwe virusdeeltjes meer kan vormen als het in een eel komt, het 
brengt slechts het gen dat de onderzoeker erin gezet heeft tot expressie. Op deze manier is de 
enige overgebleven functie van het virus het efficient naar binnenbrengen van het gen, als 
bezorger of 'carrier'. Om nu tach voldoende virusdeeltjes met het Apoptin gen te krijgen om een 
tumor mee te infecteren heb ik gebruik gemaakt van cellen die zo geconstrueerd zijn dat ze de 
ontbrekende virusgenen in hun DNA hebben, en dus de eiwitten maken die nodig zijn voor 
virusproduktie. Deze virusproducerende eel len zijn tumorcellen, en de eerste belangrijke test was 
dan ook of deze cellen wei Apoptin virus konden maken, of dat zij voor die tijd al dood zouden 
gaan door Apoptin. Gelukkig hebben de cellen maar twee dagen nodig om virus te maken, en 
gaan ze pas na een dag of vier dood door Apoptin, wat betekent dat de techniek die ik gekozen 
had bruikbaar was (hoofdstuk 2). Het volgende belangrijke punt was of Apoptin nog wei tumor-
specifiek zou zijn als het op deze nieuwe manier in cellen werd gebracht. Ook dat bleek het 
geval, infectie van menselijke levertumorcellen liet zien dat Apoptin deze cellen doodde, terwijl 
het geen effect had op normale levercellen uit een rat (figuur 1). 
Vervolgens konden we voor het eerst gaan kijken wat de gevolgen waren van expressie van 
Apoptin in een organisme. Hiervoor hebben we dezelfde menselijke levertumorcellen onderhuids 
gespoten bij naakte muizen, een muizenstam (zonder vacht) die geen goed afweersysteem heeft 
en menselijk weefsel daardoor niet afstoot. Deze cellen groeien uit tot een echte tumor, met 
ondersteunend weefsel, verschillende compartimenten en een bloedvoorziening. De tumoren 
hebben we na drie weken ge"injecteerd met het Apoptin virus, en ook met een controle virus of 
aileen een zout-oplossing (hoofdstuk 3). Uit deze experimenten bleek dat in 30% van de tumoren 
die met Apoptin-virus behandeld waren, deze geheel verdwenen, terwijl dat niet gebeurde met 
de controle behandelingen. Een ander deel van de Apoptin-behandelde tumoren groeide minder 
hard of nam in omvang af, maar bleef wei aanwezig. En op de overige tumoren had de Apoptin-
behandeling zelfs nauwelijks effect. Toen we doorsnedes van de tumoren bekeken bleek hoe dat 
kwam, namelijk door de verschillende compartimenten in de tumoren waardoor het virus niet 
overal terecht was gekomen. Het effect van de therapie hing dus af van de manier waarop de 
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Figuur 1. Gentherapie met Apoptin 
De speeifieke volgorde van DNA bouwstenen (een gen) bevat de informatie voor een eel om versehillende peptides 
zodanig aan elkaar te koppelen dat een eiwit gemaakt wordt, in dit geval Apoptin. Dit gaat via de intermediar RNA, die 
de informatie vanuit de kern (waar de informatie ligt opgeslagen) naar het eytoplasma (waar eiwitten worden 
geprodueeert) brengl Het gen voor Apoptin is in de plaats gezet van genen van het adenovirus, waardoor dit virus zieh 
in een willekeurige eel niet meer kan vermenigvuldigen. Dit kan nog wei in speeifieke virus-produeerende eellen, waar 
onderzoekers de ontbrekende virusgenen in het eellulaire DNA hebben geplaatst. Na infeetie met het Apoptin-virus 
maken deze eellen een grate hoeveelheid nieuwe virusdeeltjes met het Apoptin gen (en maken ook Apoptin eiwit). 
Deze virussen kunnen vervolgens gebruikt worden om het Apoptin-gen effieiemt in normale en tumoreellen te brengen. 
In deze eellen, bijvoorbeeld in een weefselkweeksehaaltje of in een muis, ontstaan dus geen nieuwe virusdeeltjes 
meer, er wordt sleehts Apoptin eiwit geprodueeerd. Als in tumoreellen het eiwit Apoptin wordt gemaakt, bevindt dit 
eiwit zieh zowel in het eytoplasma als in de kern van de eel en wordt een al aanwezig zelfmoordprogramma van de eel, 
apoptose genaamd, aangezet. In normale eellen daarentegen blijft het geprodueeerde Apoptin eiwit uitsluitend in het 
eytoplasma en lijken de eellen er geen last van te hebben. 
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injecties plaats hadden gevonden en hoeveel tumorcellen ook daadwerkelijk het Apoptin-virus 
hadden opgenomen. De belangrijkste conclusie uit deze experimenten is dat als Apoptin in 
tumorcellen terecht komt het in staat is deze cellen te doden, maar dat deze virus-carrier niet 
efficient genoeg is om Apoptin in aile cellen van een tumor tot expressie te brengen. Op dit 
moment wordt er gezocht naar een andere manier om Apoptin in tumorcellen te brengen. Een 
alternatief is om te onderzoeken waarom Apoptin actief wordt in tumorcellen, maar niet in 
normale cellen. Als dat proces bekend is, kan geprobeerd worden een klein molecuul te maken 
dat net als chemotherapie door aile cellen opgenomen wordt. Dit rnolecuul zou dan wei moeten 
reageren op dezelfde tumor-eigenschap waar Apoptin op reageert, en ook tot gevolg hebben 
dat de turnorcel specifiek doodgaat. Ook hier wordt aan gewerkt. 
Om nog meer inzicht te krijgen in de effecten van Apoptin in een levend organisme, zonder 
afhankelijk te zijn van een transductie-techniek, hebben we een Apoptin-transgene muis 
gemaakt (hoofdstuk 5). Deze rnuis heeft a! zijn eigen genen, metals extra het gen voor Apoptin. 
Omdat embryonale cellen in principe een aantal 'tumor-achtige' eigenschappen hebben, waren 
we niet zeker of deze muizen wei geboren konden worden. Voor de zekerheid hebben we 
gekozen een stukje DNA aan het Apoptin-gen te zetten dat ervoor zorgt dat Apoptin pas laat in 
de embryogenese tot expressie komt. De Apoptin-muizen werden geboren en er waren geen 
tekenen van afwijkingen, wat suggereert dat Apoptin geen nadelig effect had op de (normale) 
cellen van deze muizen. Het stukje DNA dat de relatief late Apoptin expressie bepaalde, heeft 
ook invloed op welke celtypen Apoptin uiteindelijk tot expressie brengen, en het bleek dat de 
Apoptin-transgene muizen het Apoptin eiwit met name tot expressie brachten in cellen van het 
afweersysteem. Deze cellen zijn onderdeel van het bloed, en hebben in de mens erg te leiden 
van chemotherapie en bestraling. Als normale afweercellen niet gevoelig blijken te zijn voor 
Apoptin dan zou dit een belangrijk argument vormen om Apoptin verder te testen als anti-kanker 
middel. En als de muizen tumoren zouden krijgen afkomstig van deze afweercellen 
('lymphomen') en het aanwezige Apoptin zou dat kunnen voorkomen, dan zou dat voor de 
eerste keer zijn dat Apoptin geen tumorcellen doodt die al eerder gekweekt zijn in een schaaltje, 
maar tumoren die ter plekke ontstaan. Uit mijn proeven met deze muizen blijkt dat de 
afweercellen inderdaad geen last hebben van de Apoptin expressie. Maar tegelijkertijd toonde ik 
aan dat het Apoptin eiwit in deze cellen niet erg stabiel is. Nu zijn er aanwijzingen dat Apoptin 
misschien stabieler wordt als een eel een tumorcel wordt, dus het zou kunnen dat dit een 
eigenschap is die bij Apoptin hoort. Maar het kan ook dat het Apoptin gen ongelukkig terecht is 
gekomen in het DNA van de transgene muis of dat Apoptin om de een of andere reden niet 
functioneel is. Voordat ik de conclusie kan trekken dat Apoptin niet schadelijk is voor 
afweercellen, moet er eerst aangetoond worden, dat als deze cellen tumorcellen worden, het 
Apoptin eiwit in deze cellen wei degelijk in staat is ze te doden. Deze proeven zijn helaas nog 
niet afgerond. 
Als er uiteindelijk een manier is gevonden om een tumor-specifieke therapie te ontwikkelen 
op basis van Apoptin, door het gen of eiwit efficient in tumorcellen te brengen, of door een klein 
molecuul te maken dat werkt volgens hetzelfde mechanisme, en de dierproeven Iaten vervolgens 
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gunstige resultaten zien, dan zou zo'n therapie getest kunnen worden op mensen. Bijvoorbeeld 
bij patienten met tumoren van de galgang (cholangiocarcinoma). Op het moment is er geen 
behandeling mogelijk van galgangtumoren, omdat ze vaak vertakt zitten in de lever en dus 
moeilijk weg te snijden zijn, en omdat ze ongevoelig zijn voor bestraling en chemotherapie. 
Vooruitlopend op de ontwikkeling van een Apoptin-therapie, heb ik bekeken of deze resistente 
tumorcellen dan misschien wei gevoelig waren voor Apoptin. Uit verschillende proeven bleek dat 
Apoptin zeer effectief tumorcellen afkomstig van drie verschillende patienten doodde 
(hoofdstuk 4), wat een additioneel argument vormt voor het verder ontwikkelen van een Apoptin-
therapie. 
Conclusie 
In het kort laat dit proefschrift zien dat het technisch haalbaar is een Apoptin-virus te maken, 
dat Apoptin in deze context tumor-specifiek blijft en ook daadwerkelijk muizen van 
geimplanteerde tumoren kan genezen. Tegelijkertijd laat het ook zien dat er een efficientere 
techniek nodig is om Apoptin in aile cellen van een tumor te krijgen. Verder zijn Apoptin-
transgene muizen levensvatbaar en lijken de afweercellen van deze muizen geen last te 
hebben van Apoptin expressie, alhoewel dit verder moet worden uitgezocht. Uiteindelijk 
zouden bijvoorbeeld galgangtumoren in aanmerking kunnen komen voor een therapie op 
basis van Apoptin, maar dit hangt af van de technische mogelijkheden om zo'n therapie 
daadwerkelijk te ontwikkelen. 
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Dankwoord 
Een promotieonderzoek in de moleculaire en medische biologie is niet aileen interessant en 
spannend, het betekent ook lange dagen, dicht op elkaar met een kleine groep mensen, 
groepsleiders die vee! van onderzoek weten maar weinig van management, en vee! mislukte 
proeven. Oat dit boekje er uiteindelijk tach is gekomen, is mede dankzij enthousiaste en 
bevriende collega's en de relativerende aanwezigheid en steun van mensen buiten 'de 
wetenschap'. Deze pagina's zijn speciaal om aan een groat publiek te Iaten weten welke 
kleurrijke personen het allemaal de moeite waard hebben gemaakt ... 
Het began allemaal op 'de vierde', op een zaal met nogal uiteenlopende persoonlijkheden: 
Stefan, driftig pipetterend met z'n benen op tafel, 'rooie rakker' en altijd in voor een paging de 
dames weer op de kast te krijgen met vrouw-onvriendelijke opmerkingen. Monique, mijn vaste 
steun als die mannen weer eens uitgelegd moest worden hoe de wereld in elkaar zit. Uiteindelijk 
is ons contact nog intensiever geworden nadat je naar de VU bent gegaan, hoe meer 
theatervoorstellingen en stapavonden hoe beter! En Rob, in driedelig pak met je lange haren op 
sollicitatiegesprek had je a! snel de toon gezet. Een die niet makkelijk te missen was, want het 
volume van zowel discussie, muziek als gelach was tot in aile gangen te horen. lnmiddels ben je 
a! jaren een belangrijk ijkpunt voor mijn beeld van de we reid, wat zeker niet wil zeggen dat ik het 
met (a!) jouw oplossingen eens ben! Maar wie weet, vinden we ooit nog ergens een landje voor 
onze sociale dictatuur .... En dan Astrid, bran van kennis over Apoptin en een voorbeeld in 
organisatie en netheid, waar ik zeker in het begin vee! van kon leren! lk vond het een eer jouw 
promotie van zo dichtbij mee te maken. Yinghui, I am glad you found your place here soon and I 
enjoyed your Chinese cooking, our discussions and your omnipresent smile. 
Een zaal verder was Hans net begonnen aan zijn baan hier in het verre westen, en hadden 
wij elkaar a! snel gevonden als kroeg- en filmmaatje. Samen hebben we onverwacht leuke 
plekjes in Leiden ontdekt ;-) In aanwezigheid van Thea sneuvelden onze voornemens tot 
gematigheid regelmatig en gingen de verhalen tot diep in de nacht over verre reizen en een 
eindeloze rij diersoorten. Leuk dat ik weer een paar nieuwe heb kunnen spotten bij jou en 
Margriet in Schotland. Leuk ook dat jullie uiteindelijk weer terugkomen (Amsterdam he?!). Thea, 
zowel jouw kunst van het levensgenieten als het aanstekelijke enthousiasme waarmee je een 
berg oprent doen goed volgen, ook a! kom ik dan wat later ... 
Aan Marjolijn de taak om mij in te wijden in de complexiteit van het dierproeven doen. 
Varierend van puzzelen voor gevorderden op de pingpongtafel tot huid-long-nier/hart-gonade-
spier en hapje links of hapje rechts heb ik vee! van je geleerd en vee! gelachen. Dierproeven 
vragen nogal wat van een mens, zeker van een vegetarier, en ik ben blij dat ik het lief en leed 
met je kon delen. En gelukkig was a! ons werk niet voor niets! Ook dankzij de toegewijde zorg 
(voor de muizen) en opgewekte pesterijen (voor ons -en Maud-) van de dierverzorgers, Johan en 
Henny. De rest van de gentherapie-groep: Diana, Rik, Martijn, HansvO, ErikSen Rob H, bedankt 
voor alles wat ik van jullie geleerd heb, behalve over proeven ook over de prachtige 
onderwaterwereld en enkele wijze levenslessen. De AIO-avonden en -weekenden waren 
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leerzaam en gezellig, met dank aan Petra, RobertS, Jaap, Volkert, Alfred, Yolande, Joost, en 
Lisette. 
Daarna werd Leadd te groot en verhuisden we naar de Annex. Gelukkig werd ons kleine 
groepje snel uitgebreid met Frederique (met een groot hart), Jenny (thanks for reading all my 
stuff!), Patrick (computer-goeroe en Star trek bron), Anne-Marijke (gezellig aanwezig) en 
natuurlijk Maud en Klaas. Maud, zoals wij samen proeven kunnen doen zijn er maar weinigen 
denk ik. Alhoewel het beeld van ons samen met de brug van een RNA blot in onze handen me 
onveranderelijk aan het lachen krijgt, hebben we erg vee! voor elkaar gekregen, zowel met vier 
handen als ieder apart. lk heb bewondering voor je stoere levensinstelling en inlevingsvermogen 
en genoten van ons discussies, over wetenschap, het nieuws, en natuurlijk de man/vrouw 
verhouding waarbij Klaas onmisbaar was. Zander verschillend standpunt geen discussie, en 
Klaas, gezellige bench-buur, was een gewillig slachtoffer of aanstichter al naar gelang het 
onderwerp. En altijd in voor een feestje, die we dan ook regelmatig hebben gehad. 
The Joint Apoptin Research Team meetings with Dominik Mumberg, Peter Donner, Bertram 
Weiss, Klaus Bosslet and other researchers from Schering AG gave me some insight into the 
long road from idea to potential therapeutic, which at times could be both inspiring and 
frustrating. It was a pleasure to collaborate with you! The same goes for our collaboration with 
your subsidiary, Berlex Biosciences. In the beginning David Henderson and later Harald Dinter: 
thank you for all the information and support and Hsiao-Lai and Georg: I am glad you were able 
to reproduce our data. Considering all the effort it took to send virus from here to the U.S., I 
might as well have put some dutch cheese and jenever in those packages, next time I will! 
lntussen waren er ook samenwerkingen op kleinere afstand, met Reumatologie bijvoorbeeld: 
bedankt Tom, Pauline, Elsbet, Tanja en later ook Sjef, Ramon en Peter. Jammer dat we niet 
genoeg bewijs hebben kunnen verzamelen om ons werk op te nemen in mijn proefschrift. En de 
samenwerking met het AMC, waar Saskia begonnen is en later verder gegaan bij Leadd. Saskia, 
congres-maatje, jij ziek in MOnchen, ik met gipsen been naar Davos, dat ging goed ... We 
hebben vee! aanverwant werk gedaan, en meer dan gemiddeld heb je pech gehad met de 
technische haalbaarheid of uitkomst van projecten. lk wens je een beter project voor in de 
toekomst! De andere pechvogel is natuurlijk Sharon. Als AIO drie keer aan een volledig nieuw 
project beginnen is niet niks en ik heb bewondering voor hoe je je er elke keer weer in hebt 
vastgebeten. En het is je dan ook wei gelukt uiteindelijk! Onze andere gentherapie AIO, Remco, 
zit een beetje klem tussen twee werelden. Ook jij weet je wonderbaarlijk staande te houden, en 
hopelijk heb je 'op de werkvloer' toch wat van de steun gevonden die je eigenlijk verdient. Rutger 
heeft gewoon al die tijd onverstoorbaar zijn proeven gedaan, of misschien heb ik daar gewoon 
minder van meegekregen, net als van sommige van je eiwit technieken. Wat wei weer hielp het 
onbegrip van mijn studenten (Marianne, Nathalie) te begrijpen als ze vonden dat ik abacadabra 
sprak. Uiteindelijk was hun stageperiode net zo leerzaam voor hen als voor mij denk ik. Joost en 
Jeroen(tje) waren daarentegen al snel thuis in het lab en ik heb met vee! plezier met jullie 
proeven gedaan. En nog steeds kwamen er mensen het bonte gezelschap bij Leadd versterken: 
Aliek, Linda, Niek en Marieke en Marian (dubbele alleskunners). Met Mathieu en Dirkjan als 
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moederkloeken is er met vallen en opstaan een structuur ontstaan die een tijd best goed heeft 
gewerkt. Helaas zijn belangen en verwachtingen uiteen gaan !open en ontstonden er 
problemen .... Mathieu en Dirkjan, bedankt voor het vertrouwen dat jullie al zo vroeg in mij 
hadden en bedankt voor aile ondersteuning. lk hoop dat iederen bij Leadd uiteindelijk daar 
terecht komt waar ze graag zouden zijn. De laatste loodjes werden aanzienlijk Iichter na de 
apoptose meeting in Salobrena. Oat ik toch pas aan het eind van mijn promotieonderzoek de 
enthousiaste apoptosis-scene in Nederland ontdek! Stephen, Jurjen, Wendy, Lucy, Michael, 
Ingrid, Elza, Eric en met name Arlette en Jan Paul, bedankt voor jullie hulp! En Paul natuurlijk, 
niet aileen vanwege de organisatie van veel van de bijna-maandelijkse uitjes, maar ook voor een 
leuk en spannend nieuw project. .. 
Frank Grosveld, bedankt dat je mij in zo'n vergevorderd stadium nog onder je hoede wilde 
nemen. En Sjaak en Marike bedankt voor aile hulp bij het halen van de strakke tijdsplanning! 
Niet aileen de wetenschappers hebben mijn AIO-schap mogelijk gemaakt, de mensen 
erbuiten waren minstens zo belangrijk. Als eerste mijn ouders natuurlijk, waar ik van de een de 
interesse voor weteoschap en van de ander voor gezondheid heb meegekregen, maar ook 
vertrouwen in mijn eigen kunnen, genieten van het Ieven, kunst en gedichten. Jako en Wieneke, 
lieve broer en zus (allang niet meer -(t)je), leuk om te zien hoe verschillend we onze eigen weg 
aan het vinden zijn. lk hoop dat we elkaar nu echt wat vaker kunnen gaan zien! En dan 
vriendinnen; Tamara, als ik mijn wetenschappelijke discussies zou voeren zoals wij onze 
telefoongesprekken dan denk ik niet dat iemand mij nog zou kunnen volgen. Gelukkig begrijpen 
wij elkaar als geen ander en ik heb bewondering voor de eigenzinnige keuzes die je maakt, je 
geloof in jezelf en hoe je voor anderen klaar staat. Oat je nog maar lang mijn liefste vriendinnetje 
mag blijven! Marlies en Leonoor zijn de stoerste wereldreizigers die ik ken, ik krijg geen genoeg 
van jullie verhalen. Maar goed dat we ook de grootste theeleuten ooit zijn. Femke, ik hoop dat je 
altijd tijd blijft houden voor je eigen kunst naast je nieuwe drukke baan want ik vind dat je 
bijzonder(e) mooie dingen maakt, zoals mijn omslag: dankjewel! Leuk dat we bijna buren 
worden en ik hopelijk nog vaker kan meegenieten van de bijzondere kijk die jij en Egbert op de 
wereld hebben. En toen was daar opeens Mathijs, en met hem nog een hele rits leuke, 
bijzondere mensen. Dieuwke en Erik (met jullie prachtige mannetjes, heerlijke etentjes en 
gezelligheid), Erik, bedankt voor de mooie vormgeving!, Peter en Ria (sociaal en ondernemend), 
Liesbeth (spiritualiteit is 66k belangrijk), Hans ( ... ), Jeroen (wanneer gaan we weer dansen?) en 
Albert en Eugenie (prachtige docurnentaires en fanatieke spelletjes). 
Mathijs, zonder jou had dit boekje en, belangrijker, mijn Ieven er heel anders uit gezien. Hoe 
bijzonder jij bent is niet iets om op print te zetten. Oat vertel ik je liever zelf! Misschien is het wei 
passend om te eindigen met de ontkrachting van een stelling die ik met veel verve heb 
verdedigd tijdens mijn promotietijd: samen(leven), het kan wei! 
Beste collega's, bedankt voor jullie bijdrage, steun en levenslessen! 
Lieve vrienden en familie, mijn wereld is mooier met jullie, 
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